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Acinetobacter baumannii is an important nosocomial pathogen, frequently associated with 
morbidity and mortality in immunocompromised patients due to the immuno-ablative treatments, 
neutropenia and prolonged hospitalization. The ability of A. baumannii to survive in the 
healthcare setting makes it a frequent problematic pathogen in cancer centres.   Much of the 
interest in A. baumannii has been attributed to its remarkable rapid acquisition of resistance 
mechanismsA. baumannii is an excellent example of genetic plasticity, with its ability to acquire 
and express resistance in plasmids and chromosome particularly to carbapenems 
 The aim of this thesis is to look at the molecular epidemiology and resistance mechanisms of 34 
non-duplicate A. baumannii in two cancer centres in Cairo, Egypt. 
Initial sequencing of the ubiquitous blaOXA-51-like gene revealed a large diversity within the 
strains, with eight different genes identified: blaOXA-64, blaOXA-65, blaOXA-66, blaOXA-69, blaOXA-71, 
blaOXA-78, blaOXA-94, blaOXA-89/100.  
Typing with Pulsed-field Gel Electrophoresis (PFGE) showed an overall similarity at only 
28.69% between the isolates, with variation in pattern for isolates with similar blaOXA-51-like 
genes.   
Typing with Multilocus Sequence Typing (MLST) identified 6 new Sequence Types: ST408 -  
ST414, in addition to ST331 and ST108 which have been previously found in other regions of 
the world. 
All three OXA-type carbapenemases: blaOXA23, blaOXA40 and blaOXA58, responsible for conferring 
carbapenem resistance were found in the collection studied. Insertion sequences ISAba1, ISAba2 
and ISAba3 have been found to upregulate the expression of blaOXA genes. ISAba1 was found 
upstream of blaOXA23 in 18 strains in this collection The first report of ISAba2 was identified 
upstream of a blaOXA-51-like gene in this collection. Additionally, ISAba3 was bracketing the 
blaOXA58 genes, and two isolates harboured hybrid promoters with IS1006 and IS1008 
interrupting the upstream ISAba3 sequence.   
Resistance to Ceftazidime was mediated by Extended-spectrum β-lactamase (ESBL) genes 
belonging to PER-like group: blaPER-1, blaPER-7 and the first report of blaPER-3 gene and its genetic 
environment in A. baumannii.  
In conclusion, this study shows the diversity exhibited by A. baumannii in Egypt. The various 
resistance mechanisms illustrate the ability of A. baumannii in acquiring and expressing 
resistance genes, either on plasmids or in the chromosome. Furthermore, the results indicate an 
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Chapter 1: Introduction 
 
1.1 The history of the genus Acinetobacter 
The development of Acinetobacter spp. taxonomy was confusing and full of uncertainties. 
Acinetobacter spp. was initially described by Beijerinck in 1911 and assigned the name 
Micrococcus calcoaceticus (reviewed by Henriksen, 1973). The organism shared 
characteristics with Moraxella spp and was classified in the same group for some time; 
however significant differences  were identified and led to the designation of this organism as 
Achromobacter spp (reviewed by Henriksen, 1973; reviewed by Peleg et al., 2008). 
Acinetobacter was then proposed by Brisou and Prévot in 1954 to distinguish the non-motile 
species in Achromobacter group (reviewed by Henriksen 1973). A. calcoaceticus and A. 
lwoffii were the proposed names given to the first described species and were distinguished 
by their ability, or not, to acidify glucose  (reviewed by Peleg et al. 2008). 
 
1.2 Taxonomy of Acinetobacter  
Acinetobacter is defined as Gram-negative, strictly aerobic, glucose non-fermenting, non-
motile, catalase-positive, oxidase-negative coccobacilli, usually occurring in diploid 
formation and with DNA G-C content of 39% to 47% (Giamarellou et al., 2008; reviewed by 
Peleg et al., 2008).  
DNA-DNA hybridization studies performed by Bouvet in 1986 identified 12 genospecies 
including A. baumannii, A. calcoaceticus, A. haemolyticus, A. johnsonii, A. junnii and A. 
lwoffii (reviewed by Peleg et al. 2008). Further work by Bouvet and Jeanjean, Tjernberg and 
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Ursing, and Neshmara et al. added more genospecies and resulted in the current genus 
Acinetobacter comprising 23 named species (Table 1) with the A.calcoaceticus-A.baumannii 
complex being closely related and the most clinically relevant (reviewed by Nemec et al. 
2011; Peleg et al. 2008).  
The A. calcoaceticus-A. baumannii complex is difficult to distinguish by conventional 
phenotypic methods and comprises A. calcoaceticus, an environmental organism, frequently 
isolated from soil and water (Henriksen, 1973; Nemec et al. 2011), Acinetobacter genomic 
species 3 (now referred to as Acinetobacter pittii), Acinetobacter genomic species 13 TU 
(now referred to as Acinetobacter nosocomialis) and A.baumannii which are implicated in 














Species Genomic Species Source 
A. calcoaceticus 1 Soil and humans 
A. baumannii 2 
Humans (clinical specimen), 
soil, meat and vegetables 
A. pittii 3 
Humans (clinical specimen), 
soil and vegetables 
A. haemolyticus 4 Humans (clinical specimen) 
A. junii 5 Humans (clinical specimen) 
A. johnsonii 7 
Humans (clinical specimen) 
and animals 
A. lwoffii 8/9 
Humans (clinical specimen) 
and animals 
A. radioresistens 12 
Humans (clinical specimen), 
soil and cotton. 
A. bereziniae 10 
Humans (clinical specimens), 
soil and vegetables 
A.guillouiae 11 
Humans (clinical specimens) 
and animals 
A. nosocomialis 13TU Humans (clinical specimen) 
Acinetobacter ursingii  Humans (clinical specimens) 
Acinetobacter schindleri  Humans (clinical specimens) 
Acinetobacter parvus  
Humans (clinical specimens) 
and animals 
Acinetobacter baylyi  Activated sludge and soil 
Acinetobacter bouvetii  Activated sludge* 
Acinetobacter towneri  Activated sludge* 
Acinetobacter tandoii  Activated sludge* 
Acinetobacter grimontii  Activated sludge* 
Acinetobacter tjernbergiae  Activated sludge* 
Acinetobacter gerneri  Activated sludge* 
Acinetobacter venetianus  Sea water 
 13BJ, 14TU Humans (clinical specimens) 
 14BJ Humans (clinical specimens) 
 15BJ Humans (clinical specimens) 
 16 Humans (clinical specimens) 
and vegetables 
 17 Humans (clinical specimens) 
and soil 
 15TU Humans (clinical specimens) 
and animals 
 ‘Between 1 and 3’ Humans (clinical specimens) 
 ‘Close to 13TU’ Humans (clinical specimens) 
 13BJ, 14TU Humans (clinical specimens) 
 
Table 1: Classification of the genus Acinetobacter Adapted from (Dijkshoorn et al. 2007; 




1.3 Identification of Acinetobacter spp. 
Acinetobacters have been previously assigned to the Mimae group due to the difficulty in de-
staining hence misidentifying the organism either as Gram-positive or Gram-negative cocci 
(reviewed by Henriksen 1973; Peleg et al., 2008). Acinetobacter from human clinical 
samples grow well on conventional laboratory media at 37°C incubation, whereas species not 
belonging to the A.calcoaceticus-A.baumannii complex may not grow on McConkey agar 
(Nemec et al. 2011; Peleg et al. 2008).  
Phenotypic detection methods and metabolic tests are not suitable for comprehensive 
identification of Acinetobacter and distinguishing it from other non-fermenting Gram-
negative bacteria. They also do not allow the discrimination of the different genomic species. 
DNA-DNA hybridization scheme proposed by Bouvet and Grimont in 1986 assesses growth 
at 37°, 41° and 44°C, the ability to produce acid from glucose, gelatine hydrolysis, and 
assimilation of carbon sources, and this scheme identified 95.6% of 136 Acinetobacter 
isolates from human samples (reviewed by Peleg et al., 2008). However, this poorly 
discriminates between isolates belonging to the A.calcoaceticus-A.baumannii complex. 
Additionally, DNA-DNA hybridization and conventional phenotypic detection methods are 
not suitable for routine microbiology diagnostic laboratories due to the laborious nature of 
these methods. Laboratories hence rely mostly on automated and semi-automated machines 
such as Pheonix, Vitek, and MicroScan for identification and susceptibility testing, as they 
provide results much faster. Nevertheless, limitations still exist for using these machines in 
identifying acinetobacters, particularly the A.calcoaceticus-A.baumannii complex.  
Molecular methods are subsequently much better tailored for accurate species identification 
of acinetobacters. These include amplified 16s rRNA gene restriction analysis (ARDRA), 
amplified fragment length polymorphism (AFLP), ribotyping, tRNA spacer fingerprinting, 
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restriction analysis of the 16s-23srRNA intergenic spacer sequences, and sequencing of the 
rpoB gene (Dijkshoorn et al., 2007; Dolzani et al., 1995; Nemec et al., 2011; Peleg et al., 
2008). More recently, the amplification and sequencing of the intrinsic blaOXA-51-like gene has 
also been widely used for identification of A. baumannii isolates (Evans et al., 2008; 
Hamouda et al., 2010; Woodford et al., 2006).  
 
1.4 Natural habitat of Acinetobacter species 
The natural habitat of Acinetobacter spp has been investigated extensively in the past few 
years and it is now considered a ubiquitous organism in nature. They can be recovered from 
soil, water, vegetables, animals and human body lice (reviewed by Peleg et al., 2008; 
Giamarellou et al,. 2008; La Scola & Raoult, 2004). A. johnsonnii, A. junnii and A. 
radioresistens are also frequent colonizers of human skin and mucous membranes (reviewed 
by Peleg et al. 2008; Giamarellou et al. 2008). (Table 1) 
Acinetobacter baumannii however is rarely identified as a commensal organism on human 
skin, and is not an environmental organism; so far we have failed to elucidate its natural 
habitat (Seifert et al. 1997). Despite being identified in the soil, the reports are not sufficient 
to provide conclusive evidence that A. baumannii’s natural habitat is soil.   
Environmental wound contamination has also been investigated, as soldiers wounded in the 
Afghanistan, Iraq and Vietnam wars had a high rate of A. baumannii wound and blood 
infections (Hujer et al., 2006). Additionally,  A. baumannii was isolated from human body 
louse from homeless people in France (La Scola & Raoult, 2004). Acinetobacter spp. 
including A. baumannii have also been isolated from vegetables (Berlau et al., 1999). 
Overall, the results indicate the wide distribution of A. baumannii and may provide insight 
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into its potential natural habitat as well as providing a route for the dissemination into the 
hospital setting.  
The hospital environment serves as a suitable habitat for A. baumannii, A. pittii (formerly 
known as geno.sp.3) and A. nosocomialis (formerly known as geno.sp. 13TU) (Nemec et al. 
2011; Peleg et al. 2008; Dijkshoorn et al. 2007). These species are able to persist on 
inanimate surfaces for prolonged durations up to several months. Furthermore, the hospital 
environment provides a larger number of hosts that A. baumannii can infect. The moist 
conditions in hospitals, the room temperature together with the numerous devices it can 
contaminate, all provide ideal environments for A. baumannii to survive and disseminate.  
 
1.5 Clinical manifestations of A. baumannii infections 
A. baumannii infections are associated with increased morbidity and mortality as well as 
prolonged hospital stay (Metan et al., 2009). However the mechanisms of virulence of A. 
baumannii are unclear (Gordon & Wareham, 2010). Biofilm formation is an important 
feature of A. baumannii as it readily adheres to inanimate surfaces and hence facilitate 
colonization and infection in the hospital setting (Gordon & Wareham, 2010; Peleg et al. 
2008). Biofilms are difficult to get rid of as they are highly dense colonies of A. baumannii 
and exhibit high levels of resistance to disinfectants. Their persistence on inanimate surfaces 







1.5.1 A. baumannii in nosocomial infections  
Patients at risk of developing A. baumannii infections are those with immunosuppression, 
prolonged hospitalization and critically ill patients in Intensive Care Units (ICUs) 
(Dijkshoorn et al. 2007). Nosocomial infections caused by A. baumannii include: pneumonia, 
bloodstream infections, skin and soft tissue infections, wound infections, urinary-tract 
infections (UTI) and, rarely, gastrointestinal tract (GIT) infections (Zarrilli et al., 2009).  
 
1.5.1.1 Hospital acquired pneumonia 
Pneumonia, mainly ventilator-acquired pneumonia (VAP), is the most commonly identified 
clinical manifestation of A. baumannii (Dijkshoorn et al. 2007; Peleg et al. 2008). This could 
be attributed to the colonization of airways by A. baumannii which soon develop into true 
pneumonia upon prolonged hospital admission and extensive administration of antibiotics. 
Furthermore, data from the National Nosocomial Infections Surveillance (NNIS) System in 
USA show that ICU VAP rates due to A. baumannii reached 7% in 2003 (Falagas & 
Kopterides, 2006). A recent study by Lee et al. (2012) was aimed to study the different 
clinical manifestations associated with A. baumannii  vs A. nosocomialis in pneumonia and 
revealed that A. baumannii pneumonias seem to be more severe and more likely to have 
associated abnormal haematological findings. The higher resistance rates observed in A. 
baumannii resulted in administration of inappropriate therapy as well as a higher mortality 






1.5.1.2 Blood stream infections and sepsis 
Bloodstream infections, particularly sepsis, is common in A. baumannii infections worldwide 
(Dijkshoorn et al., 2007; El-Mahallawy et al., 2005; Munford, 2006). In the USA, A. 
baumannii was found as the 10
th
 most common aetiologic agent in nosocomial blood-stream 
infections (reviewed by Peleg et al. 2008). A. baumannii bacteraemia can be secondary to 
pneumonia, and can also result from central-venous line catheters, which act as a main route 
for dissemination of organisms into the blood stream (Simon et al. 2000). In a study 
performed on paediatric cancer patients in Cairo in 1999, Acinetobacter accounted for 6.7% 
of the total bloodstream infections in one centre (El-Mahallawy et al. 2005).  
 
1.5.1.3 Skin and soft tissue infections 
Skin, soft-tissue and wound infections caused by A. baumannii are increasingly reported and 
highlight the importance of environmental contamination in causing infections. Most reports 
are from wounded military personnel, as well as in burn patients (Adams-Haduch et al., 
2008; Hujer et al., 2006). Twenty-three soldiers wounded in the Iraq war of 2003 had 
A. baumannii-A. calcoaceticus wound infections, presented by different manifestations such 
as osteomyelitis, deep wound infections and burn infections (Davis et al., 2005; Hujer et al., 
2006). Such infections are not associated with high mortality rates but may be a source of 
bacteraemia and sepsis if inappropriate therapy is given. 
 
1.5.1.4 Other manifestations 
A. baumannii infections have also been reported in causing urinary tract infections (UTI) 
commonly associated with urinary catheters, as well as meningitis particularly with the 
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presence of an external ventricular drain (reviewed by Peleg et al. 2008). These infections 
represent less common clinical manifestations and occur due to the presence of external 
catheter-devices which in turn can be infected by contaminated hospital environments as well 
as by hospital personnel. Furthermore, air-borne transmission of bacteria plays a role in 
colonizing external catheters and hence providea a way of infections, particularly if the 
catheter is not sealed properly. Contaminated hands of the patients themselves or by their 
carers during the routine cleaning of the area around the catheter is also an important route of 
transmission.   
  
1.5.2 Risk factors for developing A. baumannii infections 
There are certain risk factors that predispose patients for infection with A. baumannii. These 
risk factors can occur simultaneously or separately, but contribute significantly to the 
morbidity and mortality observed with A. baumannii infections. Those include: surgery, 
trauma, underlying malignancy, previous administration of broad-spectrum antibiotics, 
previous admission to the ICU, exposure to contaminated equipment, mechanical ventilation, 
invasive procedures and presence of indwelling devices such as catheters (Falagas & 
Kopterides, 2006; Dijkshoorn et al. 2007; Giamarellou et al. 2008). Co-morbidities are 
associated with more severe A. baumannii infections that lead to unfavourable outcomes. It is 
however debatable whether mortality is due to the A. baumannii infection or is caused by the 
underlying co-morbidity. In a study by Turkoglu et al. (2011), A. baumannii was investigated 
in critically ill patients with haematological malignancies and despite the high rate of 
mortality in A. baumannii infections, it was not an independent risk factor for mortality. A. 
baumannii infections contributed, however, to longer ICU admission and prolonged duration 
of mechanical ventilation (Turkoglu et al. 2011). 
10 
 
1.5.3 Cancer-related infections 
Infections in cancer patients are a common complication due to the immunoablative therapy 
as well as underlying illness (Santolaya et al., 2001). Febrile neutropaenia is a common 
medical emergency in cancer patients where fever is defined as a single oral temperature of 
38.5° or greater, or two consecutive readings of 38.0° an hour apart, with neutropaenia 




 with an expected 
decline (Meckler & Lindemulder, 2009). Approximately 60% of febrile and neutropaenia 
episodes are caused by bacterial infections, and require the immediate administration of 
broad-spectrum antibiotics (Klastersky et al., 2011). The epidemiology of pathogens, 
however, differs from one geographical region to another and also from one centre to another. 
Data from the USA show a predominance of Gram-positive pathogens, whereas in Taiwan 
Gram-negative pathogens predominate (Chen et al., 2010). Data from Egypt also show a 
higher incidence of Gram-positive infections in paediatric cancer patients, but resistance to 
the first-line antibiotics such as amikacin and ceftazidime was much higher in Gram-negative 
pathogens; in addition to 50% of Gram-negative pathogens being resistant to the second-line 
antibiotic Imipenem (El-Mahallawy et al. 2005).  
Bloodstream infections and central venous line infections are most commonly identified in 
paediatric cancer patients, particularly with haematological malignancies (Simon et al., 
2008). In a study performed by Turkoglu et al. (2011) which investigated the characteristics 
of A. baumannii infections in patients with haematological malignancies, pneumonia was 
found as the most common infection site, with a higher mortality rate in patients with A. 
baumannii. The risk factors identified were similar to other clinical A. baumannii infections 
including ICU admission, prolonged hospitalization, presence of indwelling catheter devices, 
prior antibiotic therapy, underlying malignancy, intensified chemotherapy, neutropaenia, and 
immunosuppressive state (Santolaya et al., 2001; Turkoglu et al., 2011).  
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The rise in antibiotic resistance is alarming in cancer patients, and has been attributed to the 
frequent antibiotic administration and the use of broad-spectrum antibiotics not only as 
treatment, but also as prophylaxis therapy (Saghir et al., 2009). Monitoring of the 
susceptibility and cycling of the first-line antibiotics is therefore recommended in many 
cancer centres, and most importantly complying with the guidelines of antimicrobial use. The 
National Comprehensive Cancer Network (NCCN) have developed guidelines for the 
prevention and treatment of cancer-related infections, but individual centres should routinely 
monitor their antibiogram and prescribe antibiotics accordingly (NCCN Prevention and 
Treatment of Cancer-Related Infections, 2012).  
 
1.5.4 A. baumannii in community-acquired infections 
A. baumannii is rarely identified in community-acquired infections mainly due to its 
prevalence in the hospital setting. Reports have included community acquired pneumonia in 
patients with previous alcohol abuse with a mortality rate up to 60%. The source of the 
infection was attributed to throat carriage by individuals with excessive alcohol consumption  
(Anstey et al., 2002; Falagas et al., 2007). Community acquired Acinetobacter infections 
have been reported in tropical and sub-tropical regions and is commonly associated with a co-
morbidity, such as chronic obstructive pulmonary disease, renal disease, diabetes and heavy 
smoking (Falagas et al., 2007). 
 
1.5.5 Pathogenicity and virulence mechanisms of A. baumannii 
Limited data is available on the pathogenicity and virulence mechanisms of A. baumannii; 
however, colonization with A. baumannii is more frequent than infection, which indicates a 
12 
 
relatively low pathogenicity when compared with other Gram-negative organisms 
(Dijkshoorn et al. 2007). Sixteen genomic islands carrying putative virulence genes 
associated with cell-envelope and biogenesis, lipid metabolism,  iron uptake and metabolism, 
quorum sensing and a type IV secretion system as have been identified (reviewed by 
Dijkshoorn et al. 2007; Gordon & Wareham, 2010). The ability of A. baumannii to adhere to 
biotic and abiotic surfaces allow formation of biofilms, which are mediated by pili. Pili 
thereafter interact with human epithelial cells and production of lipopolysaccharide (LPS) 
promotes adherence to the host cells (reviewed by Dijkshoorn et al. 2007; Gordon & 
Wareham, 2010). LPS also acts as an immunostimulatory factor leading to pro-inflammatory 
responses in A. baumannii infections (reviewed by Dijkshoorn et al. 2007). 
Figure 1 gives a clear and detailed representation of the factors contributing to A. baumannii 
infections.  Resistance to the bactericidal activity of the human serum is crucial for survival 
in the human host; in addition to quorum sensing and its role in biofilm formation. This 
consequently shows the ability of A. baumannii to survive and adapt to diverse environments, 




Figure 1: Factors contributing to Acinetobacter baumannii colonization and infection. 




Iron uptake is an important mechanism in A. baumannii infections. The ability of A. 
baumannii to obtain and utilise iron has contributed to its ability to survive both in the host 
and in the environment, which is mediated by the secretion of a variety of molecules involved 
in iron acquisition, including the siderophore acinetobactin, and also the production of a 
haemin utilisation system (Gordon & Wareham, 2010; Vallenet et al., 2008).  
Reduction in free extracellular iron concentrations by iron-binding proteins is one of the host 
defence mechanisms in response to bacterial infections (Vallenet et al., 2008). With the use 
of siderophores, A. baumannii is able to overcome this iron starvation by binding to host iron- 
binding proteins (reviewed by Dijkshoorn et al. 2007; Gordon & Wareham, 2010; Vallenet et 
al., 2008).  
Vallenet et al. (2008) studied the genomes of three Acinetobacter isolates: A. baumannii 
AYE, a multi-drug resistant strain involved in outbreaks in France (Fournier et al., 2006), A. 
baumannii SDF, a susceptible strain isolated from human body louse (La Scola & Raoult, 
2004) and A. baylyi, an environmental soil organism. Differences in the presence of 
pathogenicity genes revealed the different environmental conditions to which each bacterium 
is exposed. Strain AYE has the highest catabolic capacities, which are useful in surviving the 
nosocomial environments. Interestingly, siderophores were not identified in SDF indicating 
its ability to use haemoglobin as a source of iron. This could be due to the fact that SDF is in 
frequent contact with the gut of haematophage organisms and hence blood cells (Vallenet et 






1.5.6 Recommended treatment of A. baumannii infections 
The resistance patterns observed for A. baumannii in the clinical setting is leaving very few 
treatment options. Combination therapy is relied on in many centres to treat MDR strains of 
A. baumannii, where a significant synergy is observed in vitro. Combination therapy relies on 
an aminoglycoside with a 3
rd
 generation cephalosporin, or colistin combined with rifampicin, 
ceftazidime or imipenem (Dijkshoorn et al., 2007; Gordon & Wareham, 2010). Combination 
therapy aims to prevent the emergence of resistance when using two different compounds, as 
well as provide coverage of a broad spectrum of pathogens in the case of mixed or 
unidentified infections (Legrand et al., 2011; reviewed by Peleg et al., 2008). Most 
importantly, antibiotic selection should rely on the susceptibility data of individual 
institutions (Peleg et al. 2008). Due to A. baumannii being inherently resistant to many 
antibiotics, carbapenems are the ideal drugs in treating A. baumannii infections, but 
resistance is emerging very rapidly, leaving few available treatment options (Knapp & 
English, 2001). Fluoroquinolones were used to treat sporadic cases of A. baumannii, but 
resistance is now widespread in endemic strains (reviwed by Dijkshoorn et al., 2007; Legrand 
et al., 2011). The use of polymyxins and tigecycline has emerged in recent years to overcome 
carbapenem and multi-drug resistance, and have proven success in treating severe A. 
baumannii infections (Dijkshoorn et al., 2007; Gordon & Wareham, 2010). Resistance is still 
relatively rare for these compounds; however the use must be closely monitored in order to 
monitor the emergence of resistance. The use of tigecycline for bloodstream infections is 
debatable as it is most effective in treating skin and soft-tissue infections, and its enhanced 
tissue penetration leads to serum concentrations below the pharmacodynamic breakpoint, 
resulting in recurrent bacteraemia and even aid in the emergence of resistance (Gordon & 
Wareham, 2009). Colistin (polymyxin E) has proven clinical efficacy in treating carbapenem 
and multi-drug resistant strains of A. baumannii, but the main issues of concern are 
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nephrotoxicity and heteroresistance (Perez et al. 2007; Peleg et al. 2008). Interestingly, 
colistin is combined with rifampicin or a carbapenem in treating  metallo-β-lactamase 
producing A. baumannii (Legrand et al. 2011). Colistin is not available in most Egyptian 
hospitals and must be ordered from other countries to treat severe cases. Unfortunately, most 
Egyptian governmental hospitals lack the appropriate surveillance and monitoring of 
antibacterial consumption, so we are unable to get a clear indication of the most commonly 
used compounds.  
Cancer patients are usually under prolonged antibiotic therapies due to neutropaenia. 
Antimicrobial therapy, and particularly carbapenems, may be administered for up to 10 days 
in a proven A. baumannii infection, and this increases the risk of development of resistance 
(Owens, 2008). This is why the resistance pattern is high in cancer centres, reaching up to 
50% in some cases (Saghir et al., 2009; El-Mahallawy et al., 2005; Neuburger & 
Maschmeyer, 2006; Zarrilli et al.,  2009). Persistent neutropaenia with clinical deterioration 
also requires antibiotic administration up to two weeks (Legrand et al., 2011). The guidelines 
published by the National Comprehensive Cancer Network (NCCN) strongly recommends 
close monitoring of resistance patterns of pathogens, as well as consider prophylactic 
antimicrobial therapy only in patients at a high risk of developing an infection, and not for all 
patients, in order to prevent the emergence of resistance (NCCN: Prevention and Treatment 
of Cancer-Related Infections V1.2012). Furthermore, it is recommended to use carbapenems 
as a second-line of treatment, to prevent the emergence of resistance (Knapp & English, 
2001). The strategy of antibiotic usage in neutropenic patients is that it should start 
immediately with the onset of febrile neutropaenia and first-line antibiotics should cover the 
most probable pathogens, based on the local epidemiology and patient history (Legrand et al., 
2011). Patient history is particularly important because the carriage of MDR strains may last 
several weeks or months, and may be latent until neutropaenia.  
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There is an urgent need for the development of novel antibacterial agents to combat the MDR 
organisms in the healthcare setting. However the pharmaceutical industry has reduced 
antibacterial drug development programs due to the low profit margins, and the current 
‘novel’ antibacterials are merely a modification of already existing compounds (Rolston, 
2009; Chopra et al. 2010). Doripenem, for example, is the latest carbapenem approved for 
clinical usage, but its activity is very similar to imipenem and meropenem (Rolston, 2009). 
Chopra et al., (2010) tested 1040 FDA approved drugs against a susceptible (ATCC 17978) 
and a resistant (BAA 1605) A. baumannii strains. Only 20 exhibited significant antimicrobial 
activity, and of these, only five compounds were active against the resistant strain, showing 
that even the susceptible strain (ATCC 17978) is naturally resistant to many classes of 
antibiotics.  
 
1.6 Mechanisms of Antibiotic Resistance 
A. baumannii is rapidly developing as a multi-drug resistance pathogen with the ability of 
acquiring and upregulating resistance mechanisms. All major resistance mechanisms reported 
in Gram-negative bacteria have been identified in A. baumannii such as modifications of 
target site, active efflux pumps, enzymatic deactivation of drugs and decreased influx 
(reviewed by Gordon & Wareham, 2010; Hawkey, 1998; McGowan, 2006). This has 
rendered all current major antibacterial agents such as penicillins, cephalosporins, 
aminoglycosides and quinolones as inefficient treatment options for A. baumannii infections, 
which can also partially be attributed to the intrinsic resistance that the organism harbours 
towards these classes of antibiotics (Dijkshoorn et al. 2007). Carbapenems have been the 




Hancock (1998) suggested three classes of antibiotic resistance: Intrinsic resistance 
comprising mechanisms present in the species, irrespective of antibiotic exposure; acquired 
resistance comprising the induction of foreign resistance determinants but without change to 
the strain’s genotype, and includes reversion to full susceptibility once the inducing 
conditions are removed; and lastly genetic resistance comprising the stable acquisition of 
novel resistance mechanisms as genetic material incorporated into the genome, which can 
occur by mutation of an existing gene or the acquisition of a foreign plasmid.  
Recent research suggests that the observed increase in resistance can be attributed to the 
interplay of several resistance mechanisms: enzymatic and non-enzymatic, such as the 
decreased influx together with the expression of a resistance gene (Poirel & Nordmann, 2006; 
Poirel et al., 2012).  
 
1.6.1 Non-enzymatic mechanisms  
1.6.1.1 The role of penicillin-binding proteins (PBPs) and outer-membrane proteins (OMP) 
The role of PBPs in conferring antibiotic resistance in A. baumannii has been poorly 
investigated, but the reduced expression of PBPs has been reported to contribute to 
carbapenem resistance in isolates from Spain (Bou et al., 2000; Giamarellou et al., 2008). 
Another study found that the modification of PBPs was a source of imipenem resistance 
(Poirel & Nordmann, 2006).  
Porin loss has been found to significantly contribute to resistance to carbapenems (reviewed 
by Dijkshoorn et al.,  2007; Giamarellou et al.,  2008). The loss of 22 and 33 kDa and OMPs 
together with the expression of an acquired β-lactamase resulted in carbapenem resistance 
(Bou et al., 2000). CarO is an important OMP in the influx of carbapenems in A. baumannii, 
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and studies have shown that the disruption of carO by insertion elements contributes to 
carbapenem resistance in clinical isolates (Poirel & Nordmann, 2006).  
 
1.6.1.2 The role of efflux pumps  
Strain AYE, an epidemic multi-drug resistant A. baumannii strain was sequenced and the 
genome was found to encode several multi-drug efflux system (Fournier et al., 2006). 
AdeABC is best characterized efflux pump in A. baumannii (reviewed by Peleg et al. 2008; 
Giamarellou et al. 2008). It contains a three-component structure: AdeB forming the 
transmembrane component, AdeA forming the inner membrane fusion protein and AdeC 
forming the outer-membrane protein (reviewed by Peleg et al. 2008). It is also widely 
distributed in A. baumannii isolates and is chromosomally encoded (Dijkshoorn et al. 2007; 
Peleg et al. 2008). Interestingly, AdeABC acts against virtually all classes of antibiotics 
including carbapenems (Giamarellou et al. 2008; Nikaido 1998).  
Tetracycline resistance is also mediated by transposon-mediated tetracycline-specific efflux 
pumps encoded by tetA and tetB, as well as ribosomal protection protein encoded by tetM, 
serving to protect the ribosome from the action of tetracycline (Giamarellou et al. 2008; 
Peleg et al. 2008; Perez et al. 2007).  
 
1.6.1.3 The role of target site modifications 
Target site modifications in A. baumannii seem to confer resistance to quinolones and 
aminoglycosides. Topoisomerase IV is the target of quinolones, and mutations at Ser80 and 
Glu84 of ParC subunit, combined with mutations at Ser83 of gyrA subunit contribute 
significantly to quinolone resistance (Dijkshoorn et al., 2007; Vila et al., 1997). 
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Aminoglycosides, on the other hand, bind to a highly conserved motif of 16s rRNA subunit, 
and methylation of armA prevents the antibiotic from binding to its target site, rendering the 
isolate resistant to aminoglycosides (Dijkshoorn et al., 2007; Lee et al., 2006; Peleg et al., 
2008).  
 
1.6.2 Enzymatic mechanisms of resistance 
1.6.2.1 Aminoglycoside resistance 
Aminoglycoside resistance is mediated by the AdeABC efflux pump as well as 
aminoglycoside modifying enzymes: phosphotransferases, acetyltransferases and 
nucleotidultransferases, with some strains containing multiple enzymes simultaneously 
belonging to the different classes (Perez et al., 2007; Seward et al., 1998). Target site 
modification of armA is also responsible for aminoglycoside resistance, as described 
previously. Genes encoding aminoglycoside-modifying enzymes can be located on plasmids 
and transposons, and some have been identified on class-1 integrons (Nemec et al., 2004). 
Seward et al. (1998) investigated 24 clinical Acinetobacter spp isolates from 11 countries and 
found that similar aminoglycoside modifying enzymes are present in unrelated isolates and 
the genes are not restricted to specific geographical areas. The location of these genes on 
mobile genetic elements such as plasmids and integrons contribute significantly to the wide 
dissemination of these genes around the world.  
 
1.6.2.2 β-lactam resistance 
β-lactam antibiotics are widely used in the hospital setting and comprise the penicillins, 
cephalosporins, monobactams and carbapenems. Their high efficacy and safety in clinical use 
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has increased the usage and consecutively resulted in emergence of resistance to β-lactam 
antibiotics (Livermore & Woodford, 2006). The main mechanism of resistance to β-lactam 
antibiotics is the production of β-lactamases, in addition to the non-enzymatic mechanisms 
previously mentioned such as target site alteration, changes in PBPs and efflux.  There are 
four classes of β-lactamases described in A. baumannii (reviewed by Dijkshoorn et al., 2007). 
The spread of β-lactamases correlates with the usage and development of β-lactam 
antibiotics. Benzylpenicillin, was the first β-lactam antibiotic but had poor penetration 
activity towards Gram-negative bacteria. The development of semi-synthetic penicillins was 
compromised by the spread of penicillinases among Gram-negative bacteria (Livermore & 
Woodford, 2006; Nordmann & Poirel, 2008). This was overcome by the development of 
third- and fourth- generation cephalosporins as well as β-lactamases inhibitors. The wide 
success of these compounds worldwide led to extensive usage in the clinical setting and 
subsequently resulted in emergence of resistance. Carbapenems, the last development of β-
lactam antibiotics are now the ‘drug of choice’ for many serious and multi-drug resistant 
infections, but we are entering an era of resistance to carbapenems, no newly developed 
compounds, which will ultimately result in untreatable infections (Livermore & Woodford, 
2006). 
 
1.6.2.2.1 Class A β-lactamases 
Class A β-lactamases are extended-spectrum β-lactamases (ESBLs) primarily responsible for 
resistance to broad-spectrum cephalosporins. The first class A β-lactamases was found in an 
E. coli isolate in 1965 and designated as blaTEM  (reviewed by Turner, 2005).  The majority of 
ESBLs contain a serine at their active site and inhibited by clavulanic acid (Bush, 2001; 
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Bradford, 2001). They are more commonly identified in Enterobacteriaceae, but reports in A. 
baumannii are increasing around the world.  
 
1.6.2.2.1.1 TEM-like β-lactamases 
TEM-like enzymes were the first described and now the most commonly identified β-
lactamases (reviewed by Bradford, 2001). The early enzymes, TEM-1 and TEM-2, were 
plasmid-mediated and had a spectrum limited to aminopenicillin resistance together with 
early-cephalosporin resistance (Naas et al., 2008; Turner, 2005). The TEM-3 β-lactamase 
reported in 1987 was the first TEM-like enzyme to display ESBL properties (reviewed by 
Bradford, 2001). 
TEM-92 and -166 are ESBLs identified in clinical A. baumannii isolates from Italy and the 
Netherlands (reviewed by Peleg et al. 2008). All Enzymes displaying ESBL phenotypes are 
TEM-1 and -2 derivatives, with mutations occurring in the active site, causing an 
enlargement thereby allowing the attack of the β-lactam ring (Livermore & Woodford, 2006; 
Poirel et al., 2012).  
 
1.6.2.2.1.2 SHV-like β-lactamases 
SHV-type β-lactamases are also narrow-spectrum predominantly present in 
Enterobacteriaceae, and can be both plasmid and chromosomally located (reviewed by 
Bradford, 2001; Poirel et al., 2012). There are slightly fewer derivatives of SHV-like variants 
than there are in the TEM enzymes  (http://www.lahey.org/Studies/ last accessed 5 December 
2012). SHV-like variants displaying ESBL phenotypes are SHV-2, SHV-5 and SHV-12 and 
have been reported worldwide (reviewed by Poirel et al., 2012).  
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SHV-like enzymes are rarely reported in clinical A. baumannii isolates, but included reports 
from China and the Netherlands of A. baumannii isolates producing SHV-12 (reviewed by 
Perez et al. 2007).  
 
1.6.2.2.1.3 CTX-M-like β-lactamases 
CTX-M (CefoTaXiMease) enzymes were initially characterized in a clinical E. coli isolate in 
1989 (Bauernfeind et al., 1990). CTX-M –type β-lactamases are extended-spectrum β-
lactamases conferring resistance to penicillins and extended-spectrum cephalosporins, and 
they are plasmid mediated which largely facilitates the worldwide spread of these β-
lactamases (reviewed by Poirel et al., 2012). CTX-M enzymes can be classified into five 
clusters according to their amino acid sequences, with the main cluster implicated in 
Enterobacteriaceae clinical infections identified as the CTX-M-1 (Bonnet, 2004; Perez et al., 
2007; Poirel et al., 2012). CTX-M-15, CTX-M-3 and CTX-M-1 enzymes are among the 
variants belonging to CTX-M-1 cluster and are prevalent in different regions of the world 
such as Europe, India and the Middle East (reviewed by Livermore & Woodford, 2006; 
Poirel et al., 2012). However, although CTX-M enzymes are not commonly identified in A. 
baumannii, CTX-M enzymes belonging to cluster 2 have been reported in A. baumannii. 
CTX-M-2 carrying A. baumannii has been identified in a neurosurgery ward outbreak in 
Japan (Nagano et al., 2004). Furthermore, reports from Bolivia and Pennsylvania have also 
detected A. baumannii producing CTX-M-2 and CTX-M-43, also a member of CTX-M-2 






1.6.2.2.1.3 GES-like β-lactamases 
GES-like enzymes are extended-spectrum β-lactamases which can be either plasmid or 
chromosomally located (Bonnin et al., 2011; Poirel et al., 2012). blaGES-1 was initially 
identified in Klebsiella pneumoniae in France (Poirel et al., 2000). In A. baumannii GES-11, 
GES-12 and GES-14 have been identified in Belgium and France, where the patients had 
originated from Egypt, Palestine and Turkey (Bogaerts et al., 2010; Bonnin et al., 2011; 
Moubareck et al., 2009). This indicates the worldwide dissemination of blaGES in different 
parts of the world. Interestingly, GES-14 possesses an amino acid change at position 170 
(Gly170Ser) which contributes to extending the hydrolysis spectrum to include carbapenems 
(Bogaerts et al., 2010; Poirel et al., 2012). GES-14 has been identified in France, Belgium 
and Turkey which raises a threat of the dissemination of this gene which could contribute to 
carbapenem resistance worldwide (Bogaerts et al., 2010; Bonnin et al., 2011).  
 
1.6.2.2.1.4 VEB-like β-lactamases 
VEB-like β-lactamases are distantly related to other ESBLs but confer high resistance to 
extended-spectrum cephalosporins in Enterobacteriacea and Pseudomonas aeruginosa 
worldwide, including Europe, Thailand and Kuwait (reviewed by Poirel et al., 2012). VEB-1 
was identified in P. aeruginosa in South East Asia as part of gene cassette located in a class 1 
integron on the chromosome (Poirel et al., 2003).  
VEB-1 was identified in clinical isolates of A. baumannii involved in nosocomial outbreaks 
in France, Belgium and Argentina (Carbonne et al., 2005; Naas et al., 2006; Pasterán et al., 
2006). One strain in France was responsible for a nation-wide outbreak in 2003-2004 and 
belonged to Worldwide clone 1 (WW1) (Naas et al., 2006; Poirel et al., 2012). The outbreak 
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in Belgium was reported in hospitals located close to the French border and typing by pulsed-
field gel electrophoresis and integron analysis revealed that the strains in Belgium were 
clonally related to those identified in the French epidemic (Naas et al., 2006). 
 
1.6.2.2.1.4 PER-like β-lactamases 
PER-like enzymes are widespread in P. aeruginosa, from which they get their name: P. 
aeruginosa extended resistance, and were initially described in 1993 from a Turkish patient 
in France (Poirel et al., 2005). blaPER-1 is commonly identified in A. baumannii isolates in 
Turkey, where it was reported to be present in 32% of ceftazidime resistant A. baumannii 
nosocomial infections (Kolayli et al., 2005). Furthermore, PER-1 has been reported in 
France, Belgium, Japan and Russia (Bonnin et al., 2011; Poirel et al., 2005).  
PER-like variants are distinguished in two groups: point-mutant derivatives of PER-1 (PER-
3, PER-4, PER-5 and PER-7), and PER-2 and PER-6 sharing 85% amino acid homology to 
PER-1.  
PER-2 has been reported primarily in South America (Poirel et al., 2012), whereas PER-3 has 
been reported in Taiwan and France in Aeromonas punctata (Wu et al. 2011). PER-3 has also 
recently been identified in a clinical A. baumannii isolate in Egypt (Al-Hassan et al., 2012). 
Localization of PER-3 can be either plasmid or chromosomal in A. punctata, but found to be 
chromosomally located in A. baumannii (Al-Hassan et al. 2012) 
PER-7 contains four amino acid substitutions compared with PER-1  and has been detected in 
clinical A. baumannii isolates from the United Arab Emirates (UAE), France and recently 
Egypt (Bonnin et al., 2011; Opazo et al., 2012a; Al-Hassan et al., 2012). The localization of 
PER-7 differed between the two geographical locations, with the French isolate harbouring a 
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chromosomal copy of blaPER-7, whereas the isolate from UAE harboured a plasmid containing 
blaPER-7; the genetic environment of both isolates were however identical (Bonnin et al., 
2011; Opazo et al., 2012).  
 
1.6.2.2.1.4 Other class-A β-lactamases and secondary ESBLs  
ESBLs rarely reported and which are confined to certain geographical areas are referred to as 
secondary ESBLs, as their clinical significance is not well studied yet and include: blaBEL-like, 
blaBES-like, blaSFO-1, blaTLA-like and blaPME-like genes (reviewed by Poirel et al., 2012). They 
have been reported in Belgium, Brazil, Spain and Japan, Mexico and the USA, respectively, 
in different species such as P. aeruginosa, S.marcescens and E. cloacae but have not been 
characterized in A. baumannii (Poirel et al., 2012).  
 
1.6.2.2.2 Class B β-lactamases 
Class B β-lactamases are also known as metallo-β-lactamases (MBLs) due to the presence of 
zinc in the active site (Walsh, 2005). MBLs are particularly worrisome in the clinical setting 
due to their broad range, potent carbapenemase activity, and resistance to β-lactamase 
inhibitors. This is in addition to the frequent localization on mobile genetic elements, 
integrons and plasmids thereby facilitating spread (Cornaglia et al., 2011; Walsh et al., 2005). 
MBLs were initially discovered in the 1960s, but only gained interest in the clinical setting 
after its identification in Japan and the dissemination of MBL genes in the clinical setting 
(Cornaglia et al., 2011; Osano et al., 1994).  
MBLs are classified in three structural classes according to the structure of their active site, 
where classes B1 and B3 contain two zinc ions and possess larger substrate specificity, in 
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contrast to class B2 with only one zinc ion (Cornaglia et al., 2011). Most important and 
clinically relevant acquired MBLs belong to class B1, such as IMP-type, VIM-type, SPM-
type and NDM-type (Cornaglia et al., 2011; Walsh et al., 2005). As seen in figure 2, there is 
a worldwide distribution of MBLs. blaIMP discovered in the late 1980s was localized in 
isolates from Asia, but later disseminated to other parts of the world. blaNDM although being 
the most recently characterized MBL in 2009 in India, has also been found in several 
continents, including North America and Australia.  
 
 
Figure 2: The worldwide distribution of metallo-β-lactamases (Taken from Cornaglia et 
al., 2011). 
 
MBLs are often present in P. aeruginosa isolates and are not predominant in A. baumannii, 
but their potential spread by horizontal gene transfer can lead to a serious problem in A. 
baumannii due to their carbapenemase activity (Perez et al., 2007; Cornaglia et al., 2011). 
Reports of MBL-producing A. baumannii have been from East-Asia, Taiwan, Korea, China, 
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Italy, and Greece, UAE, Israel, Germany and Egypt (Tsakris et al. 2006; Riccio et al. 2000; 
Cornaglia et al. 2011).  
 
1.6.2.2.2.1 IMP-type β-lactamases 
IMP-1 enzyme was first reported in Japan in 1988 in a clinical isolate of  P. aeruginosa 
(Osano et al.,1994; Walsh, 2005). IMP-1 was limited to reports from Japan in different 
Gram-negative organisms such as P. aeruginosa and K. pneumonia (Riccio et al. 2000). A 
review by Walsh (2005) stated that Japan was a major reservoir for IMP-type MBLs 
including IMP-1, -2, -3, -6, -10 and -11, which have occurred in Pseudomonas sp., 
Acinetobacter sp., and Enterobacteriaceae. So far 38 IMP β-lactamases have been identified 
(http://www.lahey.org/Studies/ last accessed 5 December 2012). 
In A. baumannii IMP-1, was characterized in isolates from Korea and Japan, and allelic 
variants including IMP-2, IMP-4, IMP-5, IMP-6 and IMP-11 have also been reported in 
clinical A. baumannii isolates from Italy, Japan, Hong Kong, Portugal and Brazil (Chu et al., 
2001; Jones et al., 2004; Riccio et al., 2000). IMP-like genes have been found on class 1 
integrons, which categorizes it as a transferable MBL (Walsh et al., 2005).  
 
1.6.2.2.2.2 VIM-type β-lactamases 
blaVIM-type MBL is also referred to as the ‘European MBL’ and is the second dominant group 
of MBL after IMP-type, with 34 known derivatives currently characterized 
(http://www.lahey.org/Studies/ last accessed 5 December 2012). VIM-1 was first reported in 
1997 in a P. aeruginosa isolate from Italy, and characterized in 2006 in five A. baumannii 
isolates from Greece (Tsakris et al. 2006). We currently have reports of five VIM-type 
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variants in A. baumannii: VIM-1, -2, -3, -4, and -11 from Greece, Taiwan and Korea 
(Cornaglia et al., 2011; Lee et al., 2008; Lin et al., 2010). In the Greek study in 2006, the five 
A. baumannii isolates harbouring VIM-1 belonged to four distinct groups and were not 
related by PFGE, indicating the dissemination of the gene in different clones (Tsakris et al. 
2006).  
In a study performed in Taiwan on 260 non-duplicate Gram-negative organisms, 78 A. 
baumannii isolates were found to harbour three VIM-type genes: blaVIM-2, blaVIM-3 and 
blaVIM-11 (Lee et al., 2008).  Furthermore, VIM-2 has also been identified in Acinetobacter 
14TU in Germany (Tsakris et al. 2006).  
 
1.6.2.2.2.3 SIM-type β-lactamases 
blaSIM-1 has been identified as a novel MBL in 2005 in Seoul, Korea (Lee et al., 2005). The 
study was performed to assess the prevalence of MBLs in P. aeruginosa and A. baumannii in 
a tertiary-care hospital in Seoul and identified seven A. baumannii isolates harbouring a novel 
MBL gene (Lee et al., 2005). The gene was chromosomally located and carried on a class 1 
integron, the PFGE results showed that the isolates belonged to two different clonal lineages 
(Lee et al., 2005; Perez et al., 2007). Furthermore, SIM-1 was found to share 69% similarity 
with IMP-12 and 64% similarity with IMP-9 (reviewed by Perez et al. 2007). 
 
1.6.2.2.1.4 NDM-type β-lactamases 
blaNDM is the newest MBL characterized from a Swedish patient of Indian origin, who after a 
trip to New Delhi, India acquired a carbapenem-resistant K. pneumonia harbouring a novel 
MBL designated NDM-1; an E. coli  isolate from the same patient’s faeces was found to 
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harbour a 140kb plasmid containing blaNDM, highlighting the possibility of in-vitro 
conjugation (Yong et al., 2009). NDM-1 shares little identity with other MBLs, with most 
similarity to VIM-2 at 32.4% (Yong et al., 2009). Further reports from India have shown a 
high prevalence of NDM-1-producing Enterobacteriaceae (Kaase et al., 2011; Karthikeyan et 
al., 2010). 
A. baumannii isolates producing NDM-1 were found in India, China and Germany (Chen et 
al., 2011; Karthikeyan et al., 2010; Pfeifer et al., 2011). NDM-2, with one amino acid 
substitution at position 28 (proline to alanine), was identified in an A. baumannii isolate from 
a patient transferred to Germany after an accident and hospitalization in Egypt (Kaase et al., 
2011). Reports from different regions of the Middle-East have emerged of NDM-2 producing 
A. baumannii, including Israel and the UAE (Espinal et al., 2011; Ghazawi et al., 2012).  
Isolates from the UAE were isolated, 4 months apart, from a cancer patient previously treated 
in Egypt, Lebanon and the UAE, so the origin of the isolate is difficult to determine, but 
shows a local emergence of NDM-1 in the Middle East (Ghazawi et al., 2012). A study on 
the dissemination of NDM-1 producing A. baumannii in Europe showed that the five isolates 
from Germany, France, Slovenia and Switzerland belonged to 3 pulsotypes, which indicates a 
spread of NDM-producing clones in Europe (Bonnin et al., 2012).  
 
1.6.2.2.3 Class C β-lactamases 
AmpC enzymes are widespread in Gram-negative bacteria, and are naturally occurring class 
C β-lactamases in A. baumannii, with a serine at its active site, similar to class A β-
lactamases (Jacoby, 2009). It is a chromosomally encoded cephalosporinase, also known as 
Acinetobacter-derived cephalospoinase (ADC), but its expression is very low and not 
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inducible except with the presence of an insertion sequence upstream (reviewed by Peleg et 
al., 2008). ISAba1 is commonly associated with the overexpression of blaADC, providing a 
strong promoter resulting in high-level ceftazidime resistance (Corvec et al., 2003; Héritier et 
al., 2006). ADC enzymes are also penicillinase, which are able to hydrolyse narrow and 
broad spectrum cephalosporins, but not carbapenems or cefepime (Giamarellou et al. 2008; 
Perez et al. 2007). Observed resistance to cephalosporins can therefore be mediated by both 
class A and class C β-lactamases.  
 
1.6.2.2.4 Class D β-lactamases 
Class-D β-lactamases are also known as oxacillinases (OXA-type β-lactamases) and also 
contain serine at its active site, similarly to class A and C β-lactamases  (Poirel et al., 2010). 
OXA-type β-lactamases have carbapenem-hydrolysing activity (CHDL), which is alarming in 
the clinical setting (Walther-Rasmussen & Høiby, 2006). Their hydrolytic efficiency against 
carbapenems is nonetheless much lower than that observed for MBL (Poirel & Nordmann, 
2006). The origin of OXA-type carbapenemases is unknown, but it is hypothesized that 
environmental bacteria carry these genes for protection against antibiotic-producing 
organisms in the soil, and the genes can then be transmitted via horizontal gene transfer to 
other bacteria (Walther-Rasmussen & Høiby, 2006). CHDL enzymes are widespread in A. 
baumannii being located on both the chromosome as well as acquired on foreign plasmids 
(Walther-Rasmussen & Høiby, 2006; Queenan & Bush, 2007). OXA-23, OXA-40, and OXA-
58 are commonly identified acquired CHDL associated with carbapenem resistance in A. 
baumannii, whereas OXA-51-like enzymes are naturally occurring (reviewed by Peleg et al., 




Figure 3: Distribution and relatedness of OXA-type carbapenemases in A. baumannii 
(Taken from Peleg et al., 2008) 
 
1.6.2.2.4.1 OXA-23 Enzymes 
OXA-23 was the first OXA-type carbapenemase identified in a strain from The Royal 
Infirmary of Edinburgh in 1985. The strain was resistant to all known antibiotics in addition 
to imipenem, which at the time, had not yet been used in the hospital (Paton et al., 1993). The 
‘Acinetobacter resistant to imipenem’, designated ARI-1 enzyme was demonstrated to be on 
a 40kb plasmid (Scaife et al., 1995), and was renamed OXA-23 after sequencing (Donald et 
al., 2000). It has been found in A. baumannii isolates causing outbreaks around the world 
(Paton et al., 1993; Queenan & Bush, 2007). The OXA-23 cluster, as seen in figure 3, 
comprises two other enzymes: OXA-27 and OXA-49 which differ to OXA-23 by two amino 
acid substitution each, and can be plasmid or chromosomally located (Walther-Rasmussen & 
Høiby, 2006; Queenan & Bush, 2007; reviewed by Peleg et al., 2008).  
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In an outbreak of carbapenem-resistant A. baumannii clones in London and Southeast 
England, two clones were identified circulating, both harbouring blaOXA-23 as the resistance 
determinant (Coelho et al., 2006). Military personnel from Iraq and Afghanistan were also 
infected and colonized with OXA-23 producing A. baumannii strains (Hujer et al., 2006). 
Other outbreaks have been reported from Korea, China, Singapore, South America, Europe 
and the Middle East (Gur et al., 2008; Jeon et al., 2005; Mugnier et al., 2008; Opazo et al., 
2012a; Opazo et al., 2012b; reviewed by Peleg et al., 2008; Zong et al., 2008).  
The genetic context of blaOXA-23 has been investigated and revealed transposons Tn2006, 
Tn2007 and Tn2008 to be the structures harbouring this gene (Mugnier et al., 2010). These 
transposons consist of either one or two copies of the insertion sequence (IS) ISAba1. Recent 
reports have found ISAba10 inserted into the ISAba1 element upstream of the blaOXA-23 gene, 
resulting in higher carbapenem MICs (Lee et al., 2011). The role of IS elements with CHDL 
will be discussed in later sections. 
The high incidence of blaOXA-23 around the world has led researchers to investigate the 
progenitor of the gene in different Acinetobacter sp strains (Poirel et al., 2008). Screening 50 
Acinetobacter sp strains for blaOXA-23 revealed that Acinetobacter radioresistens, a 
commensal organism, harboured a chromosomally located blaOXA-23, the gene which later 
disseminated to the opportunistic A. baumannii. A. radioresistens was however negative for 
IS elements which indicated that this organism does not serve as a reservoir to these IS 
elements involved in mobilization of the gene (Poirel et al., 2008). The dissemination of 
blaOXA-23 is uncertain, but has been proposed to have occurred by mobilization of the gene by 
a plasmid-mediated ISAba1 which in turn formed a transposon structure around blaOXA-23, 
transposed and targeted a plasmid in the A. radioresistens progenitor, and finally this plasmid 




1.6.2.2.4.2 OXA-40 Enzymes 
OXA-40, originally named OXA-24, was identified in a clinical A. baumannii isolate in 2000 
from Spain. The isolate was resistant to all β-lactams, with MICs of 128mg/L and 256mg/L 
for imipenem and meropenem, respectively  (Bou et al., 2000). OXA-40 shares 60% 
similarity with OXA -23, but is not as widely distributed as OXA-23 (reviewed by Peleg et 
al.2008; Zarrilli et al. 2009) .  
The OXA-40 cluster comprise OXA-25, OXA-26, OXA-40 and OXA-72, identified in Spain, 
Belgium, France and Thailand, respectively, sharing approximately 98% homology to OXA-
40, (Afzal-Shah et al., 2001; Poirel & Nordmann, 2006; Queenan & Bush, 2007; Walther-
Rasmussen & Høiby, 2006). OXA-160 has also recently been identified in Pennsylvania as a 
new variant of OXA-40 enzyme (Tian et al., 2011).  
OXA-40 seems to be repeatedly involved in outbreaks in Spain and Portugal, but the gene has 
also been identified in other parts of the world, such as China, South Korea, Taiwan, USA, 
Iran and Bahrain (Poirel et al., 2010). Figure 4 represents the distribution of the different 
OXA-type enzymes, and it is clear that reports of OXA-40 is less prevalent in carbapenem-




Figure 4: The geographical distribution of reports of carbapenem-resistant A. 
baumannii reports. OXA-23, OXA-40 and OXA-58 are indicated by the colours yellow, 
blue and red, respectively.  Green indicates countries reporting carbapenem-resistant A. 
baumannii outbreaks in which the OXA-type enzyme has not been identified (Taken 
from Zarrilli et al. 2009). 
 
The localization of blaOXA-40 can be both chromosomal or plasmid mediated and is not 
associated with any insertion sequences (reviewed by Peleg et al. 2008; Walther-Rasmussen 
& Høiby, 2006). In a large A. baumannii-calcoaceticus outbreak in Spain, plasmid mediated 
blaOXA-40/24 was identified as the source of carbapenem resistance (Merino et al., 2010). 
Sequencing of the plasmid harbouring the gene revealed the presence of site-specific 
recombination sites: XerC/XerD flanking blaOXA-24 suggesting its role in mobilization of the 
gene (Merino et al., 2010). The study, however, showed that there was no exchange of a 
common plasmid carrying blaOXA-40/24  during the outbreak, but that the different plasmids 
exchanged the blaOXA-40/24 gene, which was facilitated by the Xer recombination-site regions 
(Merino et al., 2010). This illustrates the different mechanisms of mobilization exhibited by 
the different OXA-type genes, and that the threat of carbapenem resistance is spreading to 
other Acinetobacter sp., including environmental species.  
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The hydrolytic activity of this enzyme against carbapenems seems to be moderate, as well as 
weak activity against cephalosporins, indicating that they these enzymes are unable to 
combine ESBL and carbapenem-hydrolysing properties (Bou et al., 2000; Héritier et al., 
2005; Poirel et al., 2010). The slow hydrolysis of carbapenems has led to speculation about 
the exact contribution of these enzymes in mediating carbapenem resistance in A. baumannii, 
but inactivation experiments of OXA-40 has rendered the isolate completely susceptible to 
carbapenems, thus endorsing the enzyme’s role in carbapenem resistance (Héritier et al., 
2005; Poirel et al., 2010).  
 
1.6.2.2.4.3 OXA-51-like Enzymes 
OXA-51-like enzymes are chromosomally located ubiquitous enzymes in A. baumannii. 
OXA-51 initially was identified in 2005 from genetically unrelated A. baumannii isolates 
from Argentina (Brown et al., 2005), with several gene variants discovered in later years 
(Brown & Amyes, 2005; Evans et al., 2007).  OXA-51-like enzymes share 56% identity with 
OXA-23 cluster, and 63% with OXA-24 cluster (Peleg et al., 2008). Its penicillinase activity, 
together with effective hydrolysis of oxacillin confirmed it to be an OXA-type enzyme upon 
discovery (Brown et al., 2005) 
blaOXA-51-like have weak carbapenem hydrolysing activity, and are only reported to contribute 
to carbapenem resistance if an insertion element is present upstream of the gene (Evans et al. 
,2008). ISAba1, ISAba9, ISAba825 and recently ISAba2 have been associated with providing 
effective promoter sequences and contribute to carbapenem resistance (Lopes et al., 2012; 
this thesis).  
Evans et al. (2008) aimed to investigate the relationship among the OXA-51-like enzymes 
and the association of these enzymes with particular clonal lineages from worldwide sources 
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and a linkage map was constructed to reveal the relatedness of the enzymes. OXA-65 enzyme 
seems to form a central hub from which all other OXA-51-like enzymes radiate, which 
thereby suggests that OXA-65 is the ancestral enzyme (Evans et al., 2008). Furthermore, 
three families were formed around OXA-66, OXA-69 and OXA-98, indicating a close 
relationship among enzymes in the respective families, while the other enzymes appeared to 
form chains rather than groups (Evans et al., 2008). The cluster around OXA-66 formed the 
largest group, which correlated with their belonging to the Worldwide (formerly European) 
clone 2 (WW2), a highly successful lineage identified in different parts of the world (Evans et 
al., 2008). OXA-69 cluster is also commonly identified in Worldwide clone 1 (WW1), 
whereas OXA-71 has been associated with Worldwide clone 3 (WW3) (Merkier & Centrón, 
2006; Evans et al., 2008). OXA-71 does not form a cluster, but a chain, and is closely related 
to OXA-64, now commonly reported in the Middle East (Mugnier et al., 2009; Opazo et al., 
2012a; personal results) The evolution of OXA-51-like enzymes seems to be an on-going 
process, with 81 enzymes currently identified, making the OXA-51-like one of the largest 
groups of β-lactamases (http://www.lahey.org/Studies/ last accessed 5 December 2012). 
 
1.6.2.2.4.4 OXA-58 Enzymes 
OXA-58 was identified from a carbapenem-resistant A. baumannii from Toulouse, France in 
2005 (Poirel et al., 2005). The enzyme effectively hydrolysed penicillins, oxacillins and 
imipenem, but not extended-spectrum cephalosporins, and the gene was identified on a 30 kb 
plasmid (Poirel et al., 2005). OXA-58 shares 48% similarity to OXA-23 cluster, 47% to 
OXA-40 cluster and 59% to OXA-51 cluster (Peleg et al., 2008). Point mutant derivatives of 
OXA-58 are OXA-97 and OXA-96 identified in A. baumannii from Tunisia and Singapore, 
respectively (Poirel et al., 2010). OXA-58 is increasingly reported in carbapenem-resistant A. 
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baumannii outbreaks from around the world, including Turkey, France, Argentina, Southeast 
Asia and the Middle East (Coelho et al., 2006; Gur et al., 2008; Peleg et al., 2008; Poirel et 
al., 2010). Figure 4 further illustrates the geographical distribution of OXA-58 outbreaks, 
which similarly to OXA-23 has a global distribution (Zarrilli et al., 2009).  
Reports of OXA-58 have not been limited to A. baumannii, but have also included A. junii, 
Acinetobacter pittii (genospecies 3) and Acinetobacter nosocomialis (genospecies 13TU) 
(Evans et al., 2010; Poirel et al., 2010).  
blaOXA-58 is found to be plasmid mediated in most cases, and flanked by two copies of 
ISAba3, in opposite orientation (Poirel et al., 2005), however other promoter sequences have 
been reported associated with blaOXA-58 such as ISAba2, ISAba1 and IS18 (reviewed by Peleg 
et al., 2008; Poirel & Nordmann, 2006). Hybrid promoters, with IS1006 and IS1008 
interrupting the upstream ISAba3, have been reported in clinical A. baumannii and A. 
calcoaceticus isolates from Taiwan (Chen et al., 2010; Chen et al., 2008). This interruption 
appears to enhance transcription of blaOXA-58 thus resulting in higher observed resistance. In 
addition to the importance of IS elements in blaOXA-58 expression and resistance, another 
study showed that multiple copies of blaOXA-58 on a plasmid resulted in higher MICs of 
carbapenem (Bertini et al., 2007). Furthermore, the level of resistance was still considerably 
higher in the original strains than in the transformants, which indicates additional resistance 
mechanisms in the clinical isolates (Bertini et al., 2007). It is therefore clear that multiple 
resistance mechanisms, such as alteration of porins and the expression of β-lactamases, act 





1.7 The genetic plasticity of A. baumannii 
A. baumannii is a perfect example of genetic plasticity in bacteria, with its remarkable ability 
to acquire and up-regulate foreign genetic material, as well as the showing the role of 
different mobile genetic elements in mediating antibiotic resistance (Peleg et al., 2008; 
Vallenet et al., 2008) 
A. baumannii strain AYE, a multidrug-resistant epidemic strain in France was studied by 
whole shotgun genome sequencing and revealed the presence of a 86-kb resistance island in 
which 45 resistance genes are clustered (Fournier et al., 2006). This genomic ‘hot-spot’ is an 
unstable genomic region which allows successive integration  of resistance determinants from 
different bacterial strains, and the mosaic-like structure in strain AYE reveals the acquisition 
of DNA fragments from different bacterial species including Pseudomonas, Salmonella and 
E. coli (Fournier et al., 2006).  
 
1.7.1 The role of plasmids in the genetic plasticity of A. baumannii 
Plasmids act as important vehicles for the transmission and dissemination of various 
antibiotic resistance genes among different bacterial species through horizontal gene transfer 
(Fondi et al., 2010). The vast majority of resistance genes in A. baumannii  have been shown 
to be localized on transferable plasmids (Poirel et al., 2010;Walsh, 2005). Genes can 
effectively be mobilized on plasmids, transferred to other hosts and get disseminated in the 
hospital setting through horizontal gene transfer. Many outbreaks reported the presence of a 
circulating plasmid harbouring the resistance gene (Jeon et al., 2005; Gallego, 2010). 
Resistance genes located on plasmids can also get inserted into the bacterial genome by 
recombination. Plasmids are, therefore, important in facilitating genome rearrangement via 
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homologous recombination, resulting in the loss or acquisition of genes without altering the 
gene content of the bacterial chromosome (Fondi et al., 2010). This is facilitated by the 
abundance of transposable elements in plasmids. Most clinically significant carbapenem 
resistance in A. baumannii is associated with plasmid mediated acquisition of either MBLs or 
CHDL, which can furthermore integrate into the chromosome (Towner et al., 2011).  
 
1.7.2 Integrons and their association with resistance genes 
Integrons are capable of capturing, mobilizing and expressing resistance genes organised in 
gene cassettes (Poirel et al., 2012). Several antibiotic resistance genes can be captured in the 
same gene cassette, thereby expressing resistance to several different antibiotic classes 
simultaneously (Weldhagen, 2004). Class 1 integrons are prevalent in clinical isolates and are 
particularly associated with class A β-lactamases (ESBLs), with VEB-1 being the first 
enzyme found to be encoded on a gene cassette in an integron  (Naas et al., 2006; Poirel et 
al., 2012). The co-expression of resistance is seen in the frequent occurrence of 
aminoglycoside resistance genes together with a class-A β-lactamase in a gene cassette, 
meaning that the administration of one class of antibiotic, such as aminoglycoside, can select 
for ceftazidime resistance (Opazo et al., 2012a; Weldhagen, 2004). Consequently, the role of 
integrons is to provide a gene capturing system useful in facing the challenge of multiple- 
antibiotic treatment regimens, thereby co-expressing simultaneous resistance (Mazel, 2006). 
All integrons are composed of three elements necessary for gene capturing: an intI integrase 
gene, an attI primary recombination site and a promoter (P) (Mazel, 2006). Gene capturing 
and integration occurs  with the intI-catalysed site-specific recombination between the attI 
site and the 59-base element located downstream of the resistance gene (Weldhagen, 2004). 
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Gene expression is mediated via the common promoter for all genes, rather than through 
individual promoters (Weldhagen, 2004) 
The 3’-end of a class 1 integron-borne β-lactamases in A. baumannii commonly contain a 
qacΔE1 and sul1, in addition to an aminoglycoside, rifampicin or chloramphinecol resistance 
genes (Opazo et al., 2012a; Weldhagen, 2004). β-lactamases reported to be located in class 1 
integrons include: SHV, GES, VEB and PER  ESBL enzymes, IMP and VIM MBL enzymes 
(Opazo et al., 2012a; Poirel et al., 2000; Poirel et al., 2012; Poirel et al., 2005; Poirel et al., 
2003; Walsh, 2005; Weldhagen, 2004).  
 
1.7.3 The role of insertion sequences as vehicles 
The dissemination and spread of antibiotic resistance genes among bacteria is mediated by 
the localization of these genes on transposable elements, and the mobilization by insertion 
sequences (ISs) which are small and abundant transposable elements, capable of independent 
transposition in the genome (Mugnier et al., 2009).  
ISs are commonly associated with resistance genes belonging to class B, C and D, but less 
frequently class A, β-lactamases in A. baumannii (reviewed by Dijkshoorn et al. 2007; 
Jacoby, 2009). blaPER-1 was found as part of a composite transposon, bracketed by ISPa12 
and ISPa13, and was not identified in a gene cassette or located inside a class 1 integron, 
unlike other PER-like enzymes (Poirel et al., 2005). ISAba1 has been, in A. baumannii, 
associated with several antibiotic resistance genes including blaOXA-23 and blaOXA-51-like and  
blaAmpC (Corvec et al., 2003; Héritier et al., 2006; Mugnier et al., 2009). The chromosomally 
located blaOXA-51-like gene has been reported to only confer resistance to carbapenems when 
ISAba1 is inserted upstream (Evans et al., 2008), but more recently ISAba825 and ISAba2 
42 
 
have also been associated with carbapenem resistance when located upstream of the blaOXA-
51-like gene (Lopes et al., 2012; this thesis). The genetic environment of blaOXA-23 gene in A. 
baumannii has been identified to include either one or two copies of ISAba1, with 
transposons Tn2006, Tn2007, Tn2008 all identified as genetic structures harbouring the gene 
(Mugnier et al., 2010). blaOXA-58 are frequently associated with ISAba3 bracketing the gene in 
opposite directions  (Poirel & Nordmann, 2006). For MBLs, NDM-type enzymes are also 
reported to be flanked by ISAba125. Evidently, insertion sequences present upstream of the 
different resistance genes serves to not only mobilize the genes, but provide effective 
promoter sequences, hence facilitating their expression. 
 
1.7.3.1 The role of common regions (CR) 
Common regions (CRs) are present in class 1 integrons, often found close to the 3’ conserved 
sequence, and resemble IS91-like family of insertion sequences (Toleman et al., 2006a). 
IS91-like elements are distinguished from other classes of ISs in that they use rolling circle 
(RC) replication for transposition, allowing genetic rearrangements that other IS elements 
cannot easily perform (Toleman et al., 2006b), hence proposing the term ISCRs.  
The first ISCR1 element was discovered in the early 1990s in class 1 integron as a 2154 bp 
DNA sequence, incorporating a putative gene with unknown function (orf513), located 
upstream of sul1 genes (Toleman et al. 2006a).  
ISCR1 are associated with a number antibiotic resistance genes in different bacterial species, 
and act in the mobilization and dissemination of these genes by RC transposition process 
(Toleman et al,. 2006a). In A. baumannii, ISCR1 has been associated with class A β-
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lactamases: blaPER-3 and blaPER-7 (Opazo et al. 2012a; Toleman et al. 2006a; Al-Hassan et al. 
2012).  
Table 2 is a summary of the β-lactamases present in A. baumannii, the associated genetic and 
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1.8 The issue of antibiotic resistance in developing countries 
Antibiotic resistance is a global problem, but unfortunately some countries lack the 
appropriate surveillance and are unaware of the problem. The decline in antibiotic 
development and the increasing reports of resistance has led public health sectors to release 
reports of action plans to combat antibiotic resistance as well as proposing incentives for 
pharmaceutical investments in antibiotic research in the US and Europe (Spellberg et al., 
2008). This continuous surveillance of the epidemiology of infections and resistance rates, as 
well as the research undertaken in the developed world is not seen in the developing world. 
Limited data is available about the prevalence of hospital acquired infections, although the 
burden of infections is very high (Allegranzi et al., 2011).  
A review of published papers about the prevalence of health-care associated infections in 
developing countries was carried out by Allegranzi et al. (2011) and they only identified 271 
relevant publications from 1995-2008. The analysis revealed that the prevalence of health-
care associated infections was much higher than data reported from Europe and the USA, 
reaching up to three-times as high. Reasons behind that include lack of infection control, 
inadequate hygiene, overcrowded wards, lack of surveillance and knowledge as well as no 
abidance of national and international guidelines (Allegranzi et al., 2011). Furthermore, 
Gram-negative pathogens represented the most common aetiology of nosocomial infections, 
but with limited reports of the associated resistance patterns (Allegranzi et al., 2011). 
Interestingly, Acinetobacter sp. was the second most frequent pathogen identified in 
ventilator-associated pneumonia and bloodstream infections.  
Recently, some data and reports have been available concerning A. baumannii infections in 
the Middle East, and they have shown a surprising and interesting diversity. Heterogeneity 
was identified in A. baumannii isolates from Bahrain, with all three CHDL enzymes present 
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resulting in the observed resistance to carbapenems (Mugnier et al., 2009). Similar 
heterogeneity is seen in A. baumannii isolates from a single centre in Cairo, in addition to the 
presence of several different blaOXA-51-like enzymes representing different clones (this thesis). 
The first report of a plasmid-mediate blaPER-7 was found in a clinical isolate of A. baumannii 
from the United Arab Emirates (Opazo et al., 2012a). blaNDM-2 has been reported in A. 
baumannii isolates from in Egypt, Israel and the UAE (Espinal et al., 2011; Kaase et al., 
2011; Ghazawi et al., 2012). American soldiers wounded in Iraq in 2003 were reported to 
have multi-drug resistant (MDR) A. baumannii (Hujer et al., 2006). These results indicate 
two important observations: first of all, there is an increased awareness of the epidemiology 
of nosocomial infections in the Middle East, and second of all, the genome of isolates 
recovered from this region shows a large degree of diversity. 
The lack of funding to undertake research in the developing world is one of the reasons 
behind the limited of reports available. Furthermore, there are no national surveillance 
systems, which in turn lead to poor and inaccurate data and un-standardized definitions. 
There is also limited communication between different healthcare facilities to alert of a 
certain outbreak. A large surveillance study was done in France and Belgium to contain the 
VEB-1 outbreak, where all hospitals were alerted managed to control the outbreak (Naas et 
al., 2006). If similar measures are taken in the Middle East, it would greatly decrease the 
incidence of nosocomial infections and spread of resistance. There is an urgent need to create 
national and international surveillance systems across the Middle East.  
International infectious disease surveillance has been conducted by the United States 
Department of Defence aiming to monitor the antimicrobial resistance by collaborating with 
civilian and military clinics, hospitals and universities worldwide, thereby creating a 
surveillance network (Meyer et al., 2011). Naval Medical Research Unit 3 (NAMRU-3) was 
created in 1946 and conducts research and surveillance to support military personnel 
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deployed to Africa, the Middle East, and Southwest Asia 
(http://www.med.navy.mil/sites/nmrc/Pages/namru3.htm last accessed 5 December 2012). 
Surveillance studies have shown that the most frequently identified Gram-negative HAI 
present in Egyptian hospitals are either ESBL-producing Enterobacteriaceae or A. baumannii. 
Furthermore, 37% of isolates are MDR with 15% being resistant to imipenem. A. baumannii 
presented approximately 15% among Gram-negative bacteria, being one the most important 
pathogens in hospital acquired infections in Egypt (Meyer et al., 2011). Interestingly, PFGE 
comparison of A. baumannii isolates from Egypt with isolates collected at a military 
treatment facility in the US showed high levels of genetic variability and diversity (Meyer et 
al., 2011).  
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1.9 Aims and objectives of this study  
Given the emergence of A. baumannii as a major clinical pathogen with high degrees of 
genomic plasticity and diversity, we aimed to study A. baumannii from Egyptian cancer 
patients to determine the genetic diversity present in two centres in Cairo.  
 Determine the prevalence of A. baumannii infections at The Children’s Cancer Hospital 
as well as The National Cancer Institute. 
 
 Study the clinical manifestations associated with A. baumannii infections in cancer 
patients.  
 
 Study the epidemiological diversity present in A. baumannii from the two centres by 
using different methods: PFGE, MLST and sequencing of the intrinsic blaOXA-51-like gene 
to assess different methods of characterizing isolates of the same species 
 
 Assess the presence of certain clones in the hospitals 
 
 Investigate multi-drug resistance present in A. baumannii in Egyptian hospitals. 
 
 Identify the diversity of resistance mechanisms and β-lactamase resistance in A. 
baumannii in Egyptian hospitals. 
 
 Identify the role of different insertion sequences in the expression and regulation of 
OXA-type carbapenemases.  
 
 Determine the genetic environments of antibiotic resistant genes.  
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Chapter 2: Materials and Methods 
 
2.1 Collection of Bacterial Isolates 
One hundred A. baumannii isolates were collected from March 2010 to June 2011 from 
paediatric cancer patients in The Children’s Cancer Hospital 57357 (CCHE 57357) and the 
National Cancer Institute (NCI), both located in Cairo, Egypt. The isolates were initially 
identified phenotypically using standard microbiological techniques and by Phoenix and 
Vitek automated machines. The isolates were stored on -80° until further use. 
 
2.2 Identification 
Isolates were identified genotypically by amplification and sequencing of the intrinsic 
blaOXA-51-like gene. Further identification was performed by restriction analysis of the 16s-23s 
rRNA spacer sequence using AluI and NdeII, as described earlier by Dolzani et al. (1995).  
 
2.3 Clinical Data 
The following information was collected from the patients’ clinical records: 
a. Date of Isolate 
b. Location of the patient at time of infection 
c. Disease 
d. Patient demographics 




2.4 Chemicals and Media 
McConkey and Iso-Sensitest agars were used for subculture and growing of the isolates. They 
were purchased in powdered form from Sigma-Aldrich (Basingstoke, UK) and prepared 
according to the manufacturers’ instructions.  
Acinetobacter selective media was used to isolate Acinetobacter spp. in mixed cultures. 
Leeds Acinetobacter Medium (LAM) as previously described by Jawad et al (1994) was used 
in addition to Acinetobacter ChromAgar.  




o 10X TAE 
48.4g of Tris Base was added to 3.72g of EDTA (disodium salt) was dissolved in sterile 
distilled water, and 11.4 ml of Glacial acetic acid to a final volume of 1 litre. For gel running, 
1X TAE buffer was used by diluting the solution 1:10. 
o 10X TBE buffer 
108g of Tris base, 55g of Boric Acid and 7.5 g of EDTA was dissolved in 1 litre of sterile 
distilled water. The pH was adjusted to 8.0 and the solution was sterilized. For Pulsed-Field 
Gel Electrophoresis, 0.5X TBE buffer was used for running.  
o 1X TE buffer 
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1.21g of Tris base and 0.372g of EDTA (disodium salt) was dissolved in 1 litre of sterile 
distilled water. The pH was adjusted to 8.0 and the solution was sterilized.  
o Lysis buffer 
6.05g of Tris base, 18.61g EDTA (disodium salt) and 10g of N-Lauroyl Sarcosine was 
dissolved in 1 litre of sterile distilled water. The pH was adjusted to 8.0 and the solution was 
sterilized. 
o Suspension buffer 
12.11g of Tris base (0.1 M) was added to 37.22g of EDTA (disodium salt) and dissolved in 1 
litre of sterile distilled water. The pH was adjusted to 8.0 and the solution was sterilized. 
 
2.6 Minimum Inhibitory Concentration 
Susceptibility testing of several classes of antibiotics including: Amikacin, 
Amoxicillin/Clavulanate, Aztreonam, Cefepime, Cefexime, Cefotaxime, Ceftazidime, 
Ceftriaxone, Ciprofloxacin, Imipenem, Meropenem, Pipracillin/Tazobactam, 
Trimethoprim/Sulfamethaxazole, Cefperazone/Sulbactam and Tobramycin is performed 
routinely in the microbiology laboratories at the NCI and CCH using two techniques: 
automated susceptibility and MIC using the Phoenix and Vitek machines, in addition to disk 
diffusion according to the CLSI guidelines v27 (http://www.microbiolab-bg.com/CLSI.pdf 
last accessed 14 December 2012). Susceptibility to Colisin was assessed by disk diffusion 
method according to the CLSI guidelines as mentioned above.  
The minimum inhibitory concentration was subsequently performed for Imipenem, 
Meropenem and Ceftazidime according to the BSAC guidelines. A single colony from an 
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overnight culture was selected and grown in 5 mL of Iso-sensitest broth at 37
o 
in an orbital 
shaker at 180 rpm. The MIC was determined by agar double dilution technique according to 
the British Society of Antimicrobial Chemotherapy (BSAC) guidelines (British Society for 
Antimicrobial Chemotherapy, Version 6.1). The results were also interpreted according to 
BSAC guidelines (Andrews & Howe 2011). Pseudomonas aeruginosa NCTC 10662, 
Escherichia coli NCTC 10418 and Staphylococcus aureus NCTC 6571 were used as control 
strains. 
 
2.7 Pulsed-Field Gel Electrophoresis (PFGE) 
All isolates were typed by PFGE according to the procedure previously described by Seifert 
et al. (2005). The isolates were subcultured overnight on Iso-sensitest agar at 37
o
. A loopful 
of bacteria was suspended in 3 mL of sterile cell suspension buffer. The final concentration of 
bacteria was adjusted to be between 1.7-2.0 nm at OD600. Plugs were prepared by mixing 
500 µl of this solution with 25 µl of Proteinase K (20 mg/L stock solution) and 500 µl of 
agarose (1.2% CHEF genomic agarose and 1% sodium dodecyl sulphate (SDS)) and 
dispensed into plug molds. The plugs were allowed to solidify for 10 minutes at 4
o
, after 
which they were placed in 5 mL of cell lysis buffer and 25 µl of Proteinase K for 2 hours at 
55
o
. After lysis, the buffer was removed and the plugs were washed twice with distilled H2O 
and 3 times with TE buffer. After the last wash, fresh TE buffer was used to store the plugs 
until further use. 
For restriction, the plugs were cut with a scapel and transferred to the microcentrifuge tube 
containing the restriction mixture, which consisted of 100µl buffer with 30 U of ApaI. The 
plugs were restricted at 37
o
 overnight in a water bath and subsequently run on 1% pulsed-
field-certified agarose gel (Bio-Rad, Hertfordshire, UK) in 0.5 X TBE buffer with initial 
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pulse of 5 and final pulse of 20 for 20 hours. The gels were stained with Gel-Red solution and 
seen using the Diversity Database software image capturing system.  
 
2.8 Extraction of DNA 
The isolates were subcultured at 37
o 
overnight, after which a loop-full of colonies was 
suspended in 200 µl of sterile distilled water. This mixture was boiled for 10-15 mins and 
then centrifuged at 6000g and the supernatant was used as DNA template.  
 
2.9 Polymerase Chain Reaction (PCR) and Primers used 
Genes were amplified by PCR in a total volume of 50 µl containing 5X Green GoTaq Flexi 
Buffer, 1.5 mM MgCl2, 800 μM PCR nucleotide mix, and 1.25 U GoTaq DNA polymerase 
(Promega, Southampton, UK). PCR conditions were as in table 3, unless stated otherwise: 
 Temperature Time Cycles 
Pre-
Denaturation 
94° 2 minutes 1 
Denaturation 94° 40 seconds 
30 Annealing Variable 50 seconds 
Extension 72° 1 minutes 
Final Extension 72° 5 minutes 1 
Cooling 4°   
Table 3: PCR conditions used in this study 
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Primers used were diluted to 100 and 25 pmol as stock and working concentrations, 
respectively. Primers listed below were either designed for the study using Biotools software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi last accessed 10 August 2012) or 
from previously published papers. 
PCR products were analysed on 1% agarose, stained with GelRed and viewed using the 
Diversity Database software image capturing system (Bio-Rad, Hemel Hempstead, UK).  
For sequencing, PCR products were purified using QIAquick PCR Purification Kit (Qiagen, 
Crawley, UK) and sequenced in both directions, with 3.2 pmol primer concentration. 
 
o  PCR for Identification of A. baumannii isolates 
Primers used were previously reported by Dolzani et al. (1995) to confirm the identification 
of A. baumannii isolates. After amplification, products were digested with AluI and NdeII for 
more specific characterization of species. The fragments specific for A. baumannii produced 
by AluI restriction enzymewere: 50, 125, 135, 165, 177 and 330 bp. Fragments produced by 
NdeII were: 50, 110,145, 330 and 360 bp. 
Primer 
Name 




    
16s-23s 
rRNA F 
TTG TAC ACA CCG CCC 
GTC A 
975 bp 55° 
16s-23s 
rRNA R 
GGT ACT TAG ATG TTT 
CAG TTC 
 






o Amplification and Characterization of blaOXA-51-like gene 
Primers used to amplify the intrinsic blaOXA-51-like gene were previously reported by Heritier et 
al. (2005). To further characterize the gene, products were purified and sequenced.  
Primer 
Name 




    
Oxa69-A CTA ATA ATT GAT CTA 
CTC AAG 
975 bp 48° 
Oxa69-B CCA GTG GAT GGA TGG 
ATA GAT TAT C 
 
Table 5: Primers used for amplification and sequencing of blaOXA-51-like 
 
A larger fragment size was seen for isolates harbouring an insertion sequence upstream of the 
blaOXA-51-like gene. The upstream region of blaOXA-51-like was subsequently amplified and 
sequenced in both directions by using primers FxOxaF and FxOxaR, previously described by 
Lopes (2012), as well as mixing primers FxOxaF and Oxa69-B, and preABprom and OXA-
51R (Heritier et al 2006; Woodford et al. 2006). 
Primer 
Name 




    
FxOxaF GAT ACC AGA CCT GGC 
AAC AT  
889 bp 57° 
FxOxaR GCA CGA GCA AGA TCA 
TTA CC 













o Detection of Acquired OXA Carbapenemases 
Multiplex PCR, previously described by Woodford et al. (2006) was used to screen the 
isolates for OXA carbapenemases.  
Primer 
Name 




    




OXA-23R ATT TCT GAC CGC ATT 
TCC AT 
OXA-24F GGT TAG TTG GCC CCC 
TTA AA 
246 bp 
OXA-24R AGT TGA GCG AAA AGG 
GGA TT 
OXA-58F AAG TAT TGG GGC TTG 
TGC TG 
599 bp 
OXA-58R CCC CTC TGC GCT CTA 
CAT AC 
OXA-51F TAA TGC TTT GAT CGG 
CCT TG 
501 bp 
OXA-51R TGG ATT GCA CTT CAT 
CTT GG 
 
Table 7: Primers used for multiplex PCR of acquired OXA carbapenemases 
 
o Amplification and sequencing of blaOXA-23 
The full blaOXA-23 gene was amplified and sequenced using primers by Afzal-Shah et al. 
(2001) and Heritier et al. (2007) for isolates harbouring the gene by multiplex PCR described 
above.  
The presence of ISAba1 upstream of blaOXA-23 was studied using a combination of primers 











    
blaOXA-23  F GAT GTG TCA TAG TAT 
TCG TCG 
1026 bp 56° 
blaOXA-23  R TCA CAA CAA CTA AAA 
GCA CTG 
    
OXA-23A GGA ATT CCA TGA ATA 
AAT ATT TTA CTT GC 
840 bp 55° 
OXA-23B CGG GAT CCC GTT AAA 
TAA TAT TCA GGT C 
    
ISAba1A GTGCTTTGCGCTCATCATGC 1100 bp 55° 
 
Table 8: Primers used for amplification and sequencing of blaOXA-23 
 
o Amplification and sequencing of blaOXA-58 
The full blaOXA-58 and associated upstream environment was amplified and sequenced by 
mixing ISAba3-F and SM2 primers described by Poirel et al. (2006) with OXA-58R used in 
multiplex PCR method. The downstream environment was amplified and sequenced by 








    
SM2 AAG TGT CTA TAT TCT 
CAC C 
Variable 56° 
ISAba3-F CAA TCA AAT GTC CAA 
CCT GC 
900 bp 55° 
ISAba3-R CGT TTA CCC CAA ACA 
TAA GC 
 





o Amplification and sequencing of blaOXA-24/40 








    
OXA-24FF ATG AAA AAA TTT ATA 
CTT CCT ATA TTC AGC 
825 bp 56° 
OXA-24RR TTA AAT GAT TCC AAG 
ATT TTC TAG C 
 
Table 10: Primers used for amplification and sequencing of blaOXA-40/24 
 
o Detection of blaADC 
PCR was performed to amplify the blaADC gene in A. baumannii isolates using primers 
previously reported by Ruiz et al. (2007). 
For larger fragment sizes produced by isolates harbouring an insertion sequence upstream of 
blaADC, primers ISADC1 and 2 were used for the detection of ISAba1 upstream of blaADC 
according to Ruiz et al. (2007). 
Primer 
Name 




    
ADC1 CCG CGA CAG CAG GTG 
GAT A 
420 bp 52° 
ADC2 TCG GCT GAT TTT CTT 
GGT T 
ISADC1 GTT GCA CTT GGT CGA 
ATG AAA A 
751 bp 52° 
ISADC2 ACG TCG CGA GTT GAA 
GTA AGT T 
 




o PCR for the detection of Extended Spectrum Beta-lactamases (ESBLs) 
Isolates resistant to Ceftazidime were screened for the presence of ESBLs by amplification 
and sequencing of blaTEM (Weill et al. (2004), blaVEB (Lopes et al, 2012), blaSHV (Findlay et 
al. 2012), blaPER (This thesis), blaGES (Lopes, 2012) blaCTX-M (Woodford et al., 2005). 
Primer 
Name 




    
TEM- F GTT GCA CTT GGT CGA 
ATG AAA A 
1080 bp 57° 
TEM-R ACG TCG CGA GTT GAA 
GTA AGT T 
SHV-F CGC CGG GTT ATT CTT 
ATT TG 
1069 bp 57° 
SHV-R CCA CGT TTA TGG CGT 
TAC CT 
VEB-F ATT TCC CGA TGC AAA 
GCG T 
360 bp 57° 
VEB-R CCA ACA GCG ATG AAC 
AAA CT 
PER-F CCT GAC GAT CTG GAA 
CCT TT 
715 bp 56° 
PER-R GCA ACC TGC GCA ATG 
ATA GC 
GES-F ATG CGC TTC ATT CAC 
GCA C 
840bp 55° 
GES-R AAC TCA TCC TGA GCA 
CGG AC 
CTX-M-F AAA AAT CAC TGC GCC 
AGT TC 
415bp 52° 
CTX-M-R AGC TTA TTC ATC GCC 
ACG TT 
 
Table 12: Primers used for detection of ESBLs 
 
 
o PCR for detecting the genetic environment of blaPER-like genes 
The genetic environment of blaPER-like genes (See Results section), was analysed by mixing 
primers of Int1 by Opazo et al. (2012a), 3’CS variable region (This study), Sul1, orf513 and 
AYE-3396, by Opazo et al. (2012a), ISPa12 and ISPa13 by Poirel et al. (2005). Products 










    
Int1 F 
GTT GCA CTT GGT CGA 
ATG AAA A 
600 bp 
52° 
Int1 R  
ORF513-F 
TCA AAG AGA CGA CTC 
TGT GAT GGA T 400 bp 55° 
ORF-513-R 
TGA CTC TTA TCC AAC 
GCT TTG GC 
5’CS 
GGC ATC CAA GCA GCA 
AG Variable 55° 
3’CS 









GAT CTC GCT TTA CAT 
TTA CC Variable 
55° 
ISPa12A 
ACA ATC GCT GAT ATA 
CAT CG 
PER ext1 

















o Amplification  for Metallo-β-lactamase genes (MBLs) 










    
IMP-F GGA ATA GAG TGG CTT 
AAY TCT C 
188 bp 53° 
IMP-R CCA AAC YAC TAS GTT 
ATC T 
VIM-F GAT GGT GTT TGG TCG 
CAT A 
390 bp 53° 
VIM-R CGA ATG CGC AGC ACC 
AG 
SIM-F TAC AAG GGA TTC GGC 
ATC G 
570 bp 56° 
SIM -R TAA TGG CCT GTT CCC 
ATG TG 
NDM -F GGG CCG TAT GAG TGA 
TTG 
650 bp 52° 
NDM-R GCA CAC TTC CTA TCT 
CGA C 
 





2.10  Multi-locus Sequence Typing 
Ten Isolates, representative of each blaOXA-51-like type from the two hospitals, were further 
typed by Multi-locus sequence typing according to the scheme published by Barutal et al. 
(2005). Briefly, DNA was prepared as previously described, and used as template for the 
PCR of the 7 house-keeping genes: gltA, rpoD, gpi, gyrB, gdhB, recA and cpn60. Products 
were subsequently purified and sequenced in both directions, analysed, and isolates were 




The PCR conditions were as follows: 
 Temperature Time Cycles 
Pre-
Denaturation 
94° 2 minutes 1 
Denaturation 94° 1 minute 
30 Annealing Variable 1 minute 
Extension 72° 2 minutes 
Final Extension 72° 2 minutes 1 
Cooling 4°   
 





Primers were designed by Bartual et al. (2005) but modifications were made to the annealing 
temperatures as shown below. 
Primer 
Name 




    
Citrato F1 AAT TTA CAG TGG CAC 
ATT AGG TCC C 
722 bp 55° 
Citrato R12 GCA GAG ATA CCA GCA 
GAG ATA CAC G 
APRU F TGT AAA ACG ACG GCC 
AGT GCN GGR TCY TTY 
TCY TGR CA 
909 bp 45° 
UP1E R CAG GAA ACA GCT ATG 
ACC AYG SNG GNG GNA 
ART TYR A 
GDHB 1F GCT ACT TTT ATG CAA 
CAG AGC C 
775 bp 59° 
GDHB 
775R 
GTT GAG TTG GCG TAT 
GTT GTG C 
RA1 CCT GAA TCT TCY GGT 
AAA AC 
425 bp 55° 
RA2 GTT TCT GGG CTG CCA 
AAC ATT AC 
CPN 3F2 ACT GTA CTT GCT CAA 
GC 
479 bp 59° 
CPN R2 TTC AGC GAT GAT AAG 
AAG TGG 
GPI F1 AAT ACC GTG GTG CTA 
CGG G 
508 bp 55° 
GPI R1 AAC TTG ATT TTC AGG 
AGC 
70F RPOD ACG ACT GAC CCG GTA 
CGC ATG TAY ATG MGN 
GAR ATC GCN CAN CT 
492 bp 58° 
70R RPOD ATA GAA ATA ACC AGA 
CGT AAG TTN GCY TCN 
ACC ATY TGY TTY TT 
 





Sequencing of gyrB, gdhB and rpoD required different primers sequences than those used for 
sequencing. Primers are listed below.  
Primer 
Name 
Sequence 5’-3’ Gene 
   
M13 [−21] TGT AAA ACG ACG GCC 
AGT 
gyrB 









GTT GGC GTA TGT TGT 
GC 
70FS ACG ACT GAC CCG GTA 
CGC ATG TA 
rpoD 
70RS ATA GAA ATA ACC AGA 
CGT AAG TT 
 
Table 17: Primers used for sequencing in MLST 
 
 
2.10.1 e-BURST analysis 
Evolutionary relationships and clonal complexes within the isolates were investigated by 
eBURST analysis, using the software on the eBURST website 
(http://eburst.mlst.net/v3/enter_data/single/ last accessed 16 December 2012) 
 
2.11 S1 nuclease  
S1 nuclease was used to detect and size plasmids. Plugs were digested with 10 units of s1 
nuclease at 37° for 45 minutes, and subsequently run on PFGE. Gels were stained with Gel-
Red and viewed by the gel-doc system. 
 
2.12  Plasmid curing 
Plasmid curing was performed on strains harbouring blaPER-7 and blaPER-3 to detect if the 
plasmid harbouring the resistance gene was lost. The strains were serially subcultured for 10 
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consecutive days and incubated at elevated temperatures. Ceftazidime resistance was 
measured by disk-diffusion method after curing and compared with the zone exhibited by the 
strain before curing. S1 nuclease was also performed to confirm the loss of plasmid.  
 
2.13  Conjugation 
Conjugation was attempted with the isolate harbouring blaPER-3 (See results). E. coli J62.2 
was used as a recipient. The donor and recipient were cultured overnight in IST broth, after 
which they were mixed in 1:4 ratio. Cells were collected by centrifugation and inoculated in 
30μL of saline. 5 μL of this suspension was plated on Nutrient Agar plates containing 
Rifampicin (16 mg/L) and Ceftazidime (512 mg/L). 
 
2.14  Phenotypic detection of MBL  
All isolates were screened for MBL production by using Imipenem-EDTA Disk Method as 
described by Yong et al. (2003). Isolates were Nutrient Agar and disks containing Imipenem 
(30μg) and EDTA disks (5 and 20mM) were placed 10 mm apart. Plates were incubated at 
37° for 18-20 hours and MBL production was confirmed when the imipenem zone was 
expanded by EDTA. 
 
2.15  RNA extraction and Reverse Transcription 
RNA was extracted using the RiboPure Bacteria Kit (Applied Biosystms). RNA was reverse 
transcribed to cDNA by incubation at 45°C/1 hr, followed by PCR gene amplification of 






2.16  Sequence Interpretation : BLAST and multalin 
Sequencing was performed by Sanger method using an ABI 373A DNA sequencer (PE 
Applied Biosystems, Warrington, UK). All sequences were interpreted by BLAST 
(http://blast.ncbi.nlm.nih.gov/ last accessed 15 October 2012) and sequence alignment of 
DNA or amino acids were performed using Multalin tool 





Chapter 3: Results 
 
3.1 Collection of bacterial isolates 
Cancer patients are prone to several opportunistic infections due to their immune-suppresive 
state. It was therefore expected to isolate mixed organisms from patients during their febrile 
neutropaenia episode. Work undergone in Cairo included storing all non-fermenting Gram-
negative organisms, identifying them phenotypically as well as using automated machines 
such as Pheonix and Vitek.  
Several cultures obtained contained mixed organisms: Gram-positive and Gram-negative, or 
mixed Gram-negative. Therefore purification of the cultures was done in these cases. A total 
of 100 isolates were identified as non-fermenting Gram-negative Acinetobacter spp. A. 
baumannii was identified in 46 isolates, while the remaining 54 were identified as 
Acineotbacter sp. or A. lwoffii. Phenotypic and automated identification is not nearly as 
accurate as molecular identification. Further genotypic identification by restriction analysis of 
the 16s-23s rRNA spacer sequences using AluI and NdeII as well as amplification and 
sequencing of the blaOXA-51-like gene, served to identify the Acinetobacter sp as well as 
confirm the A. baumannii isolates. Due to the large number of patients in the hospitals, many 
samples are processed during a regular working day, which is why the microbiology 
laboratories at CCH and the NCI rely on automated machines for identification and 
susceptibility testing of the organisms. Due to the large similarities shared by isolates in the 
A. baumannii-A. calcoaceticus complex, automated machines poorly distinguish between 




Thirteen Acinetobacter sp. isolates were identified as A. baumannii genotypically. 
Additionally, 10 isolates identified as A. baumannii by the automated machines, were found 
to be non-baumannii genotypically, but part of the A. baumannii-A. calcoaceticus complex. 
The remaining 21 isolates were identified as A. baumannii both by the automated machines 
and genotypically. A total of thirty-four non-duplicate A. baumannii isolates were used in the 
study. Some patients had several A. baumannii cultures from different sites within a small 
time period, therefore cultures taken within one week from the same patient were considered 
in the same episode, and only one culture was chosen for further studies.  
 
3.2 Automated and phenotypic susceptibility testing 
Routine susceptibility testing in the centres in Cairo is done by disk diffusion according to the 
CLSI guidelines. Susceptibility is tested furthermore using the automated machines as stated 
earlier. 
For the 100 Acinetobacter sp identified, overall resistance (MIC >4mg/L or zone diameter 
>17mm) was 64% to Amikacin, 67% to Amoxillin/Clavulanate, 58 % to Aztreonam, 65% to 
Cefepime, 67% to Cefexime, 68% to Cefotaxime, 62% to Ceftazidime, 73% to Ceftriaxone, 
57% to Ciprofloxacin, 53% to Imipenem, 57% to Meropenem, 58% to 
Pipracillin/Tazobactam, 66% to Trimethoprim/Sulfamethaxazole, 47% to 
Cefoperazone/Sulbactam and 26% to Tobramycin. All isolates were susceptible  to Colistin 
by disk diffusion (disk content 10 mg, zone diameter ≥11 mm).  
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3.3 Clinical data associated with isolates 
Of the 34 A. baumannii isolates, 25 were recovered from patients in the Children’s Cancer 
Hospital (CCH) and the remaining nine were from patients hospitalized in the National 
Cancer Institute (NCI).  
Clinical data was unavailable for some patients hospitalized at the NCI. Only data obtained 
from the microbiology report could be incorporated into the analysis.  
The age of patients ranged from 8 months to 25 years, with the median age of 5 years.  
All patients had an underlying malignancy, with the majority of patients (n=20) having 
haematological disease (leukaemia or lymphoma) and seven patients with solid tumours.  
As seen in table 18, twenty-four isolates were recovered from blood or CVP-related cultures, 
accounting for 70% of the total. Six isolates were recovered from respiratory and wound/pus 
samples and four GIT and urine samples accounted for 18% and 12%, respectively. In a 
report by El-Mehallawy et al. (2005), the majority of isolates were recovered from blood or 









SITE OF ISOLATE AGE (Years) SEX DIAGNOSIS WARD OUTCOME
4248 CCHE 15/03/2010 CVP tip 9 F Non-hogkins Lymphoma IP - 5C Alive
4343 CCHE 17/03/2010 CVP Blood >1 F Neuroblastoma IP - 3B Alive
4842 CCHE 23/03/2010 CVP tip 2 F Rhabdomyosarcoma ICU Dead
7947 CCHE 17/05/2010 Wound 5 M Medulloblastoma Stepdown 2014 Dead
9930 CCHE 15/06/2010 Blood 1.9 M Acute Myeloid Leukemia Stepdown 2016 Dead
10262 CCHE 19/06/2010 CVP 2 M Non-hogkins Lymphoma ICU Alive
12435 CCHE 23/07/2010 Blood 4 M Non-hogkins Lymphoma ICU Dead
14298 CCHE 22/08/2010 Cath tip 5 F Hodgkin's Disease ICU Alive
14611 CCHE 27/08/2010 CVP Blood 1.2 M Rhabdomyosarcoma ICU Dead
15094 CCHE 05/09/2010 Urine 9 F Osteosarcoma IP - 4B Alive
15324 CCHE 09/09/2010 Cath tip 2 F Acute Myeloid Leukemia IP - 3A Alive
21174 CCHE 09/12/2010 Blood 4 M NHL - Burkitt's Lymphoma IP - 3A Alive
21382 CCHE 13/12/2010 CVP Culture 4 F Acute Lymphoblastic Leukemia ICU Dead
22055 CCHE 25/12/2010 CVP Blood 15 F Acute Lymphoblastic Leukemia IP - 3C Alive
161 CCHE 03/01/2011 Sputum 6 F Hodgkin's Disease MSC - PULM Alive
634 CCHE 11/01/2011 Cath tip 3 F Non-hogkins Lymphoma ICU Dead
1447 CCHE 24/01/2011 CVP Culture 16 F Acute Myeloid Leukemia ICU Alive
1780 CCHE 31/01/2011 Stool 8 F Non-hogkins Lymphoma Stepdown 2015 Dead
1750 CCHE 31/01/2011 BAL 11 F Hodgkin's Disease ICU Dead
2106 CCHE 08/02/2011 Blood 8 M Acute Myeloid Leukemia Stepdown 2012 Dead
2632 CCHE 20/02/2011 Stool 1.6 F Intraventricular ATRT IP - 5A Alive
2625 CCHE 20/02/2011 Urine 14 M Ewing Sarcoma IP - 4C Alive
7052 CCHE 5/7/2011 BAL >1 M Astrocytoma ICU Alive
8357 CCHE 5/29/2011 CVP Blood >1 M Neuroblastoma DSCH Alive
8768 CCHE 6/4/2011 Blood >1 M JMML IP - 4B Alive
Abd NCI 02/09/2010 Ear swab 14 M Acute Myeloid Leukemia 5th floor - room 5 Alive
Bas NCI 04/09/2010 Ear swab 12 F Acute Myeloid Leukemia 5th floor - room 2 Dead
P391 - Ahm NCI 14/09/2010 Blood 2.8 M Acute Lymphoblastic Leukemia 5th floor Dead
Shay NCI 11/10/2010 Blood 2 F Non-hogkins Lymphoma Alive
461 - Seif NCI 15/12/2010 Blood M 7th floor
Sam NCI 15/12/2010 Blood 25 M Acute Lymphoblastic Leukemia 7th floor Dead
P38 - Ysf NCI 04/01/2011 Blood M 5th floor
P49 - Ham NCI 05/01/2011 Blood M 5th floor
P67 - Azak NCI 09/01/2011 Blood 5 M OP  
Table 18: Clinical and demographical data for isolates. CVP: Central Venous Port, 
JMML: Juvenile myelomonocytic leukaemia, MSC-PULM: Pulmonary clinic. OP: Out-
patient ward, IP: In-patient ward 
 
The location of patients at time of infection varied considerably. CCH has three floors for in-
patient (IP) admissions, two floors for ICU, bone-marrow transplantation unit and the 
surgical department, and one floor for out-patient admissions and clinics. The NCI however 
has two floors for paediatric oncology admissions in addition to outpatient clinics floor, 
whereas the rest of the building is for adult malignancies and surgery. The location of patients 
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at the time of infection varied considerably in CCH. The majority of isolates (n=14) were 
recovered from patients in the ICU, four isolates from patients hospitalized in the 3
rd
 IP floor, 
three isolates from patients at the 4
th
 IP floor, two isolates from 5
th
 IP floor, and two isolates 
from outpatient clinics. As for the NCI the distribution of isolates were more clustered with 
the majority (n=5) being recovered from patients hospitalized in paediatric oncology 5
th
 floor, 
one isolate from the adult ward (7
th
 floor) and one isolate from the outpatient clinics. 
The patients were monitored during their Febrile Neutropenia episode during which they had 
A. baumannii infection. Mortality was only recorded if the patient died within the Febrile 
Neutropenia episode and outcome was hence recorded two weeks after the end of the A. 
baumannii infection and before the onset of the next chemotherapy treatment. In terms of 
patient outcome, 38% (n=13) died after the A. baumannii infection. For patients at CCH, they 
were hospitalised in the ICU and most suffered from an underlying haematological 
malignancy. The reason for this is the chemotherapy regimen for haematological malignancy 
is more immuno-ablative, which makes the patients more prone to opportunistic infections. It 
is debatable whether death in those patients can be attributed to the A. baumannii infections 
or not, as the existence of co-morbidity can significantly affect the outcome of the patient.  
No specific distribution was seen for the sex of patients with A. baumannii infection. 
 
3.3.1 Patient Origin and Governorates 
The two centres from which the isolates were obtained are tertiary referral hospitals, so 
patients come from different governorates in Egypt. Data was only obtainable from patients 
in CCH, and identified 11 different governorates. Table 19 shows the number of patients 
originating from each governorate. As seen in figure 5, there was a large geographical 
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distribution of patient origin. The relevance of this diversity will be explained in later 
sections.  
GOVERNORATE NUMBER OF PATIENTS 
Alexandria 2 











Table 19: Distribution of patients originating from different governorates in Egypt. 
 
 
Figure 5: Map of Egypt showing the different governorates 
(6
th
 of October is now part of the Giza governorate) 
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3.4 Diversity in blaOXA-51-like gene 
Amplification and sequencing of blaOXA-51-like gene revealed a large diversity among the 
strains with 8 difference genes identified. This is peculiar given the relatively short time of 
study (1.5 years) and that the strains were obtained from only two hospitals.  
Genes identified were blaOXA64, blaOXA65, blaOXA66, blaOXA69, blaOXA71, blaOXA78, blaOXA94, 
blaOXA89/100. Details are listed in table 20. In each case below the sequence is compared 





HOSPITAL DATE OF 
SAMPLE
SITE OF ISOLATE bla OXA-51-like 
GENE
WARD
4343 CCHE 17/03/2010 CVP Blood 64 IP - 3B
7947 CCHE 17/05/2010 Wound and Sputum 64 Stepdown 2014
12435 CCHE 23/07/2010 Blood 64 ICU
14298 CCHE 22/08/2010 Cath tip 64 ICU
8357 CCHE 5/29/2011 CVP Blood 64 DSCH
4248 CCHE 15/03/2010 CVP tip 65 IP - 5C
4842 CCHE 23/03/2010 CVP tip 65 ICU 
9930 CCHE 15/06/2010 Blood and CVP 65 Stepdown 2016
10262 CCHE 19/06/2010 CVP 65 ICU
15094 CCHE 05/09/2010 Urine 65 IP - 4B
15324 CCHE 09/09/2010 Cath tip 65 IP - 3A
1780 CCHE 31/01/2011 Stool 65 Stepdown 2015
1750 CCHE 31/01/2011 BAL 65 ICU
2106 CCHE 08/02/2011 Blood 65 Stepdown 2012
2632 CCHE 20/02/2011 Stool 65 IP - 5A
2625 CCHE 20/02/2011 Urine 65 IP - 4C
8768 CCHE 6/4/2011 Blood 65 IP - 4B
14611 CCHE 27/08/2010 CVP Blood 66 ICU
21382 CCHE 13/12/2010 CVP Culture 66 ICU
7052 CCHE 5/7/2011 BAL 66 ICU
634 CCHE 11/01/2011 Cath tip 69 ICU
1447 CCHE 24/01/2011 CVP Culture 69 ICU
161 CCHE 03/01/2011 Sputum 71 MSC - PULM
21174 CCHE 09/12/2010 Blood 78 IP - 3A
22055 CCHE 25/12/2010 CVP Blood 100 IP - 3C
Bas NCI 04/09/2010 Ear swab 64 5th floor - room 2
P67 - Azak NCI 09/01/2011 Blood 64 OP
Sam NCI 15/12/2010 Blood 64 7th floor
P391 - Ahm NCI 14/09/2010 Blood 65 5th floor
461 - Seif NCI 15/12/2010 Blood 65 7th floor
Abd NCI 02/09/2010 Ear swab 66 5th floor - room 5
Shay NCI 11/10/2010 Blood 71 5th floor
P38 - Ysf NCI 04/01/2011 Blood 94 5th floor
P49 - Ham NCI 05/01/2011 Blood 94 5th floor  
Table 20: Isolates harbouring the respective blaOXA-51-like genes, with date, site and 
location of patients. 
 
3.4.1 blaOXA-64  
blaOXA-64, now common in the Middle East, was found in both CCH and NCI in a total of 
eight isolate. No correlation was found among isolates harbouring blaOXA-64, as they were 
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isolated in different months and anatomical sites. Interestingly, isolates from CCH harbouring 
blaOXA-64 were all from patients in the ICU.  
Silent mutations in the nucleotide sequences are seen in position 43 (A to C) for 7947 and 
P67-AZak, in addition to position 44 (T to C) for 7947, as seen in figure 6.  
 
Figure 6: Nucleotide alignment for blaOXA-64 
 
Isolates harbouring blaOXA-64 were typed by PFGE and their profiles compared as seen in 
figure 7. No epidemiological linkage can be seen between the profiles, as all isolates are 
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<80% similar in their patterns. Maximum similarity is seen at 60% for isolates 12435 and 
8357 from CCH in addition to 679-BAS and P67-AZak from the NCI. 





























































Figure 7: PFGE profiles for blaOXA-64 isolates 
 
3.4.2 blaOXA-65 
blaOXA-65 was the most prevalent gene identified, found in 14 isolates from both hospitals. As 
seen in table 20, isolates harbouring blaOXA-65 gene were distributed in several wards of both 
hospitals and they were isolated in different months. Only 3 isolates, 1750, 1780 and 2106 
were from an ICU outbreak in early 2011, and harboured the blaOXA-65 gene. 
Three silent mutations were present in all isolates harbouring blaOXA-65 except isolate P361-
AH from the NCI (Figure 8). These mutations were present at positions 90 (T to C), 636 (C to 
T) and 663 (A to G). Additionally, isolates 4842 and 8768 harboured silent mutations at 




Figure 8: Nucleotide alignment for isolates harbouring blaOXA-65
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PFGE patterns of the isolates were compared as seen in figure 9. Isolates 461-SF and 4842 seem 
to be clonally related, in addition to isolates 10262 and P361-AH, as they share >80% similarity 
in their pattern. The isolates were from different hospitals and detected in different months. 
Additionally, isolates 1750 and 1780, which were from the ICU outbreak, also have similar 
patterns.  



























































































Figure 9: PFGE profiles for blaOXA-65 isolates 
 
3.4.3 blaOXA-66 
Three isolates harbouring blaOXA-66 were recovered from patients at the CCH, all of which were 
hospitalized at the ICU but in different months. One isolate was also recovered from a patient in 
the NCI.  
Fifteen silent mutations were identified in isolates harbouring blaOXA-66 (figure 10). These 
mutations were at positions 90 (T to C), 107 (A to T), 108 (C to A), 171 (A to T), 177 (T to C), 
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309 (A to G), 318 (G to T), 319 (G to A), 328 (C to T), 349 (A to G), 369 (T to C), 390 (G to A), 
511 (C to T), 636 (C to T), 801 (T to C).  
 
Figure 10: Nucleotide alignment for isolates harbouring blaOXA-66 
 
PFGE patterns in figure 11 of the isolates shows that only isolates 21382 and 7052 were clonally 
related, showing 100% similarity. These isolates were both from patients in the ICU of the same 
hospital, but in different months: December 2010 and later in May 2011. This similarity may 
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indicate the persistence of this clone in the ICU, and managed to be transmitted to the patient 
upon admission. 







































Figure 11: PFGE profiles for blaOXA-66 isolates 
 
3.4.4 blaOXA-69 
Two isolates harbouring blaOXA69 were recovered from patients hospitalized in the ICU during 
the A. baumannii outbreak in early 2011. 




Figure 12: Nucleotide sequence alignment for isolates harbouring blaOXA-69 
 
The PFGE profiles (figure 13) of the isolates show a 100% similarity. This correlates with the 
isolates being in the same ward and isolated in the same outbreak, indicating the presence of a 
single clone of blaOXA-69 in the hospital.  





















3.4.5  blaOXA-71 
Two isolates harbouring blaOXA-71 were found in each hospital, CCH and NCI. No silent 
mutations were found within these sequences (figure 14).  
 
Figure 14: Nucleotide sequence alignment for isolates harbouring blaOXA-71 
Although the isolates were from different hospitals and different months, their PFGE pattern 
shows a 100% similarity suggesting clonal relatedness of the strains (figure 15). 
 




One isolate harbouring blaOXA-78 was recovered from a patient in CCH in December 2010.  No 
silent mutations were identified in the sequence as seen in figure 16. 
 
Figure 16: Nucleotide sequence alignment for blaOXA-78 
 
3.4.7 blaOXA-94 
Two isolates from NCI were recovered from the same floor, 1 day apart, were found to have 
blaOXA-94. No silent mutations were seen in the sequences (figure 17). Surprisingly, their PFGE 




Figure 17: Nucleotide sequence alignment for isolates harbouring blaOXA-94 





























Figure 18: PFGE profiles for blaOXA-94 isolates 
 
3.4.8 blaOXA-89/100 
One isolate, from a patient hospitalized in CCH was found to harbour blaOXA89. No silent 
mutations were found in the nucleotide sequence (figure19). During amplification, this isolate 
showed a larger band size for the blaOXA-51-like gene product, suggesting the presence of an 
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insertion sequence upstream (figure 20). Sequencing revealed the presence of ISAba2 directly 
upstream of the blaOXA-89  (figure 21). ISAba2 has been associated with the upstream 
environment and providing suitable promoter sequences to blaOXA-58 gene, and this is thus the 
first identification of ISAba2 upstream of blaOXA-51-like gene. The -35 (ttatat) and -10 (ttgtaggat) 
promoters were 29bp apart, and located102bp and 82bp upstream of blaOXA-89 respectively. 
 
Figure 19: Nucleotide sequence alignment for the isolate harbouring blaOXA-89/100 
 




Figure 20: Amplification of blaOXA-51-like genes. Isolate 22055 has a larger band size indicating 
the presence of an insertion sequence upstream of the gene when compared to isolates 9925-
SAM with no IS. L: ladder.  
 
                            
                                    FxsA              ISAba2                  blaOXA-89 
Figure 21: Schematic representation of ISAba2 upstream of blaOXA-89 
 
3.5 Multi-locus Sequence Typing 
A total of 10 isolates, representative of each blaOXA-51-like gene and hospital, were chosen for 
MLST, to assess whether similar Sequence Types (STs) were present in either hospital, and 
whether a correlation could be made between a specific ST and blaOXA-51-like genes. 
Ten distinct Sequence Types (STs) were identified, seven of which were novel and assigned as 
ST408-ST414. The remaining three STs were identified as ST331, ST108 and ST208 (Table 21). 
Typing by MLST further illustrated the large diversity found within the strains, as isolates with 
similar blaOXA-51-like gene had different STs. Isolates 9925-SAM and P67-AZak, both are from the 







NCI and have blaOXA-64, but they belong to different STs 409 and 411, respectively. When 
compared with another blaOXA-64 positive isolate, 8357, which is from a patient at CCH, we see 
that another ST is identified in this case: ST408.  
ISOLATE 
NUMBER 
gltA gyrB gdhB recA cpn60 gpi rpoD ST 
8357 18 14 2 28 11 107 5 408 
Sam 1 15 2 28 11 58 32 409 
1780 24 46 96 11 16 40 26 410 
634 10 12 4 11 4 9 5 108 
P67 -Azak 13 15 2 28 1 55 32 411 
21174 1 34 80 28 1 52 45 412 
22055 1 17 6 1 4 116 6 413 
161 2 35 45 48 1 11 5 414 
P38 - Ysf 28 38 45 1 16 4 2 331 
14611 1 3 3 2 2 97 3 208 
 
Table 21: Alleles identified and assigned STs for isolates by MLST. 
 
e-BURST analysis was used to determine evolutionary relationships and clonal complexes 
within isolates. The analysis uses a default group definition of 6 or more (6/7) shared loci 
between the STs, with a relaxed definition at 5 or more shared loci out of the 7 (5/7). The 
analysis was done at the default as well as the relaxed definition and revealed no clonal 
complexes between the STs and detected 10 singletons.  
Despite the diversity, some of the STs identified in this thesis share similarities with each other 
and other STs from around the world. ST409 and ST411 assigned for isolates 9925-Sam and 
p67-AZak, respectively, have four similar loci. ST409 shares five alleles with ST35, ST36, 
ST110 and ST156. ST413 shares six alleles with ST283, whereas it shares five alleles with 
ST120, ST284 and ST299. ST208 has been previously identified in USA and China, and shares 
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six alleles with 18 STs including ST74, ST75, ST88, ST89, ST92 and ST118. ST331 has six 
similar alleles with ST330 and ST332, whereas it shares five alleles with ST65 and ST352. 
ST108 has six similar alleles with ST109 and ST419. ST108 has five similar alleles to 19 STs 
including ST109, ST16, ST48, ST95, ST197, ST216 and ST231. ST412 shares six alleles with 
ST172, and five alleles with ST110, ST169, 224 and 235. ST408, ST410 and ST414 share no 
similarities with other STs.  
The population-snapshot as seen in figure 22 further illustrates the diversity of these isolates as 
no link can be established between the STs. As seen in figure 22, ST208 is the ancestral ST in its 
group, from which the related STs are radiating. ST108 is closely related to ST109, which seems 
to be the ancestral ST in its group. Furthermore, ST419 descended from ST108, according to 
figure 22. ST331 is closely related to ST330, ST332 and ST65 but the ancestor ST cannot be 
determined (figure 22). Similar interpretation can be made to ST413 with its relation to ST283, 







Figure 22: Population snapshot of the e-burst analysis 
 
MLST, on four non-repetitive and distinct clinical strains, isolated in 2004 in the USA, was 
performed to compare with the diversity of the strains obtained from a single centre in Egypt. 
The American strains belonged to a single sequence type: ST114 (1, 15, 8, 10, 28, 57, 32). We 
can hereby see the large diversity of strains in the current collection when compared with other 
A. baumannii strains from another part of the world.  
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3.5.1 PFGE analysis for MLST  
The PFGE pattern of isolates is shown in figure 23. Maximum observed similarity is seen as 
60%, thereby further illustrating the epidemiological diversity of the strains.  

























































































Figure 23: PFGE pattern of isolates typed by MLST, with the site, location of patients, date 
and OXA-51-like enzymes. 
 
 
3.6 Class D β-lactamases 
Detection of class D β-lactamases was performed by Multiplex PCR according to Woodford et 
al. (2006). Isolates positive for the individual genes were examined further as explained below.  
As seen in the figure 24, the blaOXA-58 gave an amplicon size of 599 bp, blaOXA-23 gene gave an 
amplicon size of 501 bp, and blaOXA-24 gave an amplicon size of 246 bp. The intrinsic blaOXA51-like 





Figure 24: Amplification of Carbapenem-Hydrolysing Class D β-lactamases (CHDL)  by 
PCR and the relative amplicon sizes. L:Ladder, N: Negative Control, Isolate 9930 is positive 
for blaOXA-23, isolate 14298 is positive for blaOXA-58 and isolate 14611 is positive for blaOXA-40 
 
3.6.1 OXA-23 
Eighteen isolates were positive for blaOXA-23, they were sequenced in both directions to reveal 
any insertion sequences upstream as well as to determine the full sequence of the gene. 
 
3.6.1.1 MIC 
The MICs of carbapenems for these 18 isolates is listed in the table 22. All isolates harbouring 
blaOXA-23 were resistant with MICs ranging from 8mg/L to 128mg/L, except one isolate: 1447, 
which was sensitive to carbapenems (MIC <1mg/L). The MIC of meropenem was 4mg/L for 
some isolates, which is interpreted as intermediate resistance according to the BSAC guidelines. 






L 9930 14298 14611 
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3.6.1.2 Upstream Environment 
Sequencing upstream of blaOXA-23 gene revealed the presence of ISAba1 in 12 isolates, providing 
suitable promoter sequences for the transcription of the gene, and thus expressing resistance to 
carbapenems. High-level resistance was not correlated with the presence of ISAba1 in the 
upstream environment of blaOXA-23 in some isolates (table 22) hence suggesting that resistance 
can be mediated by the presence of the blaOXA-23 gene alone. For example, isolate 1780 has a 
very high MIC to both imipenem and meropenem (MIC = 128mg/L), but does not have ISAba1 
upstream.  
Isolates 1780, 1750, 2106, 1447 and 634 were obtained during an A. baumannii outbreak in early 
2011. Resistance was mediated by all five isolates harbouring blaOXA-23. Although some isolates 
were shown to be clonally related, and had similar blaOXA-51-like genes, the upstream environment 
of blaOXA-23 differed significantly. Isolate 1780, 1750 and 2106 were all positive for blaOXA-65 
gene and shared >80% homology in PFGE, but only 1750 and 2106 had ISAba1 upstream of 
blaOXA-23. MICs were also different for these strains ranging from 8mg/L and 64mg/L in isolates 


















4248 CCHE 15/03/2010 65 + 8 4 
4842 CCHE 23/03/2010 65 +  64 32 
9930 CCHE 15/06/2010 65   32 16 
10262 CCHE 19/06/2010 65 + 64 128 
12435 CCHE 23/07/2010 64   16 32 
21382 CCHE 13/12/2010 66 + 16 4 
634 CCHE 11/01/2011 69 + 8 4 
1447 CCHE 24/01/2011 69   0.5 0.06 
1780 CCHE 31/01/2011 65   128 128 
1750 CCHE 31/01/2011 65 + 32 64 
2106 CCHE 08/02/2011 65 + 8 8 
2632 CCHE 20/02/2011 65 + 8 8 
2625 CCHE 20/02/2011 65   16 16 
7052 CCHE 5/7/2011 66 + 8 16 
6332-Abd NCI 02/09/2010 66  + 16 8 
461-SF NCI 15/12/2010 65 + 16 32 
9925-Sam NCI 15/12/2010 64 + 16 8 
P391-AH NCI 14/9/2010 65  8 16 
 
Table 22: blaOXA-23 isolates, hospital, date of culture, associated blaOXA-51-like gene, and MIC 
for carbapenems 
 
3.6.1.3 PFGE for blaOXA-23 isolates 
There is a large diversity within isolates harbouring blaOXA-23, as seen in the PFGE profile (figure 
25) comparison of the isolates below. All isolates from the ICU outbreak in early 2011 are 
divided into two groups: 1447 and 634 sharing 100% identity in their PFGE pattern, and the 
other group comprising 2106, 1750 and 1780 sharing <80% similarity (figure 26). 
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Three clones, although present in different hospitals, have similar PFGE profiles and are positive 
for blaOXA-23. They were 6332-Abd and 634 and 1447, 461-SF and 4842 CCH, and P391-AH and 
10262. That could indicate a clonal dissemination of the strains within hospitals, or transmission 
by physicians, as some physicians work in both hospitals. Noteworthy, isolate 6332-Abd 
harboured a different blaOXA-51-like gene when compared to isolates 634 and 1447, however their 
PFGE patterns are very similar and they were both positive for blaOXA-23 gene.  
As seen in figure 25, four clonal groups can be seen, sharing >80% homology of their PFGE 
pattern.  







































































































































Figure 25: PFGE pattern for blaOXA23 isolates 


































































One isolate, 14611, was found positive for blaOXA-24/40. The isolate was from a CVP culture of a 
15 month old patient in the ICU at CCH.  
 
3.6.2.1 Upstream Environment and localization 
ISAba1, ISAba2 and ISAba3 were screened for, but no insertion sequence was detected upstream 
of the blaOXA-24/40 gene.  
S1 nuclease digestion detected no plasmids in this isolate, hereby suggesting the chromosomal 
location of the blaOXA-24/40 gene.  
 
3.6.2.2 MIC 
The isolate was highly resistant to carbapenems, with MICs of 128mg/L and 32 mg/L for 




Five isolates were positive for blaOXA-58. They were isolates from both hospitals, in several wards 
and different times of the year. From CCH, isolate 14298 was from a catheter tip culture of a 
Hodgkin’s disease patient obtained in August 2010 whereas isolate 2625 was from an Ewing 
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Sarcoma patient in February 2011. As for isolates from the NCI, P67-AZak and P49-Ham were 
both blood cultures isolated in January of 2011, but in different wards. 679-Bas was an ear swab 
culture in September 2011.  
 
3.6.3.1 MIC 
As shown in table 23, all isolates were resistant to Imipenem and Meropenem with MICs ranging 
from 8mg/L to 64mg/L, except isolate 14298 which was sensitive to Meropenem (MIC 2mg/L). 
ISOLATE 
NUMBER








14298 CCHE 22/08/2010 64 ISAba3-IS1006 8 2
2625 CCHE 20/02/2011 65 16 16
Bas NCI 04/09/2010 64 8 8
P49 - Ham NCI 05/01/2011 94 8 8
P67 - Azak NCI 09/01/2011 64 ISAba3-IS1008 64 16  
Table 23: blaOXA58 isolates: associated blaOXA51-like gene, insertions upstream and MIC for 
carbapenems 
 
3.6.3.2 Upstream environment of blaOXA-58 
The blaOXA-58 gene was bracketed by ISAba3 in all isolates. Larger product sizes were observed 
for two isolates (figure 27), and sequencing upstream of blaOXA-58 revealed the presence of 
ISAba3 interrupted by two insertion sequences: IS1006 in one isolate: 14298 (from CCH), and 
IS1008 in P67-AZak (from the NCI). Using BProm (Softberry, Inc., Mount Kisco, NY) promoter 
sequences for 14298 were located in IS1006 with -35 (TTGCA) and -10 (TGGTAAGCT) 17bp 
apart and located 807bp and 786bp upstream of blaOXA-58. As for isolate P67-AZak, promoter 
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sequences were also located in IS1008 with –35 (ATCACA) and -10 (TTTTATACT) 20bp apart 
and located 548bp and 568bp upstream of blaOXA58. The current results show that the promoter 
sequences are provided solely by the IS1006 and IS1008 sequences, rather than forming a hybrid 
promoter with ISAba3. RT-PCR results showed no difference in gene expression level between 
the isolates, with a ratio of ~1, even when compared to an isolate harbouring ISAba3 alone in the 
upstream region. 
 
Figure 27: Amplification of upstream region for blaOXA-58. Strain 14298 &AZak harbour an 
interrupted ISAba3, giving a larger amplicon than strain 18981 (not in strain collection), 
harbouring ISAba3 only. 
 
IS1008 and IS1006 both belong to IS6 family. They do however differ in 15 amino acids, as 
shown in figure 28. The nucleotide alignment significantly differs between the sequences as well 
(figure 29). The location of promoters hence differs in the sequences and no alignment can be 
inferred. Although part of the same family, IS1006 and IS1008 appear to act with different 
mechanisms and have distinct functions, mainly in their contribution in resistance to 






gene, as the MIC to imipenem and meropenem is 64mg/L and 16mg/L, respectively. Whereas in 
isolate 14298, the imipenem MIC was significantly less: 8mg/L and it was intermediate to 
meropenem. The sequences, however, appear to transpose in a similar manner and interrupt the 
ISAba3 sequence approximately after 350bp. Additionally, neither IS1006 nor IS1008 act as 
hybrid promoters and interrupt the promoter sequences of ISAba3 upon transposition.   
 
 
Figure 28: Protein Sequence alignment of IS1006 and IS1008 
 




3.6.3.3 Plasmids and localization of blaOXA-58 
S1 nuclease digestion of isolates 14298 and P67-AZak revealed the presence of 3 plasmids at 
50 kb, 60 kb and 100 kb. Hybridization of blaOXA-58 to these plasmids revealed that the gene was 
located on the 50 kb plasmid. This may indicate that a similar plasmid with blaOXA-58 is 
circulating in the isolates.  
 
3.6.3.4 PFGE analysis for blaOXA-58  
PFGE analysis of blaOXA58 isolates showed a large diversity among the strains, with the 
maximum similarity at 60% (figure 30). Noticeably, isolates 14298 and P67-AZ have similar 
patterns, although they were from different hospitals and harboured a distinct upstream 
environment. This further confirms the localization of blaOXA-58 on plasmids, hence facilitating 
the dissemination of the gene into different clones and hospitals.  


















































3.7 Extended-Spectrum β-lactamases (ESBLs) 
Screening for the presence of an ESBL was performed for isolates resistant to ceftazidime. All 
isolates were negative for SHV, CTX-M and VEB. Positive results are described below. 
 
3.7.1 PER-like enzymes 
Three different blaPER-like genes: blaPER-1, blaPER-3 and blaPER-7 were identified in 3 different 
isolates, from both hospitals.  
Figure 31 shows the amino acid sequence comparison of the three PER-like enzymes identified. 








blaPER-1 was identified in isolate 2625 from CCH. It was from a urine sample of a 15-year old 
Ewing Sarcoma patient. The same isolate was positive for blaOXA-58 and harboured the intrinsic 
blaOXA-65 gene.  
The MIC of ceftazidime was >256mg/L. Phenotypic tests confirmed the presence of an ESBL. 
PCR was positive for blaPER-like genes and sequencing revealed the presence of blaPER-1 gene. 
 
3.7.1.1.1 The genetic environment of blaPER-1 
The genetic environment of blaPER-1 gene was analysed and showed that the gene was flanked by 
two insertion sequences: ISPa12 upstream and ISPa13 downstream (figure 32). This is similar to 
results published by Poirel et al. (2005), who in their report analysed the genetic environment of 
blaPER-1 from different Gram-negative organisms and found the gene to be part of a composite 
transposon, flanked by these two insertion sequences.  
 
           ISPa12              blaPER-1                                   ISPa13 
Figure 32: Schematic representation of the genetic environment of blaPER-1 
 
ISPa12 and ISPa13 both belong to the same IS4family. They do however differ significantly in 
their amino acid with 63% similarity (figure 33). 




Figure 33: Protein sequence alignment for ISPa12 and ISPa13 
 
3.7.1.2 PER-3 
blaPER-3 has only been found in Aeromonas punctata (Wu et al. 2011). This is thus the first 
identification of this gene in A. baumannii. It was found in a urine culture of a 9-year old 
Osteosarcoma patient in CCH.  
Isolates 15094 was resistant to ceftazidime with MIC of 64 mg/L. The intrinsic blaOXA-51-like gene 
was identified as blaOXA-65. The isolate was however sensitive to carbapenems, and did not 
harbour any of the acquired class-D carbapenemases.  
 
3.7.1.2.1 Upstream environment of blaPER-3 
The upstream environment of blaPER-3 was sequenced and revealed the following structure: A 
complex-integron-class-1 structure, harbouring sul1, qacEΔ-1 in the variable 3’CS and orf513 




             Int1  ant(3')-Ij-aac(6')Ib     blaOXA-30    catB3          qacEΔ1    sul1      orf513         blaPER-3 
Figure 34: Schematic representation of the genetic environment of blaPER-3 
 
3.7.1.2.2 Localization of blaPER-3 
Previous reports have shown that blaPER-3 gene could be localized on both plasmids and 
chromosomes (Wu et al., 2011) therefore identification of the location of the gene was attempted 
with this isolate.  
The S1 nuclease digestion revealed the presence of three plasmids, the sizes of which were 60, 
70 and 145.5 kb, respectively. There was no hybridization of blaPER-3 specific probes to any of 
these plasmids, suggesting chromosomal localization of the gene.  
 
3.7.1.2.3 Plasmid curing and conjugation 
Plasmid curing was done to confirm the chromosomal localization of the gene. Ceftazidime 
susceptibility was tested after 10 days of curing, and the zone of inhibition did not increase 
showing no loss of resistance, thus endorsing the chromosomal localization. Furthermore, 
attempted conjugal transfer was also negative. 
 




blaPER-7 has been reported in France (Bonnin et al., 2011) and the UAE (Opazo et al., 2012a). 
Isolate 9925-SAM from the NCI was found to be positive to this gene. 
The MIC of Ceftazidime was 256 mg/L and the isolate had the intrinsic blaOXA-64 gene. MLST 
identified a novel ST for this isolate, assigned ST409. The isolate was furthermore positive for 
blaOXA-23, and was also resistant to carbapenems.  
 
3.7.1 3.1 Upstream environment of blaPER-7  
The upstream environment of blaPER-7 was identical to that reported by Opazo et al. (2012a) in 
that it was located in a complex class-1 integron, with qacEΔ1, sul1  in the variable region, and 
orf513 serving as the promoter of the gene. Downstream of blaPER-7   was a gst gene (figure 35). 
 
 
                    Int1       variable region     qacEΔ1    sul1       orf513             blaPER-7            gst 
Figure 35: Schematic Representation of the genetic environment of blaPER-7 
 
3.7.1.3.2 Localization of blaPER-7 
S1 nuclease digestion revealed 4 plasmids for the isolate. The sizes of these plasmids were 
approximately 60 kb, 140 kb, 145.5 kb and ~155 kb.  
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Upon plasmid extraction from the gel, hybridization of PER-7 was attempted and it was positive 
for the ~155 kb plasmid.  
Plasmid curing was also performed on isolate 9925-Sam to confirm the plasmid localization of 
the blaPER-7 gene, and after 10 days of curing, the ceftazidime zone of inhibition increased from 
1mm to 5mm, thereby confirming the localization on the lost plasmid.  
 
3.7.2 TEM-like enzymes 
TEM-like enzymes are widely found in A. baumannii around the world and confer resistance to 
Ceftazdime as well as other third and fourth generation cephalosporins. . 
Six isolates were positive for blaTEM-like PCR and sequencing of the gene revealed that they all 
harboured the blaTEM-1 gene, a narrow spectrum β-lactamase. TEM-1 is a penicillinase, and is not 
capable of hydrolysing third-generation cephalosporins (Woodford & Ellington, 2007). Only 
TEM-like variants have evolved to hydrolyse third-generation cephalosporins. A disk diffusion 
assay to test susceptibility to ampicillin was performed and revealed that all six isolates had no 
zone of inhibition.  
 
3.7.3 blaADC 
ADCs are naturally occurring cephalosporinases in A. baumannii, the overproduction of which 
causes resistance to cephalosporins. 
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All isolates harboured ADCs, and 6 isolates had ISAba1 upstream of the blaADC gene. The 
presence of the insertion sequence upstream correlated with high resistance to ceftazidime as 
seen in table 24. 
ISOLATE       MIC - CAZ 
7052        >256mg/L 
634        >256mg/L 
21382        >256mg/L 
1447        >256 mg/L 
Abd        >256mg/L 
14611         >256mg/L 
Table 24: Isolates harbouring ISAba1 upstream of blaADC and the associated ceftazidime 
MIC 
 
No other mechanism of ceftazidime of resistance was detected in the isolates harbouring ISAba1 
upstream of the blaADC gene, suggesting the overexpression of blaADC is the sole resistance 
determinant.  
Furthermore, the overexpression of blaADC seems to correlate with blaOXA-23, where five of the 
isolates harbour the acquired blaOXA-23 gene contributing to carbapenem resistance. Only isolate 
14611 harboured blaOXA-24/40. Interestingly, the overexpression of blaADC was associated with 






3.8 PFGE profile analysis 
Banding pattern similarity was assessed using the Dice co-efficient. Overall similarity was 
calculated as 28.69%. A large variability is seen in the PFGE profiles of the isolates, with only 6 
groups of 2 isolates sharing >80% similarity (figure 36). The majority of isolates had <60% 
similarity, even if they harboured the same blaOXA51-like gene. The results indicate the presence of 
several clones from different origins in the hospital. This is particularly apparent given the clonal 
diversity found within one ward at the hospital. 
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Figure 36: PFGE pattern for all isolates, location of patients, date of isolate, blaOXA-51-like 
gene, CHDL and blaADC 
  
3.8.1 Diversity in the NCI 
The isolates obtained from patients at the NCI were localized in that most of them were 
recovered from patients on one floor of the hospital, with the exception of two isolates. The 
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PFGE profiles of these isolates were very diverse, and also showed the presence of several 
clones in this case not only within the hospital, but in one floor of that hospital (figure 37).   




















































































Figure 37: PFGE pattern for isolates from the NCI, site of isolate, location of patients, date 
of isolate, blaOXA-51-like gene, CHDL and ST.  
 
 
3.8.2 Association of blaOXA-51-like clones at CCH with governorates 
Given the large diversity within strains from CCH as well as the different governorates from 
which patients originate, a comparison using the PFGE profile and blaOXA-51-like gene was carried 
out to assess whether a particular clone originated from a particular governorate and 








Two patients from Alexandria had A. baumannii infections at CCH. They had different 
blaOXA-51-like genes and were epidemiologically different according to their PFGE patterns as seen 
in figure 38. It can therefore not be concluded that the strains were brought by the patients. 































Figure 38: PFGE pattern of isolates obtained from patients form Alexandria 
 
3.8.2.2 Bani Sweif 
Two patients from Bani Sweif were found to harbour A. baumannii with blaOXA-65 as their 
intrinsic genes. Although the isolates were recovered on closely related dates (Figure 39) the 
patients were hospitalized in different wards at the hospital.  Despite having similar blaOXA-51-like 
genes, their PFGE profiles indicate the isolates are epidemiologically distinct.  































Similar to the results seen above, isolates obtained from patients originating from Cairo have 
similar blaOXA-51-like genes: blaOXA-65, but have distinct PFGE profiles (figure 40).  










































Figure 40: PFGE patterns of isolates obtained from patients from Cairo 
 
3.8.2.4 El Dakahleya 
Four isolates obtained from patients originating from El-Dakahleya identified 2 intrinsic genes: 
blaOXA-66 and blaOXA65. Two isolates: 21382 and 7052 were both located in the ICU but in 
different months, they both harboured blaOXA-66 and had identical PFGE profiles (figure 41). This 
may indicate they were brought from the patients into the hospital, which is hence representative 
of the clones present in El Dakahleya. On the other hand, although isolate 14611 was also 
positive for blaOXA-66, it had a very distinct PFGE profile.  Some similarity to isolate 4248, 
positive for blaOXA-65 was seen when PFGE profile was compared with that of 21382 and 7052, 
which may also indicate a common origin from which clones evolved in that governorate. 
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Figure 41: PFGE patterns of isolates obtained from patients from El Dakahleya 
 
3.8.2.5 El Fayoum 
Two patients from El Fayoum were both hospitalized in the ICU but in different months. They 
both had blaOXA-65 as the intrinsic enzyme but very distinct PFGE profiles (figure 42). No 
epidemiological link can be established between these strains, as they seem to originate from 
different origins.  




































3.8.2.6 El Sharkeya 
Two patients from El-Sharkeya were infected with two distinct A. baumannii isolates harbouring 
blaOXA-78 and blaOXA-64. The difference in PFGE pattern (figure 43), blaOXA-51-like, location and 
date of infection indicated that the isolates did not have a common origin, and they cannot be 
attributed to the governorate from which the patients were from.  



























Figure 43: PFGE patterns of isolates obtained from patients from El Sharkeya 
 
3.8.2.7 Giza 
Four isolates were recovered from patients from Giza, with 3 genes identified: blaOXA-65, 
blaOXA-89/100 and blaOXA-69. Isolates 1447 and 634 were part of the ICU outbreak and given their 
identical PFGE pattern, they seem to have been clonally related and of similar origin. Strain 634, 
which was isolated first, was probably transferred in the ICU by a healthcare worker and hence 
caused the infection in another patient, yielding strain 1447 two weeks later. Additionally, some 
homology in PFGE profile is seen to strain 15094, which may again postulate the possibility a 
common evolutionary origin (figure 44).  
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Figure 44: PFGE patterns of isolates obtained from patients from Giza 
 
3.8.2.8 Qina 
Two genetically and epidemiologically distinct isolates were recovered from patients from Qina. 
blaOXA-64 and blaOXA-71 genes have been reported to be closely related enzymes (Evans et al. 
2008) which therefore might mean that both isolates have evolved separately but from a common 
origin. Figure 45 shows the distinct patterns of the isolates.  



































3.9 Carbapenem susceptibility  
A total of 16 and 18 isolates were resistant to imipenem and meropenem by disk-diffusion assay, 
respectively.  
A total of 26 isolates representing 76% were resistant to either Imipenem, Meropenem or both 
(MIC ≥8mg/L) according to the BSAC guidelines. Four isolates (4248, 634, 21382 and 14298) 
were resistant to Imipenem but intermediate to Meropenem. Eight isolates were sensitive to both 
Imipenem and Meropenem.  
Resistance to either Imipenem or Meropenem was associated with the presence of CHDL as 
stated previously. Isolates 4248, 634, 21283, which were resistant to Imipenem and intermediate 
to Meropenem, encoded blaOXA-23 with an associated ISAba1 upstream, whereas isolate 14298 
encoded blaOXA-58 with a hybrid promoter ISAba3-IS1008 upstream. This means that the 
presence of insertion elements upstream of resistance genes did not result in resistance to all 
classes of carbapenems. Additionally, for isolate 22055, carbapenem resistance was attributed to 
the presence of ISAba2 upstream of blaOXA-89/100, as no CHDL was detected.  
Sensitive isolates contained no CHDL, with the exception for isolate 1447, which was positive 








3.10 Metallo β-lactamases 
The isolates were screened for the presence of metallo β-lactamases (MBL) phenotypically in 
addition to amplification of genes by PCR. Both methods yielded negative results, suggesting no 

















Chapter 4: Discussion 
 
4.1 Diversity in blaOXA-51-like genes 
blaOXA-51-like genes are ubiquitous in A. baumannii and are used for identification as well as 
typing-scheme in assigning isolates to particular sequence groups (Hamouda et al., 2010) 
In the current study a large diversity was found in the sequences of blaOXA-51-like with eight 
different gene families identified. This is particularly interesting given the short duration of 
isolate collection (1.5 years) as well as the isolates deriving from only two hospitals. 
Previous reports of the genetic diversity of A. baumannii isolates showed the presence of seven 
different blaOXA-51-like genes collected from 200 isolates between 1982 and 2005 (Merkier & 
Centrón, 2006). The current study hence gives an insight into the diversity of isolates present in 
Egyptian hospitals.  
Three large groups around OXA-66, OXA-69 and OXA-98 were identified by Evans et al. 
(2008) in addition to other unrelated branched enzymes (Figure 46). European Clones (EC), now 
known as Worldwide clones 1 and 2, are successful lineages reported in outbreaks from around 
the world and associated with OXA-69 and OXA-66 clusters respectively (reviewed by Zander 
et al. 2012; Evans et al. 2008). Evans et al. (2008) identified OXA-65 as a central hub and 
ancestral to all other OXA-51-like enzymes and that there was a clear pathway to the OXA-69 





Figure 46: OXA-51-like enzyme linkage map with the enzymes identified in this study 
circled in red. From Evans et al (2008). 
 
As seen in figure 46, the blaOXA-51-like genes identified in the current study are widely scattered in 
the linkage map and not clustered around the same group.  This indicates a diverse origin on the 
isolates.  
The majority of isolates in the current study belonged to blaOXA-65 (n=14), which shows the 
presence of the ancestral blaOXA-51-like gene in A. baumannii in Egypt. This may also explain the 
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large diversity found in the current collection was a result of evolution of the ancestral gene, 
rather than the foreign carriage of clones into the country.  
blaOXA-94, forms a branch of blaOXA-65 cluster with three amino acid substitutions in the resultant 
protein. Two isolates from the NCI were recovered one day apart, both harbouring blaOXA-94. The 
NCI is an old hospital in Cairo, built in the early 1970s. If we assume that A. baumannii has been 
present in the NCI since it was built, blaOXA-94 might have evolved from blaOXA-65. This can 
however only be determined if a study is performed on all A. baumannii isolates since the 
establishment of the NCI.  
The OXA-66 enzyme cluster is the largest group identified by Evans et al (2008) with seven 
different groups originating from it. blaOXA-69, blaOXA-66 and blaOXA-71 have been associated with 
Worldwide (WW) Clones I, II and III respectively and all have been identified in the current 
study  (Zarrilli et al. 2009; Evans et al. 2008; Seifert et al. 2005; Zander et al. 2012). WW1 and 
WW2 seem to be more geographically widespread than other clones (Higgins et al. 2010). 
blaOXA-66 and blaOXA-71 genes were identified in both hospitals which may indicate local 
distribution in Egyptian hospitals. blaOXA-69, on the other hand, was found in two isolates in the 
ICU outbreak in early 2011 at CCH only. This illustrates the extent of spread of the major 
lineages of A. baumannii. Furthermore, the presence of the cluster enzymes OXA-66 and OXA-
69 shows the presence of the major lineages of A. baumannii in Egypt.  
The OXA-98 cluster contains five related enzymes: OXA-89 with three amino acid substitutions, 
OXA-78 with two amino acid substitutions, OXA-68, OXA-77 and OXA-91 with one amino 
acid substitution. blaOXA-89 and blaOXA-78 were both identified in single isolates from CCH. It 
cannot be determined if the mutations from blaOXA-98 happened in Egypt to generate these 
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enzymes. Reports of A. baumannii encoding OXA-78 and OXA-89 from as early as the 1980s 
(Evans et al. 2008) in Argentina, suggest that the presence of these enzymes occurred before the 
identification of A. baumannii as a major hospital pathogen (Evans et al. 2008).  
blaOXA-71 and blaOXA-64 belong to branches rather than belonging to a group. Both enzymes are 
present in both hospitals. blaOXA-64 is now repeatedly reported in isolates from the Middle East 
(Opazo et al. 2012a; Al-Hasan 2012). blaOXA-71 is closely related to blaOXA-64 as they seem to 
originate from a common ancestor, but are part of different clones: WW3 and WW7, respectively 
(Figure 46) (Zander et al. 2012). 
The current results suggest sporadic cases of A. baumannii rather than the presence of a single 
clone in the hospitals.  
WW1 and WW2 contain the largest group of blaOXA-51 variants, which according to (Zander et al. 
2012) might indicate relatively older lineages. Furthermore, carbapenem therapy may also play 
an important role in the selection of successful lineages of OXA-51, especially when it is the sole 
carbapenem resistance mechanism and associated with ISAba1.  
 
4.1.1 Insertion of ISAba2 upstream of blaOXA-89 
blaOXA-51-like genes associated with the presence of ISAba1 upstream in conferring resistance to 
carbapenems (reviewed by Peleg et al. 2008). ISaba9 has also been reported upstream of blaOXA-
51 in a carbapenem resistant A. baumannii (Figueiredo et al., 2009). ISAba2 has been found 
upstream of blaOXA-58 serving to mobilize the gene as well as providing promoter for the 
expression of resistance (Poirel & Nordmann, 2006b).   
121 
 
In isolate 22055 from CCH, ISAba2 was identified upstream of blaOXA-89. The isolate was 
resistant to carbapenems (MIC 128mg/L for imipenem and 256mg/L for meropenem). With no 
other resistance mechanism identified, the resistance was attributed to the localization of ISAba2 
upstream of blaOXA-89/100 and providing a suitable promoter. This is the first report of ISAba2 
upstream of a blaOXA-51-like gene. 
 
4.1.2 Epidemiological relatedness of blaOXA-51-like genes by PFGE 
The diversity of blaOXA-51-like genes was further illustrated in their PFGE pattern. The overall 
similarity at 28% suggested the presence of different clones within the same hospital. This could 
be due to the localization of the patients in different wards and at different times in the hospital. 
Even for isolates recovered from the ICU at different times, there seems to be significant 
variability in profiles. 
The distribution of blaOXA-51-like genes in the different governorates was assessed aiming to 
explain the observed diversity. blaOXA-65 gene, the most prevalent gene identified, was found in 
patients from diverse origins from eight different governorates. blaOXA-64 was present in patients 
from four governorates. blaOXA-66 seems more localized in patients from one governorate, and 
similarly for blaOXA-69. All other genes are found in a single isolate, and would therefore not give 
an accurate result.  
If we assume that the different clones were brought by patients into the hospital we can therefore 
see the wide distribution of clones in the different regions in Egypt. Additionally, since blaOXA-65 
is thought to be ancestral to all blaOXA-51-like genes (Evans et al., 2008), the prevalence of this 
enzyme in many governorates may reflect the evolution of the different genes in bacteria in the 
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different regions of Egypt. Furthermore, five worldwide clones are present in the two Egyptian 
hospitals: WW1, WW2, WW3, WW5, WW7 (Zander et al., 2012). 
If this hypothesis is to be taken further, two patients from Qina, a governorate in Upper-Egypt 
were found to harbour blaOXA-64 and blaOXA-71 which are closely related enzymes (Evans et al. 
2008). These two isolates might have evolved from the same origin and got disseminated in the 
environment and was later brought by the patients to CCH. 
The linkage map below shows the relationship of enzymes identified in the different Egyptian 
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4.2 Multi-locus sequence typing 
A total of 10 isolates were chosen for analysis by MLST. The 10 isolates were representative of 
each blaOXA-51-like gene identified, and when the same gene was identified in both hospitals, an 
isolate from each hospital was randomly selected for comparison. Table 25 shows the isolates 





8357 CCH 64 408 
9925-Sam NCI 64 409 
1780 CCH 65 410 
634 CCH 69 108 
P67 - Azak NCI 64 411 
21174 CCH 78 412 
22055 CCH 100 413 
161 CCH 71 414 
P38 - Ysf NCI 94 331 
14611 CCH 66 208 
 
Table 25: List of blaOXA-51-like gene associated with the different STs. 
 
Given the diversity of the isolates in this study, it was expected to find novel STs. In fact, of the 
10 isolates typed by MLST, seven novel STs for isolates: 8357, 9925-SAM, 1780, P67-AZak, 
21174, 22055, 161 and 14611 were assigned ST408 – ST414. Isolates 634, P38-Ysf and 14611 
were assigned ST108, ST331 and ST208, respectively. These STs have previously been 




Isolates 9925-SAM and P67-AZak both from the NCI harboured the same blaOXA-51-like gene, 
were assessed for their similarity, and the prevalence of STs in the same hospital. Interestingly, 
these two isolates were assigned two novel STs: ST409 for SAM and ST411 for P67-AZak. As 
seen in table 21 (results section), ST409 and ST411 share, however, four similar alleles: gyrB, 
gdhB, recA and rpoD. This similarity shows a degree of relatedness in those strains.  
The different STs identified in this study further illustrate the large diversity found in the 
collection of strains. This could indicate the presence of distinct clones in the two hospitals, 
especially that they were isolated at different months and in separate wards. Additionally, this 
diversity may also represent dissimilar clones brought to the hospitals from diverse geographical 
locations. To determine the prevalence of a certain ST in Egyptian hospitals, a larger study 
should be done on more Egyptian hospitals in diverse geographical locations.  
Furthermore, no evolutionary relationship or clonal complexes can be inferred for the isolates in 
this study using e-BURST, endorsing the diversity of the strain collection. A population snapshot 
represented no linkage between the STs (figure 22). However, the population snapshot showed 
the relatedness to other STs identified from around the world. ST208, for example, is ancestral to 
several STs including ST89, ST88, ST190, ST225, ST75 identified in different parts of the world 
such as Japan, China, Thailand, Korea, Italy, Australia, Portugal and the Czech Republic. ST108 
has been identified in Argentina and Brazil an shared six alleles with ST109 from Argentina, and 
which also seemed to be the ancestral ST in its group. ST419, also sharing six alleles with 
ST108, decended from ST108, according to the population snapshot (figure 22).  
MLST is useful in global epidemiological studies particularly due to the transferability of typing 
data between different laboratories resulting in an easier comparison of results (Hamouda et al. 
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2010; Bartual et al. 2005; Wisplinghoff et al. 2008). The given results lead us to speculate about 
the efficiency of using MLST as a typing method for sporadic cases such as those represented in 
this study. A larger population of isolates, preferably from different hospitals in Egypt may be 
better represented by MLST to determine the prevalent ST as well as the evolutionary 
relationship of the isolates and their relatedness.  
Previous reports of the different typing methods have shown a better correlation between 
sequencing of blaOXA-51-like and MLST than with PFGE (Hamouda et al. 2010) . In this study, as 
the isolates are sporadic, MLST was not correlated with blaOXA-51-like genes, as seen in the case of 
P67-AZak, 9925-SAM and 8357, all harbouring blaOXA-64 but assigned different STs. 
The PFGE profiles of isolates typed by MLST further illustrate the diversity, showing the 
distinct patterns. Thus, this endorses the hypothesis of the isolates being brought into the centres 
by different patients and from distinct geographical locations around Egypt. 
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4.3 The contribution of acquired class D β-lactmases to carbapenem resistance  
The NCCN guidelines for treatment of Febrile Neutropenia are followed by physicians in both 
the National Cancer Institute and The Children’s Cancer Hospital in Cairo. First line antibiotics 
are a broad-spectrum plus an anti-pseudomonal agents. Changing the antibiotics occur either 
according to the blood culture susceptibility profile or if the patient condition is not improving 
after three days of antibiotics administration. The second line of treatment are carbapenems in 
proven Gram-negative infections. Colistin is not available in most Egyptian hospitals, which is 
the reason behind the extensive use of carbapenems to treat severe A. baumannii infections, 
sometimes even despite resistance. Imipenem and Meropenem are the only carbapenems 
available in Egyptian hospitals.  
Seventy-three percent of the isolates were resistant to carbapenems, and this is associated with 
all three CHDL genes found in this study. 
 
4.3.1 blaOXA-23 
blaOXA-23 was the most common gene identified in the isolates, accounting for 53%. Three 
genetic structures were determined to harbour and mobilize blaOXA-23: Tn2006, Tn2007, and 
Tn2008 (Mugnier et al. 2010; Wang et al. 2011) . ISAba1 was only found upstream of blaOXA-23 
in the current study, which indicates the mobilization of the gene by the presence of the IS 
element, showing a structure of a truncated transposon. . This is consistent with the observed 
resistance to carbapenems, provided by the promoters in ISAba1 upstream of the gene.  
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blaOXA-23 has been reported in different regions of the Middle East, in strains from The United 
Arab Emirates, Algeria, Libya and Bahrain and the associated genetic structures were diverse: 
Tn2008, Tn2006, Tn2007 as well as ISAba1 (Mugnier et al. 2010; Mugnier et al. 2008; Mugnier 
et al. 2009). Interestingly, an isolate from Egypt harbouring blaOXA-23 was found to be plasmid-
mediated and associated with ISAba1 as its genetic structure (Mugnier et al. 2010). The given 
results might indicate the prevalence of this genetic environment of blaOXA-23 in Egyptian 
isolates. 
According to the PFGE pattern (figure 25), four epidemiologically related groups can be seen, 
sharing >80% similarity. Isolates SF-461 and 4842 were from two different hospitals but shared 
similar blaOXA-51-like genes, and a similar situation was found for isolates P391-AH and 10262.  
PFGE profiles of the isolates are also very diverse which shows the dissemination of blaOXA-23 in 
different A. baumannii clones. The ICU outbreak in CCH belonged to two clones, as revealed by 
their PFGE profiles and sequencing of the instrinsic blaOXA-51-like, but the carbapenem resistance 
was mediated by blaOXA-23, detected in all isolates in the outbreak.  
blaOXA-23 was detected in different clones with different blaOXA-51-like genes. The majority of 
blaOXA-23 genes were present in isolates harbouring blaOXA-65 (10 out of 18 isolates). This 








Five isolates were positive for blaOXA-58 genes in this study, all being resistant to imipenem and 
meropenem, with the exception of isolate 14298 which was intermediate to meropenem. ISAba3 
was detected flanking blaOXA-58 genes in all isolates. Two isolates: 14298 and P67-AZak 
harboured an interrupted ISAba3 upstream, and sequencing revealed the presence of IS6 family 
sequences: IS1006 and IS1008 in those strains.  
 
 
Figure 48: Schematic representation of the genetic environment of blaOXA58 
blaOXA-58 has been frequently identified in carbapenem-resistant A. baumannii from different 
regions of the world (Coelho et al. 2006; Poirel & Nordmann,2006). ISAba3 was found flanking 
the gene and hence served as a promoter upstream in addition to effective mobilization of 
blaOXA-58 (Chen et al. 2008). Hybrid promoters, with an interrupted ISAba3 sequence upstream, 
have also been identified to confer high level of carbapenem resistance by enhancing the 
transcription of blaOXA-58 (Chen et al. 2010). Other ISs including ISAba1 and ISAba2 have also 
been identified in providing suitable promoters for blaOXA-58 in A. baumannii (Poirel & 
Nordmann, 2006) 
This thesis shows that, although the upstream ISAba3 in both strains was interrupted by insertion 
sequences, the promoters were not hybrid, as the -35 and -10 sequences were solely located in 
IS1006 and IS1008. Additionally, the ISAba3 was truncated upstream of blaOXA-58 gene by the 
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transposition of IS1006 and IS1008, which hence illustrates that IS1006 and IS1008 inserted 
upstream of blaOXA-58, and provided promoter sequences for effective transcription of the gene. 
The localization of IS1006 and IS1008 disrupted the promoter provided by ISAba3.  
IS1006 has only been characterized in Acinetobacter nosocomialis (Chen et al., 2010), so the 
current finding is the first report of this IS in A. baumannii. The plasmid containing blaOXA58 and 
the associated upstream environment was probably transferred to A. baumannii by horizontal 
gene transfer. In the study by Chen et al (2010), IS1006 was inserted into the ISAba3 sequence 
rather than interrupting it, thus explaining the presence of a hybrid promoter. The MIC of 
imipenem was 16mg/L (Chen et al., 2010), whereas in isolate 14298, the MIC was 8mg/L and it 
was intermediate to Meropenem (MIC 2mg/L). This may indicate that IS1006 on its own does 
not provide a strong promoter, when compared to the resistance observed in the isolate 
harbouring a hybrid promoter.  
IS1008 also reported by Chen et al. (2006), was detected on a plasmid of a carbapenem-resistant 
A. baumannii isolate. In contrast to IS1006, the ISAba3 upstream of blaOXA-58 was truncated by 
the insertion of IS1008. Hence, this is similar to isolate P67-AZak in the current study. On the 
other hand, the promoter in the report by Chen et al. (2006) was hybrid with -10 box located in 
the ISAba3 and -35 box located in the IS1008, whereas for isolate P67-AZak they were both 
located in IS1008. Interestingly, the MICs of imipenem and meropenem (64mg/L and 16 mg/L, 
respectively) reported by Chen et al (2006) were identical to those of isolate P67-AZak in the 
current study. The given results show that IS1008 alone can provide a suitable strong promoter 
for high-level resistance to carbapenems. 
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Although both IS1008 and IS1006 both belong to the same family IS6, they seem to differ in 
their contribution to carbapenem resistance. Their localization upstream of blaOXA-58 serves to 
provide promoter sequences for transcription of the gene by interrupting the upstream ISAba3 
sequence. The promoter provided by IS1008 was stronger as a higher MIC was seen for 
imipenem and meropenem when compared to the isolate harbouring IS1006, which was only 
resistant to imipenem and intermediate to meropenem.  
IS6 family sequences act as effective promoters for the expression of carbapenem resistance by 
blaOXA-58. In the current study, IS1006 and IS1008 were found to interrupt the ISAba3 sequence 
upstream and hence they alone provided the promoters. Additionally, the similarity in results 
between the current study to those reported by Chen et al. (2006, 2010) illustrates how similar 




One carbapenem-resistant isolate was found positive for blaOXA40. Sequence alignment showed 
no silent mutations in the sequence, with 100% identity to OXA-40 sequence described by Bou 
et al. (2000). No plasmid was detected in that isolate, suggesting a chromosomal localization of 
the gene. blaOXA-40 has been identified in different parts if the world, including Spain, USA and 
Bahrain (reviewed by Peleg et al. 2008; Mugnier et al. 2009). Localization can be chromosomal 
or plasmid-mediated, and is not associated with any insertion sequence (Peleg et al. 2008; 
Castanheira et al. 2008). blaOXA40 appear to produce high MICs of imipenem and meropenem, 
even without an IS element, and inactivation of this gene leads to sensitivity to carbapenems 
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(reviewed by Peleg et al. 2008; Héritier et al. 2005). The MICs for isolate 14611 harbouring 
blaOXA40 was 128mg/L for imipenem and 32mg/L for meropenem, revealing the effect of this 
gene on carbapenem resistance. These MICs are amongst the highest seen in the isolates, 
suggesting that blaOXA-40 contribute to produce higher MICs to carbapenems when compared 
with MIC for isolates with blaOXA-23 and blaOXA-58 genes (reviewed by Peleg et al. 2008; Héritier 
et al. 2005).  
blaOXA24 was reported in a plasmid isolated from A. calcoaceticus (Merino et al. 2010). The full 
plasmid was sequenced and revealed that the blaOXA24 gene was flanked by XerC/XerD-like sites, 
responsible for mobilization of the gene. This structure was not detected in the current study, 
which may explain the limited spread of this gene in the isolates, particularly as it was not 
localized on a plasmid. The localization of blaOXA-40 in the chromosome, in addition to the lack 
of associated insertion sequences largely contributes to the limited distribution not just in the 
Egyptian isolates, but around the world, with fewer reports of outbreaks caused by blaOXA-40 than 










4.4 The contribution of Extended-spectrum β-lactamases to ceftazidime resistance 
Extended-spectrum β-lactamases (ESBLs) are increasingly reported in A. baumannii. They 
contribute to resistance toward broad-spectrum cephalosporins such as ceftazidime, cefotaxime 
and ceftriaxone and are inhibited by β-lactamase inhibitors such as tazobactam, clavulanic acid, 
sulbactam (Poirel et al. 2012). blaPER-like, blaVEB, blaTEM, blaCTX-M and blaGES genes have been 
reported in clinical A. baumannii infections worldwide (reviewed by Peleg et al. 2008).  
In the current study, three variants of blaPER-like genes were identified in three strains: blaPER-1, 
blaPER-3, and blaPER-7, as well as the identification of blaTEM-1 in 6 isolates.  
 
4.4.1 blaPER-1  
blaPER-1 was detected in isolate 2625 from CCH. The associated genetic environment was 
determined to consist of two insertion sequences: ISPa12 and ISPa13 flanking blaPER-1.  
blaPER-1 was initially identified in Pseudomonas aeruginosa and later in several bacterial species 
including A. baumannii (reviewed by Peleg et al., 2008; Poirel et al., 2005; Bonnin et al., 2011). 
The localization of blaPER-1 gene can either be on plasmids or chromosome with an associated 
upstream IS enhancing its expression (reviewed by Peleg et al., 2008; Poirel et al., 2005a; Poirel 
et al., 2012). The gene was not located in a class 1 integron, but rather associated with a 
transposon-related structure: Tn1213 (Poirel et al., 2005a).  
Poirel et al. (2005) identified Tn1213 always localized inside an ISPa14 element, which is 
similar to ISAba3  in A. baumannii, and this may suggest that the acquisition of the genetic 
environment of blaPER-1 initially occurred in A. baumannii rather than P. aeruginosa.  
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No plasmids harbouring blaPER-1 were detected in the current isolates, which may explain the 
limited dissemination of blaPER-1. Isolate 2625 harboured blaPER-1 which represented a sporadic 
case of PER-1 enzyme in the hospital.  
Additionally, the genetic environment of blaPER-1 seems to be conserved in isolates from distinct 
geographical locations, with the mobilization and expression of the gene mediated by the 
presence of insertion sequences. PER-1 is widely distributed in the Mediterranean region, with 
several reports in Greece and Turkey. In fact, a study conducted in Turkey found 32% of A. 
baumannii harbouring blaPER-1 as the resistance mechanism against ceftazidime (Poirel et al. 
2012). A case report of a Hungarian tourist, hospitalized in Egypt was found to harbour a PER-1 
producing A. baumannii strain. Hence, this means that PER-1 is present in other Egyptian 
hospitals, but maybe due to the lack of reports, we cannot get an accurate estimation of the 
prevalence PER-1 in Egypt.  
 
4.4.2 blaPER-3 
This is the first identification of blaPER-3 in a clinical A. baumannii isolate, resistant to all 
antibiotics except carbapenems. Previous reports of this gene have been from Aeromonas 
punctata isolate from France and recently also in Taiwan. In that strain, blaPER-3 was reported to 
be localized on both plasmids and chromosome (Wu et al. 2011; Toleman et al. 2006); however, 
in this study, it was identified on the chromosome alone. The genetic environment upstream of 
blaPER-3 was similar to the A. punctata isolate identified in France (GenBank accession no. 
AY740681.1), being located in a complex-class-1 integron.  
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The mechanism of acquisition of the gene by A. baumannii is unknown, but I hypothesize that 
the blaPER3 gene was acquired by A. baumannii through horizontal gene transfer from A. 
punctata. The genetic transfer of blaPER-3 is also facilitated by the localization of the gene within 
an integron, which can easily be transferred between organisms. Much of the increasing 
incidence of resistance around the world has been attributed to the localization of resistance 
genes within mobile genetic elements (Toleman et al. 2006a). blaPER-3 might have been 
transferred to A. baumannii by a plasmid harbouring the integron, which later migrated into the 
chromosome.  
The structure of PER-1 has been studied by Trainer et al (2000) and revealed a completely new 
fold of the Ω-loop region, organised in secondary structure elements, compared with other 
ESBLs. PER-3 is a point-mutant derivative of PER-1 (Wu et al. 2011) harbouring the following 
change H134L. According to the structure determined by Trainer et al (2000), this mutation is 
positioned in H4 helix of the secondary structure of the Ω-loop region. The Ω-loop region is 
associated with the active site of class A β-lactamases (Banerjee et al. 1998), and the observed 
mutation could explain the reduced resistance to ceftazidime, MIC = 64 mg/L, in the isolate 
harbouring blaPER-3 when compared with other A. baumannii isolates harbouring blaPER-1 and 
blaPER-7, MIC >256 mg/L and 256 mg/L, respectively. 
Although blaPER-3 shares considerable homology to blaPER-1, the upstream regions of these genes 
differ significantly. blaPER-3 lacks IS elements flanking the gene and harbours ISCR1, which is 
closely associated with class A ESBLs and facilitates the movement of these resistance genes 





blaPER-7 was identified in a single isolate from the NCI, resistant to all antibiotics. The first 
identification of blaPER-7 was in a clinical A. baumannii isolate from France  (Bonnin et al. 2011) 
and later in an isolate from the United Arab Emirates (Opazo et al., 2012a). The localization of 
this gene can be chromosomal or plasmid-mediated (Bonnin et al. 2011; Opazo et al. 2012a). In 
the current isolate, blaPER-7 was located on a ~155kb plasmid, smaller than the 200kb plasmid 
identified harbouring the same gene in the United Arab Emirates isolate (Opazo et al. 2012a).  
Interestingly, many similarities are shared between the current isolate and those reported in 
France and UAE. All three isolates contained the blaOXA-64 intrinsic gene, as well as harbouring 
the acquired blaOXA-23. ISAba1 was present upstream of blaOXA-23 in the current isolate as well as 
the one reported in UAE. The genetic structure of blaPER-7 was similar in the three strains, being 
located within a complex class-1 integron. orf513 is a putative transposase associated with 
several antibiotic resistance genes (Toleman et al. 2006b) and it was found directly upstream of 
blaPER-7 hence mediating the expression of the resistance gene. orf513 is also associated with 
class-1 integron structures (Toleman et al. 2006b; Bonnin et al. 2011).  
A novel ST, ST409, was assigned for the isolate harbouring blaPER-7 in the current study. The 
isolate from UAE was also typed by MLST and assigned ST110 (Opazo et al, unpublished 
results). ST409 and ST110 are closely related and only differ at two loci. This indicates that both 
isolates may share a similar origin. 
Given that the strains in UAE and France were isolated in 2008 and 2010, respectively, plasmid-
mediated PER-7 originated in the UAE, and later migrated to the chromosome as seen in the 
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French isolate (Opazo et al., 2012a). The results further suggest the presence of the plasmid 
containing PER-7 in the Middle East.  
 
4.4.4 blaTEM  
TEM-like enzymes comprise one the largest group of ESBLs identified in the clinical setting, 
comprising 196 variants (Poirel et al. 2012). TEM-like enzymes are mainly plasmid mediated 
and frequently associated with Enterobactericea. To date, more than 130 variants of TEM-like 
enzymes have been reported (http://www.lahey.org/Studies/ last accessed 5 December 2012). In 
A. baumannii, only TEM-92 and -116 have been identified in Europe to cause resistance to 
cephalosporins (Peleg et al. 2008).  
In this thesis, blaTEM-1 was identified in 6 isolates, 5 of which are from CCH. TEM-1 enzymes 
are penicillinases, with a narrow-spectrum ESBL activity. This enzyme is prevalent in A. 
baumannii and has low-level ceftazidime hydrolyzing activity (Poirel et al. 2012; Peleg et al. 
2008; Bush 2001; Livermore & Woodford 2006). TEM-like variants have developed to 
hydrolyse third-generation cephalosporins more efficiently and hence cause resistance.  
Furthermore, TEM-1 was identified in 40% of isolates in Walter Reed Army Medical Centre, 
obtained from soldiers injured in Iraq and Afghanistan (Hujer et al. 2006).  
In the current study, the detection of a narrow-spectrum β-lactamase TEM-1 does not serve as a 
threat to the spread of resistance, but can create a potential problem if mutations occur in the 
gene, giving rise to enzymes with ceftazidime-hydrolysing activity such as TEM-96. The 
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plasticity of ESBLs structurally and functionally, facilitates evolutionary processes to give rise to 
a large variety of enzymes with expanded substrate spectrum (Gniadkowski, 2008).  
 
4.5 Acinetobacter-derived cephalosporinases (ADC) 
blaADC are chromosomally encoded genes inherent to A. baumannii (reviewed by Peleg et al. 
2008; Segal et al. 2004). Resistance to ceftazidime and extended-spectrum cephalosporins is 
only mediated when an IS is present upstream of blaADC gene, thereby upregulating the 
expression. ISAba1 is the most commonly associated IS element with ADC (Segal et al. 2004; 
Corvec et al. 2003; Mugnier et al. 2009). ISAba125 has also been identified upstream of blaADC 
genes and contributed to ceftazidime resistance (Lopes et al., 2011. P601, ECCMID). 
blaADC was detected in all the strains in the current strains, with 6 isolates harbouring ISAba1 
upstream of blaADC gene and contributing to an MIC of ceftazidime of 256mg/L. ADC 
β-lactamases are only capable of hydrolysing extended-spectrum cephalosporins when it is 
‘overproduced’.  
The results give insight into the importance of ISAba1 in the of A. baumannii genome. It plays a 
vital role in expression, acquisition and mobilization of several resistance genes, such as 
blaOXA-51-like, blaOXA-23 and blaADC (Héritier et al. 2006). ISAba1 seems to enhance the plasticity of 
the A. baumannii genome. It is widely distributed in A. baumannii worldwide, present in both 
susceptible and resistant isolates (Mugnier et al. 2009). ISAba1 is capable of transposition and 




Chapter 5: Conclusions: 
A variety of resistance mechanisms are present in the isolates obtained from the two centres in 
Egypt. Additionally, several clones are present which harbour and express these resistance 
mechanisms. Unlike most hospitals, there were several clones spreading through and a number 
of sporadic strains as well. The diversity in blaOXA-51-like genes is seen in the isolation of 8 
different genes in thirty-four isolates from two hospitals. The PFGE pattern also distinguishes the 
isolates into different groups and does not correlate with blaOXA-51-like, suggesting the presence of 
epidemiologically diverse clones. Typing by MLST further illustrates the diversity of strains, 
with 8 different STs assigned, and the identification of the 10 isolates as singletons rather than 
belonging to a group.  
The resistance to carbapenems is largely mediated by the expression of acquired 
carbapenemases: blaOXA-23, blaOXA-24 and blaOXA-58. blaOXA-23 was the most commonly identified 
gene in the current study and it contributed to carbapenem resistance which was facilitated by 
ISAba1 located directly upstream of the gene. blaOXA-24 was identified in a single isolate, 
probably located on the chromosome. blaOXA-58 was identified in six isolates from both hospitals 
all flanked by ISAba3 element. Two isolate, however had IS6 family ISs present upstream of 
blaOXA-58, thereby interrupting ISAba3. ISAba2 was identified upstream of blaOXA-89, contributing 
to high-level resistance to carbapenems. This serves to further illustrate the role of insertion 
sequences in mediating resistance in A. baumannii. 
The role of ISAba1 in expression of resistance genes is not only present in the acquired blaOXA-23 
gene, but also in its association with blaADC. The presence of ISAba1 upstream of blaADC 
correlated with high-level ceftazidime resistance.  
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Ceftazidime resistance in three other isolates was attributed to the presence of blaPER-like genes in 
those isolates. The first identification of blaPER-3 in a clinical A. baumannii isolate serves to 
illustrate the genetic plasticity in the acquisition of novel resistance genes from other organisms.  
The heterogeneity of resistance mechanisms present in this study is very unique. It shows how 
different resistance mechanisms act together in response to the environment and the selective 
pressures undertaken by the usage of antibiotics, as well as more importantly, it highlights the 
role of evolution of A. baumannnii genome and the presence of different clones within the same 
hospital in a relatively short time. The role of the different IS elements further enhances the 
expression of different resistance mechanisms and provide more plasticity in the genome.  
Previous reports of the genetic diversity of A. baumannii isolates showed the presence of seven 
different blaOXA-51-like genes collected from 200 isolates between 1982 and 2005 (Merkier & 
Centrón 2006). The current study hence gives an insight into the diversity of isolates present in 
Egyptian hospitals.  
More research is required to determine the prevalence of a clone in Egyptian hospitals. The 
diversity seen in the current study may be attributed to the centres being tertiary referral 
hospitals, where the isolates have consequently been brought to the hospitals by the patients from 
different regions in Egypt. 
The lack of adequate infection control together with the lack of reporting and the limited funds 
available for research in developing countries all contribute to the lack of knowledge we have of 
the epidemiology of hospital acquired infection. There is an urgent need to fund and support 
research in developing countries, in order to prevent the clonal dissemination of antibiotic 
resistant organisms not only in the hospital setting, but in the community.  
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Antimicrobial stewardship programs aimed to preserve the activity of antibiotics and limiting the 
rates of resistance are strongly needed in developing countries like Egypt, as the inadequate 
usage of antibiotics in the community and hospitals all contribute to the rise in resistance, and 
promotes the organism to acquire and express novel resistance mechanisms.  
A. baumannii is a very interesting pathogen due to its rapid development of resistance and the 
plasticity of its genome. Further research into the epidemiology of the organism, not only in 
Egyptian hospitals, but in other regions of the Middle East is one of my future research aims in 
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Letter  to  the  Editor
First report of blaPER-3 in Acinetobacter baumannii
Sir,
Acinetobacter baumannii is an important opportunistic nosoco-
mial pathogen with a remarkable ability to survive and disseminate.
In addition, A. baumannii can acquire new antibiotic resistance
genes and upregulate them, making it a problematic pathogen caus-
ing numerous outbreaks worldwide [1,2]. Patients at high risk for
developing A. baumannii infections are those with prolonged hos-
pitalisation and immune suppression, such as cancer patients [2].
Antibiotic selective pressure also contributes to the rising incidence
of resistance [1].
The mechanisms of resistance in A. baumannii that cause most
concern are the -lactamases, and all the Ambler class enzymes
(A–D) have been found in this species. Class D and class B -
lactamases mainly confer resistance to the carbapenems, whilst
class A are mainly extended-spectrum -lactamases (ESBLs) [1].
The first report of an ESBL in A. baumannii was blaPER-1 in France [3],
with PER-like variants in A. baumannii now increasingly reported
worldwide. PER-3 was initially characterised from an Aeromonas
punctata in France (GenBank accession no. AY740681.1) and
recently in a medical centre in Taiwan [3],  sharing 99% homology
to blaPER-1. Here we report the first identification of a blaPER-3-
producing A. baumannii isolate.
Isolate AB-15094 was obtained from a 9-year-old patient with
osteosarcoma in 2010 at the Children’s Cancer Hospital 57357
(Cairo, Egypt). Phenotypic identification was followed by sequenc-
ing of the blaOXA-51-like gene and restriction analysis of the 16S–23S
rRNA spacer sequence [2,4].
Minimum inhibitory concentrations (MICs) were determined
and interpreted according to British Society for Antimicrobial
Chemotherapy (BSAC) guidelines for imipenem, meropenem,
ceftazidime and rifampicin. Detection of the OXA-type carbapene-
mases blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 as well as class A
-lactamase genes blaPER-like, blaVEB, blaGES and blaTEM and the class
C -lactamase gene blaADC was done by standard PCR [3,4]. The class
1 integron harbouring the blaPER-3 gene was analysed by standard
PCR and sequencing methods [4]. S1 nuclease digestion was per-
formed to detect and size plasmids [3]. To investigate whether
blaPER-3 was plasmid-borne, a plasmid curing experiment was  con-
ducted. Susceptibility to ceftazidime was examined after curing
and was compared with the initial susceptibility of the uncured
strain.
Int1 ant(3')-Ij -aac(6')Ib blaOXA-30 catB3  qacEΔ1   sul1 orf513 blaPER-3
Fig. 1. Schematic diagram of the genetic environment of blaPER-3. The genetic orientations are represented by horizontal arrows. The figure is to scale.
Isolate AB-15094 was confirmed as A. baumannii harbouring
the blaOXA-65 gene. It was  sensitive to imipenem and meropenem
but resistant to ceftazidime and rifampicin, with MICs of 64 mg/L
and 256 mg/L respectively. The isolate was  positive for blaPER-3 as
revealed by sequencing. The strain was  negative for all other ESBLs
tested as well as for the acquired class D carbapenemases. No inser-
tion sequence (IS) element was  detected upstream of the blaADC
gene, suggesting no overexpression of the gene [4].
There was  no hybridisation of blaPER-3-specific probes with any
of the isolate’s three plasmids (60, 70 and 145.5 kb, respectively),
suggesting chromosomal localisation of the gene. This was sup-
ported by the lack of change in ceftazidime susceptibility after 10
days of plasmid curing. Furthermore, attempted conjugal trans-
fer was also negative. Sequencing upstream of blaPER-3 revealed a
complex class 1 integron structure harbouring sul1, qacE1 in the
variable 3’CS and ORF513 directly upstream of the blaPER-3 gene,
serving as the transcriptional promoter. Fig. 1 shows the schematic
representation of the genetic environment of blaPER-3.
This isolate was obtained from a paediatric cancer patient in
Egypt and is the first identification of blaPER-3 in a clinical A. bauman-
nii isolate. Previous reports of this gene have been from A. punctata
in France and Taiwan where the blaPER-3 gene was reported to be
localised both on plasmids and on the chromosome [3]; however,
in this study it was located on the chromosome alone. The genetic
environment upstream of blaPER-3 was similar to the A. punctata iso-
late identified in France (GenBank accession no. AY740681.1), being
encompassed in a complex class 1 integron. The upstream regions
of blaPER-3 and blaPER-1 differ significantly despite their structural
homology. blaPER-1 was  part of transposon-related structure Tn1213
consisting of ISPa12 and ISPa13 flanking the gene [1].  The blaPER-3
in this study lacks these IS elements and harbours ISCR1,  which is
closely associated with class A ESBLs and facilitates the movement
of these resistance genes [3,5].
PER-3 is a point-mutant derivative of PER-1 [3] harbouring the
change Histidine134Leucine. This mutation is positioned in the
H4 helix of the secondary structure of the -loop region, which
is associated with the active site of class A -lactamases [5].  The
observed mutation could explain the reduced resistance to cef-
tazidime (MIC = 64 mg/L) in isolate AB-15094 harbouring blaPER-3
compared with other A. baumannii isolates harbouring blaPER-1 and
blaPER-7, with MICs > 256 mg/L and 256 mg/L, respectively (unpub-
lished results).
The mechanism of acquisition of blaPER-3 by A. baumannii is
unknown but is hypothesised to be mediated through horizontal
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gene transfer from A. punctata. Genetic transfer of blaPER-3 is facili-
tated by localisation of the gene within an integron. blaPER-3 might
have been transferred to A. baumannii by a plasmid harbouring the
integron, which later migrated into the chromosome.
Nucleotide sequence accession no.
The nucleotide sequence reported in this paper has been sub-
mitted to the EMBL/GenBank nucleotide sequence database and has
been assigned accession no. JX128136.
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ISAba825 controls the expression of the chromosomal blaOXA-51-like and
the plasmid borne blaOXA-58 gene in clinical isolates of Acinetobacter
baumannii isolated from the USA
B. S. Lopes, L. Al-Hassan and S. G. B. Amyes
Medical Microbiology, The University of Edinburgh, Edinburgh, UK.
Abstract
Four non-repetitive, clonally related (ST114), carbapenem-resistant Acinetobacter baumannii strains isolated in the USA were examined
to understand the mechanisms of carbapenem resistance including screening for the presence of an insertion sequence upstream of the
blaOXA-51-like gene, which could be involved in the control and expression of the antibiotic-resistance gene. We observed that the main
mechanisms of carbapenem resistance were the result of the over-expression of the blaOXA-58-like and the blaOXA-65 gene, both of which
had the presence of ISAba825 upstream of the genes. The importance of this element was shown by isolating plasmid-cured isogenic
strains that had lost the plasmid with the ISAba825-blaOXA-58-like genes but during that same process also lost the chromosomal
ISAba825 element present upstream of the blaOXA-65 gene. A 16-fold decrease in minimum inhibitory concentration of imipenem and an
eight-fold decrease in the minimum inhibitory concentration of meropenem were seen in the isogenic strains that lost the plasmid. The
study presents the first report of ISAba825 simultaneously governing the blaOXA-65 gene and the blaOXA-58-like gene expression and also
highlights the importance of this element in carbapenem-sensitive isogenic strains, which were once carbapenem resistant.
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Introduction
Acinetobacter baumannii is an important opportunistic patho-
gen responsible for a variety of nosocomial infections [1].
Multidrug-resistant Acinetobacter baumannii causes serious
infections associated with high mortality rates, including sep-
ticaemia, pneumonia and urinary tract infections, especially in
intensive-care units because of the rapid evolution of this
multi-drug-resistant pathogen when challenged by antibiotic
therapy [2,3]. The emerging resistance to carbapenems
among nosocomial strains represents a major concern
worldwide [4,5].
The major mechanisms that play a significant role in carba-
penem resistance in A. baumannii are the expression of
OXA-type carbapenemases [1,3,4,6]. Other mechanisms,
such as alterations in outer membrane permeability, can also
contribute to carbapenem resistance in this organism [7–9].
Additionally, the disruption of the outer membrane chan-
nel CarO as a result of the natural insertional inactivation of
its coding gene by insertion sequence (IS) Aba825 or
ISAba125 has been correlated with reduced susceptibility to
carbapenems [8].
ISAba825, a member of the IS982 family (http://www-is.
biotoul.fr), is composed of an 876-bp open reading frame
and codes a DDE-type transposase bounded by a 17-bp
inverted repeat [8]. It has been shown that ISAba825 gener-
ated a 7-bp duplication (ATCGTTA) at the insertion site
within carO [8]. It is well known that insertion sequences can
cause mutations and genome rearrangements to enhance the
spread of resistance genes and virulence determinants within
the pathogenic species [10–13]. A recent report by Ravasi
et al. [14] has shown the association and the tight regulation
of ISAba825 with the plasmid-borne blaOXA-58 gene. In this
work, we evaluated the impact of ISAba825 in modulating
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A. baumannii genome plasticity and carbapenem resistance
and report for the first time ISAba825 modulating the
blaOXA-51 gene expression simultaneously with the increased
expression of the blaOXA-58 gene.
Materials and Methods
Four non-repetitive and distinct clinical strains, isolated in
2004 in the USA, were used in this study. They were con-
firmed as A. baumannii by PCR and sequencing of the rpoB
gene using the primers Ac696F and Ac1093R described pre-
viously by La Scola et al. [15].
Minimum inhibitory concentration determination
The MICs of imipenem and meropenem were determined by
the agar double-dilution method and the results were inter-
preted according to the British Society for Antimicrobial
Chemotherapy guidelines [16]. The reference strains used
for MIC testing were Escherichia coli NCTC 10418, Pseudomo-
nas aeruginosa ATCC 10662 and Staphylococcus aureus NCTC
6571.
Screening of antimicrobial resistance determinants
The isolates were tested for the OXA group of enzymes by
multiplex PCR as described by Higgins et al. [17]. Multiplex
PCR for the detection of metallo-b-lactamases such as IMP,
VIM, GIM, SIM and SPM was performed using the primers
described previously by Ellington et al. [18].
The primers FxOxaF and FxOxaR, described earlier by
Lopes et al. [19], were used for the detection of the pres-
ence of an insertion element upstream of the blaOXA-51-like
gene in all four isolates, and the primers 51F and IntaceR
described earlier [19] were used to map the OXA-51-like
gene sequence with the screening for insertion sequence if
any, present downstream from the OXA-51-like gene.
The primers preOXA-58prom+ and preOXA-58B,
described previously [6] were used to check for any varia-
tions within the blaOXA-58-like gene by sequencing. The primer
SM2 described previously by Poirel and Nordmann [20] and
the walk-58-R primer described by Lopes et al. [19] were
used to detect any insertion sequence upstream of the
OXA-58-like gene.
Pulsed field gel electrophoresis
ApaI macrorestriction was performed on all four Acinetobac-
ter baumannii strains according to the procedure described
by Seifert et al. [21]. Cluster analysis was performed using
the unweighted pair group method with mathematical aver-
aging (UPGMA), and DNA relatedness was calculated by
using the band-based Dice coefficient with a tolerance setting
of 1.5% band tolerance and 1.5% optimization setting for the
whole profile.
Gel analysis was performed using the BIONUMERICS v 2.5
software (Applied Maths, Sint-Martins-Latem, Belgium). A
value of 85% was chosen as the threshold for the establish-
ment of clonal relatedness of the strains.
Multilocus sequence typing
Multilocus sequence typing was performed according to the
scheme proposed by Bartual et al. [22].
S1 nuclease digestion and plasmid determination
S1 nuclease digestion was performed for the pulsed field gel
electrophoresis plugs according to the manufacturer’s
instructions (Promega, Southampton, UK). A total of 10 units
per plug were used for digestion with incubation at 37C/
45 min. The plasmid bands were excised from the gel and
purified using the Qiagen gel extraction kit. Chromosomal
DNA contamination was checked using the 16S-rRNA prim-
ers described earlier by Lin et al. [23].
Plasmid curing
Plasmid curing was performed using an elevated temperature
of incubation for which the strains were sub-cultured for
15 days at 46C [24]. Plasmid curing was also performed
using SDS: 200 lL of overnight culture was inoculated in
4.8 mL nutrient broth containing 200 lL of 10% SDS and
incubated at 46C/48 h [24]. Finally, SDS was coupled with
elevated temperature of incubation to check for any loss of
plasmid [24]. The strains (200 lL of overnight culture) were
incubated in 4.8 mL nutrient broth with 200 lL 10% SDS at
46C/48 h.
Conjugation
Transconjugation assays of A. baumannii strains with the
blaOXA-58-like gene were performed with E. coli J62.2 and
A. baumannii 19606 as described previously [25].
Analysis of gene expression
The gene expression was studied for all the isolates accord-
ing to the method described previously by Lopes et al. [26].
The internal blaOXA-65 gene primers 65A (5¢-CTCGTGC
TTCGACCGAGTAT-3¢) and 65B (5¢-GCTGAACAACC
CATCCAGTT-3¢) were used for the blaOXA-65 gene expres-
sion and OXA-58-like F and OXA58-like R primers as
described previously by Higgins et al. [17] were used for the
blaOXA-58 gene expression. The PCR products were quanti-
fied using the BIO-RAD QUANTITY ONE Software 4.6.1 (Bio-
Rad, Hercules, CA) (Table 1). Normalization of DNA was
2 Clinical Microbiology and Infection CMI
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performed with the 16S-rRNA primers described earlier by
Lin et al. [23] with the appropriate amounts of serially
diluted RNA used for cDNA synthesis.
Results
All the strains were resistant to imipenem and meropenem
(Table 1). ApaI macrorestriction analysis of the four isolates
exhibited genetic similarities of 99.99% by the unweighted
pair group method with arithmetic average method (data not
shown). All the isolates were found to have the sequence
type ST114 (1, 15, 8, 10, 28, 57, 32) (http://pubmlst.org/abau-
mannii/, last accessed 15 June 2011). Genes encoding known
carbapenemases were investigated as described previously
and the genes blaOXA-51-like and blaOXA-58-like were detected
in all the four strains [17]. Genes encoding OXA-40-like and
OXA-23-like carbapenemases were not detected. Nor were
metallo-b-lactamases such as IMP, VIM, GIM, SIM and SPM
detected [18] in any of the isolates.
The primers FxOxaF and FxOxaR detected the presence
of an insertion element upstream of the blaOXA-51-like gene in
all four isolates (Fig. 1). The primers 51F and IntaceR were
used for the amplification of the blaOXA-51-like gene and the
intergenic region present downstream from the blaOXA-51-like
gene and the phosphinothricin acetyltransferase (GNAT) gene
(Fig. 1). The sequencing results showed the presence of
ISAba825 upstream of the blaOXA-65 gene in all four isolates.
A putative promoter was found with )35 (TTGTCA) and
)10 (TATGAA) located 17 bp apart from each other
(BPROM, Softberry, Inc., Mount Kisco, NY) located 97 and
74 bp upstream of the blaOXA-65 gene. A target site duplica-
tion of 7 bp, AAGTCTT was seen upstream and down-
stream of the ISAba825 sequence. No insertion was seen
downstream of the blaOXA-65 gene making the ISAba825 a
defunct transposon. The ISAba825 sequence was oriented in
5¢–3¢ direction against the blaOXA-65 gene in all four isolates.
The expression of the blaOXA-65 gene for all isolates was
studied as described earlier by Lopes et al. [26] The internal
blaOXA-65 gene primers 65A and 65B showed a considerable
over-expression of the blaOXA-65 gene expression (Table 1).
Since the multiplex PCR detected the blaOXA-58-like gene,
we further examined the isolates for any variations within
the gene and insertion sequences involved in governing the
expression of the blaOXA-58-like gene. The primers preOXA-
58prom+ and preOXA-58B, described previously [6], were
used to check for any variations within the blaOXA-58-like
gene. The primers amplified a 934-bp fragment, which on
sequencing confirmed that the blaOXA-58 gene had no nucleo-
tide substitutions.
The SM2 primer and the walk-58-R primer amplified a
fragment of ISAba825 oriented in 3¢–5¢ direction in all four
parent strains. The putative promoter )35 (TTGAGA) present
148 bp upstream of the blaOXA-58 gene and )10 (TTTATA)




Quantification of gene expression (arbitrary units)
Imipenem Meropenem






Ab202 16 16 16S r-RNA 249 OXA-65 154 OXA-58 194
Ab203 16 16 16S r-RNA 250 OXA-65 167 OXA-58 189
Ab204 16 16 16S r-RNA 255 OXA-65 165 OXA-58 187
Ab205 16 16 16S r-RNA 251 OXA-65 165 OXA-58 189
Ab202s 1 2 16S r-RNA 240 OXA-65 74 OXA-58 –
Ab203s 1 2 16S r-RNA 245 OXA-65 72.1 OXA-58 –
Ab204s 1 2 16S r-RNA 255 OXA-65 67.5 OXA-58 –
Ab205s 1 2 16S r-RNA 255 OXA-65 69 OXA-58 –
Ab3 0.25 0.5 16S r-RNA 245 OXA-95 51.1 OXA-58 71.8
–, denotes the absence of the blaOXA-58 gene.








FIG. 1. Genetic arrangement of ISAba825 governing the chromosomal blaOXA-65 gene. The arrows represent the primers used for detection and
sequencing of genes. Figure is not to scale.
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present 127 bp upstream of the blaOXA-58 gene were identi-
fied 15 bp apart from each other. The blaOXA-58 gene was
highly over-expressed (Table 1). The comparison was made
with the blaOXA-58 gene of A. baumannii ATCC 17978/
pWHP3 (Ab3) [14].
S1 nuclease digestion showed a plasmid of approximately
40 kb that harboured the blaOXA-58 gene in all the strains.
The loss of plasmid was not observed when the conditions
of elevated temperature or SDS were used individually—only
when the two conditions were coupled together as
described in the Materials and Methods. The loss of plasmid
was observed in all the isogenic strains harbouring the
ISAba825 element upstream of the blaOXA-58 gene, which
was lost by the plasmid curing method as described in the
Materials and Methods section. During the same process of
curing, the ISAba825 that was present upstream of the
blaOXA-65 gene was also lost, making the isolates carbapenem
sensitive (Table 1). A 16-fold decrease in MIC of imipenem
and an eight-fold decrease in MIC of meropenem were
observed for all the sensitive isogenic strains. The isolates
did retain the basal level of the blaOXA-65 gene expression
(Table 1).
Transconjugation assays using E. coli J62.2 or A. baumannii
19606 could not transfer the 40-kb plasmid, which had the
blaOXA-58 gene with the upstream ISAba825 element.
Discussion
Insertion sequence elements are capable of independent
transposition within a genome and have evolved with mecha-
nisms of regulation of genes in host cells [19]. Transposition
of an IS element can either lead to the disruption of a gene
causing insertional inactivation of a gene [19] or provide a
signal for the activation, leading to the over-expression of
the adjacent gene by providing suitable strong promoter
sequences when present upstream of the gene [20]. The IS
activation or inactivation depends on complexes formed by
repressor–inhibitory mechanisms under antibiotic stress con-
ditions and has an important role in regulation of genes [19].
The insertion of IS elements upstream of a b-lactamase gene
provides the bacterium with the advantage of transiently
increasing the levels of gene expression to combat antibiotic
stress [19]. Transposition of the IS is therefore one of the
most important driving forces that enhances the variability
leading to a better evolutionary capacity and adaptability of
their hosts [27]. This is demonstrated in our study by the
acquisition of the plasmid-borne blaOXA-58 gene with
ISAba825 and the loss of the same gene, leading to a sensi-
tive phenotype in all the isogenic strains.
The curing event promoted the loss of the blaOXA-58 gene
and its upstream ISAba825 promoter. However, the same
event also promoted the loss of the ISAba825 element
upstream of the chromosomally encoded blaOXA-65 gene, so
making the strains carbapenem sensitive. These results sug-
gest that control of the IS elements is well coordinated by
the activators and repressors because the loss of the IS ele-
ment occurred at the same step as the loss of the plasmid
[19]. The transposition activity of an insertion element is
usually present at low levels because the change caused by
the increase in activities can have a detrimental effect on the
host cell through various modifications in the genome [27].
The transposase promoters are usually located in the termi-
nal inverted repeats, and are generally autoregulated; this
would enable the bacterium to resist antibiotic stress with-
out compromising its fitness cost [28].
The temperature sensitivities of transposition in E. coli
have been identified as the properties of the transposases,
which are inherently present within the genome and which
contribute towards genomic variability under critical growth
conditions [29]. It has been reported earlier that an increase
in the transposition activities of the seven IS elements
belonging to four different IS families of Burkholderia multivo-
rans ATCC 17616 suggested that there may be some com-
mon host factors that affect the transposition frequency at
high temperatures and so lead to genome rearrangement
[27]. Ohtsubo et al. [27] also suggested that there may be
other factors that could be responsible for changes in the
genome and could either promote or inhibit the effective
working of transposases. The observed characteristics for
the carbapenem-resistant and carbapenem-sensitive strains
indicate that the IS element examined here (ISAba825) plays
an important role in cells exposed to high temperatures, so
generating genetic diversity in a population of A. baumannii.
High temperatures may be important for A. baumannii
because it is a frequent pathogen in the Arabian Peninsula
and appears to be present in the hospital environment there,
where temperatures frequently reach 46C. Expression stud-
ies also show the importance of ISAba825 in conferring
carbapenem resistance by over-expression of the blaOXA-58-
like and blaOXA-65 genes and it can be concluded that
ISAba825 is also crucial for the adaptation and evolution of
carbapenem-resistant A. baumannii besides the well-known
ISAba1 [30]. Our results concur with those of Ravasi et al.
[14] and additionally we indicate that ISAba825 also governs
the blaOXA-51-like gene expression and this is an essential
mechanism of carbapenem resistance in A. baumannii.
Regardless of whether the b-lactamase gene was on a plas-
mid, it is important to note that ISAba825, present upstream
of the blaOXA-65 gene, can easily provide a stable mechanism
4 Clinical Microbiology and Infection CMI
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of resistance if the strain is under antibiotic pressure. When
the strain is subjected to unfavourable conditions in the
absence of any antibiotic stress, such as elevated tempera-
ture or other chemicals like SDS, the loss of plasmid or the
elimination of chromosomal ISAba825 present upstream of
the blaOXA-65 gene favours survival as the bacterium no long
needs to express the resistance genes. This presumably
reduces the energy cost on the cell. These results also high-
light that gene duplication being crucial in multi-resistant
strains of A. baumannii does involve recombination events
involving insertion elements that play an important role in
the adaptation of the bacterium. This adaptation of the bac-
terium to survive under unfavourable conditions of high anti-
biotic pressure or other unsuitable physiological conditions
clearly demonstrates the adaptation and the resilient nature
of A. baumannii. The insertion element ISAba825 belongs to
the IS982 family, once thought to be restricted to Gram-
positive bacteria [28], this denotes the interspecific spread
of insertion elements between different bacterial communi-
ties. As ISAba825 was previously reported to be plasmid-
borne in A. baumannii from Argentina, we believe that the
association and establishment of this element with the chro-
mosomal b-lactamase (blaOXA-51-like) of A. baumannii should
be of great concern [14]. It is worth noting that the
sequence type ST114 (1, 15, 8, 10, 28, 57, 32) found in our
strains has been previously described in other isolates from
Argentina (http://pubmlst.org/abaumannii/, last accessed 15
June 2011).
Nucleotide sequence accession number
The ISAba825-blaOXA-58 sequence of strain 202 has been
deposited under the accession number JQ412186 and the
ISAba825-blaOXA-51-like sequence of the same strain has been
deposited under the accession number JQ412185.
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Abstract
Acinetobacter baumannii is an important nosocomial pathogen, commonly causing infections in immunocompromised patients. It is
increasingly reported as a multidrug-resistant organism, which is alarming because of its capability to resist all available classes of antibiotics
including carbapenems. The aim of this study was to examine the genetic and epidemiological diversity of A. baumannii isolates from
paediatric cancer patients in Egypt, by sequencing the intrinsic blaOXA–51-like gene, genotyping by pulsed-field gel electrophoresis and multi-
locus sequence typing in addition to identifying the carbapenem-resistance mechanism. Results showed a large diversity within the isolates,
with eight different blaOXA-51-like genes, seven novel sequence types and only 28% similarity by pulsed-field gel electrophoresis. All three
acquired class-D carbapenemases (OXA-23, OXA-40 and OXA-58) were also identified among these strains correlating with resistance to
carbapenems. In addition, we report the first identification of ISAba2 upstream of blaOXA-51-like contributing to high-level carbapenem
resistance. This indicates the presence of several clones of A. baumannii in the hospitals and illustrates the large genetic and epidemiological
diversity found in Egyptian strains.
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Introduction
Acinetobacter baumannii has emerged as an important nosoco-
mial pathogen in the past decade, which in recent years has
developed into a multidrug-resistant problematic pathogen [1].
Acinetobacter baumannii is an opportunistic pathogen, fre-
quently isolated from immunocompromised patients with
prolonged hospitalization [2]. As a consequence of immuno-
ablative treatment, patients with cancer are at risk of
developing A. baumannii infections, including sepsis, respira-
tory, wound and tissue infections, in addition to urinary tract
infections [2,3].
A major concern in A. baumannii is its worldwide clonal
expansion and its ability to survive and disseminate in hospitals,
with numerous outbreaks reported from different regions of
the world [4]. Acinetobacter baumannii is notably resistant to
extreme environmental conditions, such as dryness, and can
survive on surfaces for a long time, hence facilitating its spread
[1,4].
Resistance to carbapenems, the b-lactam drugs of last
resort in treating A baumannii infections, has been attributed
to the expression of carbapenem-hydrolysing oxacillinase
genes, blaOXA23, blaOXA-40 and blaOXA58, which are usually
plasmid encoded [5,6]. The ubiquitous, chromosomally
encoded blaOXA-51-like gene only confers resistance when an
Insertion Sequence (IS) is present upstream of the gene [7].
Due to the prevalence of A. baumannii across the world,
suitable typing methods to investigate the epidemiological
distribution of the organism have been developed such as
ribotyping, amplified fragment length polymorphisms,
pulsed-field gel electrophoresis (PFGE) and, more recently,
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Multi-Locus Sequence Typing (MLST) [8]. Additionally, ampli-
fication and sequencing of the ubiquitous blaOXA-51-like gene has
also been used to determine clonal groups from diverse
worldwide sources [7,8].
Limited data were available concerning the epidemiological
distribution of A. baumannii in the Middle East but, in the past
few years, reports of strains in the United Arab Emirates, Iraq,
Kuwait and Egypt harbouring diverse resistance mechanisms
have emerged [9–12]. The aim of this study was to investigate
the epidemiological and molecular diversity of A. baumannii
strains isolated from two cancer centres in Cairo, Egypt.
Materials and Methods
Isolate identification
Thirty-four non-duplicate A. baumannii were obtained from two
centres; The Children’s Cancer Hospital (CCH) and The
National Cancer Institute (NCI), both located in Cairo, Egypt,
from 2010 to 2011. Initial identification and susceptibility testing
was done using VITEK and Phoenix automated machines.
Genotypic identification was carried out by restriction analysis
of 16s-23s rRNA spacer sequences using AluI and NdeII [13].
Detection of blaOXA-51-like genes
The intrinsic blaOXA-51-like genes were amplified for A. bau-
mannii isolates using primers: OXA69A and B [7]. Products
were purified using a QIAquick PCR Purification Kit (Qiagen,
Crawley, UK) and sequenced in both directions on a 3730
DNA Analyzer (Applied Biosystems, Warrington, UK). For
isolates yielding a larger product size, a PCR was performed to
screen for the associated upstream environment using primers
FxOxa-F and FxOxa-R [14].
Detection of class D oxacillinases and genetic environment
Isolates were screened for the presence of acquired OXA
carbapenemases by Multiplex PCR, as previously described
[15]. Isolates positive for the individual OXA groups were
subsequently amplified and sequenced using primers for the full
sequence of the genes. Associated genetic environment was
also amplified and sequenced. Primers used are listed in
Table 1.
Minimum inhibitory concentrations
The MIC of imipenem and meropenem were determined using
an agar double dilution technique according to the British
Society of Antimicrobial Chemotherapy (BSAC) guidelines
[16]. Pseudomonas aeruginosa NCTC 10662, Escherichia coli
NCTC 10418 and Staphylococcus aureus NCTC 6571 were
used as control strains.
Pulsed-field gel electrophoresis
All isolates were typed by PFGE according to the procedure
previously described by Seifert et al. [17]. Briefly, plugs were
incubated in 30 U ApaI at 37° overnight, and subsequently run
on 1% pulsed-field-certified agarose gel (Bio-Rad, Hertford-
shire, UK) in 0.5 9 TBE buffer with an initial pulse of 5 s and a
final pulse of 20 s for 20 h. The gels were stained with Gel-Red
solution and visualized using the DIVERSITY DATABASE (Bio-Rad)
software image-capturing system.
Multi-locus sequence typing
The PCR for the seven housekeeping genes: gltA, gyrB, gdhB,
rpoD, recA, gpi and cpn60 was performed according to the
scheme developed by Bartual et al. [18]. Products were
purified and sequenced as described above. MLST was per-
formed for ten isolates, representatives of the blaOXA-51-like
gene variants identified. If isolates from different hospitals
harboured similar blaOXA-51-like genes, an isolate from each
hospital was selected randomly for comparison. Isolates
chosen for MLST were: 8357, 9925-SAM, 1780, 634, 21174,
22055, 161, P38-YSF, P67-AZ and 14611.
Primer name Sequence 5′–3′ Use Reference
16s-23s rRNA F TTGTACACACCGCCCGTCA Identification [13]
16s-23s rRNA R GGTACTTAGATGTTTCAGTTC
Oxa69-A CTAATAATTGATCTACTCAAG blaOXA-51-like amplification and sequencing [7]
Oxa69-B CCAGTGGATGGATGGATAGATTATC




blaOXA-23 F GATGTGTCATAGTATTCGTCG Whole gene-sequence of blaOXA23 [25]
blaOXA-23 R TCACAACAACTAAAAGCACTG
ISAba1A GTGCTTTGCGCTCATCATGC Upstream environment of blaOXA23 [26]
SM2 AAGTGTCTATATTCTCACC Upstream environment of blaOXA58
ISAba3-F CAATCAAATGTCCAACCTGC Upstream environment of blaOXA58




Whole gene sequence of blaOXA24 [27]
OXA-24RR TTAAATGATTCCAAGATTTTCTAGC
TABLE 1. List of primers used in
this study
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Results
Diversity of blaOXA-51-like genes
All isolates were confirmed as A. baumannii, and sequencing of
the intrinsic blaOXA-51-like revealed the presence of eight
different genes: blaOXA-64, blaOXA-65, blaOXA-66, blaOXA-69,
blaOXA-71, blaOXA-78, blaOXA-94 and blaOXA-89 (Table 2).
blaOXA-65 was the most prevalent, found in 14 isolates,
obtained from both hospitals. blaOXA-64 is now commonly
found in the Middle East (A. Al Hasan, and S.G.B. Amyes,
unpublished results; [9]), it was found in seven isolates
obtained from both hospitals. There were representatives
from the three worldwide clones (formally known as the
European clones). blaOXA-66 was found in four isolates, three
of which were from CCH. blaOXA-69 was identified in two
isolates at the intensive care unit (ICU) of CCH and were part
of an A. baumanniii outbreak in early 2011. blaOXA-71 was found
in two isolates from different hospitals. blaOXA-78 and blaOXA-89
were both found in strains from CCH, whereas blaOXA-94 was
from two isolates from NCI, recovered from the same floor,
1 day apart.
Insertion sequences associated with blaOXA-51-like
Sequencing upstream of the blaOXA-51-like gene, blaOXA-89 in
isolate 22055 revealed the presence of ISAba2, with the -35
(ttatat) and -10 (ttgtaggat) promoters 29 bp apart, and located
102 bp and 82 bp upstream of blaOXA-89, respectively. No
other insertion sequences were identified upstream of the
blaOXA-51-like genes.
PFGE
The PFGE analysis revealed a large diversity within the
strains. Some isolates with similar blaOXA-51-like genes had
very distinct PFGE patterns, suggesting no epidemiological
similarity between the strains. As seen in Figure 1, only six
isolates harbouring blaOXA-65 show > 80% similarity in their
PFGE pattern. Additionally, blaOXA-64 isolates all shared less
than 80% similarity. Even isolates with blaOXA-94, which were
collected from patients on the same floor of the same
hospital 1 day apart, had distinct PFGE patterns. On the
other hand, the blaOXA-71 containing isolates, although from
different hospitals, had similar PFGE patterns. The similarity
for all the isolates was calculated by Dice coefficient to be
28.7%.
TABLE 2. Isolates harbouring blaOXA-51-like genes, with isolation details. carbapenem-hydrolysing class D b-lactamase (CHDL)
genes, minimum inhibitory concentration (MIC) and sequence type. Isolates in bold were in the A. baumannii outbreak in early
2011
Isolation details CHDL b-lactamase gene MIC (mg/L)
Sequence typeIsolate no. Date of sample Hospital Location Site of isolate blaOXA-51-like blaOXA-23 blaOXA-58 blaOXA-40 IMI MER
7947 17/05/2010 CCH ICU Wound 64 0.25 0.06
12435 23/07/2010 CCH ICU Blood 64 + 16 32
14298 22/08/2010 CCH ICU Catheter tip 64 + 8 2
8357 5/29/2011 CCH DSCH CVP Blood 64 8 16 ST408
4248 15/03/2010 CCH IP-5C CVP tip 65 + 8 4
4842 23/03/2010 CCH ICU CVP tip 65 + 64 32
9930 15/06/2010 CCH ICU Blood and CVP 65 + 32 16
10262 19/06/2010 CCH ICU CVP 65 + 64 128
15094 05/09/2010 CCH IP-4B Urine 65 0.25 0.12
15324 09/09/2010 CCH IP-3A Catheter tip 65 0.06 0.06
1780 31/01/2011 CCH ICU Stool 65 + 8 16 ST410
1750 31/01/2011 CCH ICU BAL 65 + 32 8
2106 08/02/2011 CCH ICU Blood 65 + 8 8
2632 20/02/2011 CCH IP-5A Stool 65 + 8 8
2625 20/02/2011 CCH IP-4C Urine 65 + + 16 16
8768 6/4/2011 CCH IP-4B Blood 65 0.008 0.03
4343 17/03/2010 CCH IP-3B CVP-Blood 66 8 16
14611 27/08/2010 CCH ICU CVP Blood 66 + 64 32 ST208
21382 13/12/2010 CCH ICU CVP Culture 66 + 16 4
7052 5/7/2011 CCH ICU BAL 66 + 8 16
634 11/01/2011 CCH ICU Catheter tip 69 + 8 4 ST108
1447 24/01/2011 CCH ICU CVP Culture 69 + 0.5 0.06
161 03/01/2011 CCH PULM Sputum 71 0.06 0.06 ST414
21174 09/12/2010 CCH IP-3A Blood 78 0.03 0.25 ST412
22055 25/12/2010 CCH IP-3C CVP Blood 89 128 128 ST413
679-BAS 04/09/2010 NCI 5th floor Ear swab 64 + 8 8
P67-AZ 09/01/2011 NCI OP Blood 64 + + 64 16 ST411
9925-SAM 15/12/2010 NCI 7th floor Blood 64 + 16 8 ST409
P391-AH 14/09/2010 NCI 5th floor Blood 65 8 16
461-SF 15/12/2010 NCI 7th floor Blood 65 + 16 32
6332-ABD 02/09/2010 NCI 5th floor Ear swab 69 + 16 8
5687-SHAY 11/10/2010 NCI 5th floor Blood 71 0.25 0.25
P38-YSF 04/01/2011 NCI 5th floor Blood 94 + 64 64 ST331
P49-HAM 05/01/2011 NCI 5th floor Blood 94 + 8 8
BAL, bronchoalveolar lavage; CVP, central venous port; IMI, imipenem; MER, meropenem.
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Seven housekeeping genes were amplified and sequenced as
described above for ten isolates. Ten distinct sequence types (STs)
were identified, seven of which are novel and assigned ST408–
ST414. The remaining three STs were identified as ST331, ST108
and ST208. Typing by MLST further illustrated the large diversity
found within the strains, as isolates with similar blaOXA-51-like genes
had different STs. This is clear for isolates 9925-SAM and NCI-P67,
both were from the NCI and possessed blaOXA-64, but they
belonged to different STs: 409 and 411, respectively. When
compared with another blaOXA-64-positive isolate, 8357, which
was from a patient at CCH, another ST was identified, ST408.
MIC and carbapenem-hydrolysing class D b-lactamase
(CHDL) genes
The majority of isolates (n = 25), representing 73%, were
resistant to imipenem and/or meropenem (MIC  8 mg/L).
This resistance could be correlated with the presence of the
acquired class-D oxacillinases: blaOXA-23, blaOXA-58 and blaOXA-40
(Table 2).
Genes encoding all three transferable OXA types associated
with resistance were identified in these strains: blaOXA-23 in 18
isolates, blaOXA-58 in five isolates and blaOXA-40 in one isolate.
All isolates, except one, possessing blaOXA-23 were resistant to
imipenem and meropenem (MIC  8 mg/L). ISAba1 was
detected upstream of blaOXA-23 in the resistant isolates, hence
providing a promoter for the expression of the gene
(Figure 2). However, this IS element was not found upstream
in the blaOXA-23-containing isolate that was carbapenem
sensitive. The analysis of the A. baumannii outbreak in the
ICU at CCH in early 2011 revealed that although the strains
harboured distinct blaOXA-51-like types and were epidemiolog-














































































































































































FIG. 1. Pulsed field gel electrophoresis profile for Acinetobacter baumannii strains in this study, showing the associated isolation site, location, date,
and blaOXA51-like genes.
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blaOXA-58-positive isolates were also found in both hospitals
and all were resistant to meropenem and imipenem, with the
exception of isolate 14298, which was intermediate to merope-
nem (MIC 4 mg/L). The genetic environment of the blaOXA-58
showed that the gene was flanked by two copies of ISAba3
(Figure 2). Two isolates harboured an interrupted sequence of
ISAba3 upstream of the blaOXA-58 gene (L. Al-Hassan, H. El
Mehallawy and S. G. B. Amyes, unpublished results).
A single isolate, 14611 from CCH, was positive for blaOXA-
40 and it was also resistant to carbapenems. No insertion
element was detected upstream of the blaOXA-40 gene.
Eight of the 11 isolates that did not harbour acquired
carbapenemase genes were sensitive to carbapenems (MIC
<8 mg/L). One isolate, 22055, lacking these genes was
resistant to carbapenems and harboured the chromosomal
OXA-89 b-lactamase. ISAba2 was found upstream of the
blaOXA-89 gene (Figure 2).
Discussion
Acinetobacter baumannii is a problematic, multidrug-resistant
pathogen identified in healthcare environments worldwide [1].
The remarkable ability of A. baumannii to capture and express
resistance genes has allowed it to become one of the major
threats in hospitals, as it becomes resistant to all available
antibiotics, including carbapenems [4]. Resistance mechanisms
such as modification of target site, efflux pumps and enzymatic
inactivation have all been reported in A. baumannii [1]. Of
major concern is the presence of several classes of b-
lactamases within the A. baumannii genome. The localization
of these resistance genes on plasmids facilitates their move-
ment from one bacterium to another [5]. Class D oxacillinase
genes: blaOXA-23, blaOXA-40 and blaOXA-58 have been repeatedly
reported in A. baumannii outbreaks from different parts of the
world [1,19].
The construction of a linkage map based on the intrinsic
OXA-51-like b-lactamases was reported by Evans et al. [7].
The sequence relationship was determined for 37 distinct
members of the OXA-51-like b-lactamase family. This study
identified three large groups around OXA-66, OXA-69 and
OXA-98 in addition to other unrelated branched enzymes [7].
In the current study a large diversity was found in the
sequences of blaOXA-51-like with eight different gene variants
identified. This is particularly interesting given the short
duration of isolate collection (1 year) as well as the isolates
deriving from only two hospitals. In fact seven different blaOXA-
51-like genes were identified in CCH alone. When looking at the
distribution of blaOXA-51-like genes in the linkage map, it is clear
that they have different origins as the genes identified are not
clustered in closely related groups. Fourteen isolates, account-
ing for 41%, harboured blaOXA-65, which according to the
linkage map forms a ‘central hub’ from which all other groups
radiate and is thought to be ancestral to all blaOXA-51-like genes
[7]. This subsequently indicates the presence of the potential
ancestral blaOXA-51-like gene in A. baumannii in Egypt, which is in
the current collection of strains and is the major gene
identified. Additionally, this may explain that the large diversity
found is an outcome of the evolution of the ancestral blaOXA-65
gene in some cases, rather than the of ‘foreign carriage’ of
clones into the country.
blaOXA-69, blaOXA-66 and blaOXA-71 have been associated with
Worldwide [European] Clones I, II and III, respectively, and all
have been identified in the current study [6,7]. blaOXA-66 and
blaOXA-71 genes were identified in both hospitals, which may
indicate local distribution in Egyptian hospitals. blaOXA-69, on
the other hand, was found in two isolates in the ICU outbreak
in early 2011 at CCH only. This illustrates the extent of spread
of the major lineages of A. baumannii.
blaOXA-89 is a member of the blaOXA-98 cluster and contains
the resultant protein showing three amino acid substitutions
from OXA-98. In the current study, one isolate from CCH
was found positive for blaOXA-89, and harboured ISAba2
upstream. The presence of an insertion sequence upstream
of other blaOXA-51-like genes has been reported to enhance the
expression and cause resistance to carbapenems [20, 21].
ISAba2 has only been reported upstream of blaOXA58 [22].
With no other resistance mechanism identified, the presence
of ISAba2 was responsible for high-level resistance to both
imipenem and meropenem (MIC 128 mg/L and 256 mg/L,
respectively). Furthermore, this shows the ability of IS to insert
upstream of these genes and act as promoters.
blaOXA genes that are not part of previously identified clusters
have also been identified in the current study: blaOXA–94 in two
fxsA         ISAba2 blaOXA-89
OXA-23
   IS
 ISAba1                  bla
Aba3             blaOXA-58            ISAba3
FIG. 2. Schematic representation showing examples of the genetic
environments of blaOXA-89, blaOXA-23 and blaOXA-58.
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isolates from the NCI and blaOXA-64 in eight isolates from both
hospitals. OXA-64 is closely related to OXA-71 and is now
commonly found in the Middle East [7, 9] (A. Al-Hasan and S.G.B.
Amyes, unpublished results). blaOXA-94, on the other hand,
forms a branch of blaOXA-65 cluster with three amino acid
substitutions in the resultant protein.
As expected from this large diversity of isolates, there is
considerable variation in their PFGE profiles. Notably, isolates
harbouring similar blaOXA-51-like genes have different PFGE
profiles and no epidemiological linkage can be inferred. This
could be a result of the localization of the patients in different
wards and at different times in the hospital. Even for isolates
recovered from the ICU at different times, there seems to be
significant variability in profiles suggesting the presence of
different clones within the same hospital. Turton et al. found a
correlation between PFGE and sequence typing, in contrast to
Evans et al. who later noted major differences between PFGE
typing and sequence typing in their study [7,23].
MLST further illustrated the diversity within the isolates as
eight out of ten isolates typed were assigned to novel STs.
Previous reports have shown that typing with blaOXA-51-like was
more consistent with MLST than with PFGE [8]. In the current
study, isolates 8357, P67-AZ and 9925-SAM had similar
blaOXA-51-like genes but, when they were typed with MLST,
they showed three different novel STs, 408, 409 and 411,
respectively. The PFGE patterns were also different for these
isolates. This could indicate the presence of three distinct
clones in the two hospitals, especially that they were isolated
in different months and in different wards. MLST, in this case,
correlated with the epidemiological data of PFGE. Hamouda
et al. [8] found MLST to be more accurate than PFGE when
studying isolates on a global scale.
Seventy-three percent of the isolates were resistant to
carbapenems, and this is associated with all three CHDL genes
found in this study. Different genetic structures are associated
with the upstream environment of blaOXA-58 and blaOXA-23 and
they have been identified in different regions of the world
[22,24]. In the current study, blaOXA-23 is associated with
ISAba1 in the upstream environment and blaOXA-58 is flanked
by ISAba3. The effective mobilization of these genes by
insertion sequences upstream together with the localization
on plasmid largely contribute the spread of these resistance
genes [4].
In conclusion, the data presented show the large diversity of
A. baumannii isolated from two centres in Cairo, Egypt. The
genetic plasticity of A. baumannii is represented by the
presence of several insertion sequences upstream of the
resistance genes, thereby facilitating the expression and
causing resistance to carbapenems. Several clones seem to
be present in Egyptian hospitals requiring increased awareness
of the healthcare personnel and stricter infection control
policies to prevent the dissemination of these isolates.
Nucleotide Sequence Accession Number
The ISAba2-blaOXA-89 sequence of strain 22055 has been
deposited under the accession number JX499236.
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Abstracts of conference posters and 
presentations 
Identification of IS1006 interrupting an ISAba3 upstream of blaOXA-58 in Acinetobacter baumannii 
from a cancer patient in Egypt. 
L. Al-Hassan, H. El Mahallawy, B.S. Lopes, S.G.B. Amyes  
Objectives: 
A. baumannii is an important opportunistic infection that is commonly found in hospitals, 
particularly intensive care units. Class D carbapenamase blaOXA-58 is increasingly identified in A. 
baumannii as plasmid-mediated and is believed to confer carbapenem resistance when associated 
with insertion sequences (IS) upstream. We hereby report a carbapenem-sensitive A. baumannii 
strain isolated from a paediatric cancer patient in Egypt, harbouring blaOXA-58 with IS1006 
interrupting an ISAba3 upstream.  
Materials and Methods: 
The isolate was obtained from a catheter tip culture of a paediatric cancer patient in Cairo, identified 
by 16s-23s rRNA restriction analysis as well as by amplification and sequencing of the blaOXA-51-like 
gene. The presence of Class D Carbapenamases was performed by Multiplex PCR, and the upstream 
region of blaOXA-58 was amplified and sequenced accordingly. Minimum inhibitory concentrations 
(MICs) were determined according to BSAC guidelines 
Results: 
The isolate possessed the chromosomal blaOXA-64 gene, now commonly found in the Middle East. In 
addition, it was also positive for blaOXA-58,. Sequencing directly upstream of blaOXA-58 revealed the 
presence of ISAba3, which would normally provide a suitable promoter and be associated with 
carbapenem resistance. However, the MICs of Imipenem and Meropenem were 4 and 1 mg/L, 
respectively. Sequencing also revealed that the ISAba3 was interrupted by the incorporation of 
another insertion sequence, IS1006, 176 bp upstream of the start codon of blaOXA-58, which is 
interfering with the promoter of ISAba3.  
Conclusion: 
ISAba3 has been previously reported upstream of blaOXA-58 conferring carbapenem resistance in A. 
baumannii. Our results suggest that the insertion of IS1006 in the ISAba3 serves to switch off the 
resistance promoter, hereby rendering the isolate susceptible to carbapenems.  
 
Diversity in Acinetobacter baumannii isolates from paediatric cancer patients in Egypt. 
 
L. Al-Hassan, H. El Mehallawy, S.G.B. Amyes 
Objectives: 
Cancer patients are at a higher risk from serious infections because they are immuno-
compromised and many causative organisms are multi-drug resistant. In this study we report 
the genetic and epidemiological diversity of Acinetobacter baumannii isolated from 
paediatric cancer patients in Egypt, an emerging problem in cancer centres. 
Materials and Methods 
Thirty-four Acinetobacter baumannii strains were collected from the Children’s Cancer 
Hospital (CCH) 57357 and the National Cancer Institute (NCI) in Cairo from March 2010 - 
June 2011. They were initially identified phenotypically and then genotypically by PCR 
amplification and sequencing of blaOXA-51-like, and restriction analysis of 16s-23s rRNA spacer 
sequences using AluI and NdeII. Minimum inhibitory concentrations (MIC) of imipenem and 
meropenem was performed and interpreted according to BSAC guidelines. Isolates were also 
screened for the presence of class D carbapenamases: blaOXA-23, blaOXA-24 and blaOXA-58 by 
PCR amplification and sequencing.  
Results: 
Sequencing of blaOXA-51-like gene revealed a large diversity among the strains with 8 different 
genes identified: blaOXA-64, blaOXA -65, blaOXA-66, blaOXA-69, blaOXA-71, blaOXA-78, blaOXA-94 and 
blaOXA-100. This large diversity showed the presence of the 3 major sequence groups (blaOXA-
66, blaOXA-69, and blaOXA-71) in addition to other unrelated clones. Overall carbapenem 
resistance was 47% in all isolates (MIC ≥8mg/L), with resistance to meropenem being 
slightly higher than Imipenem in most strains. All three class D carbapenamases were 
detected in the isolates, with blaOXA-23 being most common (18 isolates), whereas 7 isolates 
harboured the blaOXA-58 and 2 isolates had blaOXA-40. Seven blaOXA-23 isolates had ISAba1 
inserted upstream and this correlated with higher resistance to carbapenems. Two isolates had 
the unusual combination of both blaOXA-23 and blaOXA-58. 
Conclusion: 
The two Egyptian hospitals are tertiary referral centres and these results show that the A. 
baumannii isolated from their patients had diverse origins although they included the 3 major 
European clones. The data strongly suggest that many of the strains have been brought to the 
hospital by the patients themselves rather than acquired by the more usual method of 
transmission through patient-to-patient cross infection. The results also show how these 
patients can serve as reservoirs for the survival and eventual dissemination of A. baumannii.  
 
 
